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ABSTRACT 
In Acute Myocardial Infarction (AMI), inflammation is a prerequisite for healing but 
it can paradoxically extend tissue injury; hence it needs to be modulated. Here, we 
investigated the role of the pro resolving GPCR FPR2/ALX and its agonist Annexin 
A1 (AnxA1) in AMI using mice lacking of the Fpr2/3 genes and with an in-frame 
GFP gene ‘knocked-in’. 
 
We developed protocols aimed to determine GFP expression as an indication of 
Fpr2 gene activity. Also, the Left Anterior Descending Coronary Artery of male 
Fpr2/3 KO and littermate controls (WT) was occluded for 30min and re-opened for 
90min. At the end tissue injury and inflammatory response were studied. 
 
A significant proportion of Fpr2/3 KO perished during the procedure. The rest 
survived up to 90 min and exhibited a larger infarct size, with higher troponin I and 
inflammation markers (KC, TNFα) than WT animals. At the end of reperfusion, 
Fpr2/3 KO displayed an unbalanced production of pro and anti-inflammatory lipids 
(higher PGE2, PGI2, LTB4 and attenuated PGA1, RvD2, LXA4) and a deregulated 
activation of the cardioprotective IL-6/JAK/STAT3 signalling. Administration of 
AnxA1 afforded cardioprotection (reduction of infarct size; Troponin I, Caspase3 
activity and TNFα) in WT but not in Fpr2/3 KO.  
 
A parallel in vitro investigation on the functional FPR2/ALX domains required by 
AnxA1 and other agonists was also conducted. HEK-293 cells transfected with 
FPR1, FPR2/ALX and FPR1/FPR2 chimeric receptor were used and calcium flux, 
 4 
pERK and gene modulation analysed. AnxA1 required the N-terminus and the II 
and III extracellular loops of FPR2/ALX to evoke canonical responses. SAA 
interacted/activated the I and the II extracellular loops of FPR2/ALX, whereas the 
compound 43 suffices the I extracellular loop.  
 
In summary, the FPR2/AnxA1 pathway exerts a protective role in AMI. AnxA1 
mimetic that activated selective FPR2/ALX domains can be synthetize to prevent 
tissue damage caused by AMI. 
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Coronary Heart Diseases (CHD), diseases of the blood vessels supplying the heart 
muscle, are one of the leading causes of death and disability in the world. 
According to the WHO (World Health Organization), 7.3 million people died from 
CHD in 2008 (Mathers and Loncar 2006). The effects of CHD are usually 
attributable to acute myocardial ischemia-reperfusion injury (IRI) (Mathers and 
Loncar 2006).   
 
In patients affected by acute myocardial infarct (AMI) the most effective therapeutic 
intervention for reducing IRI and limiting heart damage is timely myocardial 
reperfusion using either thrombolytic therapy or primary percutaneous coronary 
intervention (PPCI). However, reperfusion is a double-edged sword. It can itself 
induce further cardiomyocyte death, a phenomenon known as myocardial 
reperfusion injury.  One of the main characteristics of reperfusion injury is a marked 
prolongation of the inflammatory response initiated during ischemia. For this 
reason, in myocardial ischemia-reperfusion injury, inflammation is a prerequisite for 
healing (Moens, Claeys et al. 2005) but it can paradoxically also extend tissue 
injury, hence it needs to be modulated. A greater understanding of this disease and 
how inflammation is involved should lead to more effective treatments. 
 
It is now appreciated that the termination of an acute inflammatory response is not 
just a passive process but relies on the active involvement of pro-resolving 
mediators, which constrain the host reaction avoiding over-shooting and self-
inflicted tissue damage (Serhan and Savill 2005, Serhan, Brain et al. 2007). 
Following this idea, appreciation of the mediators operative in the area of resolution 
of inflammation for AMI is emerging, and these include the protein Annexin A1 
 23 
(AnxA1; (Perretti and D'Acquisto 2009) and its receptor, the G protein coupled 
receptor termed formyl peptide receptor type 2 (FPR2 (Ye, Boulay et al. 2009)), 
though as yet there is little in-vivo evidence for their modulatory functions.  
 
AnxA1 is able to influence polymorphonuclear leukocyte (PMN) and macrophage 
biology.  
 
This mediator is a potent inhibitor of PMN interaction with the vascular endothelium 
(Hayhoe, Kamal et al. 2006) and promotes PMN apoptosis (Solito, Kamal et al. 
2003). In addition, AnxA1 promotes efferocytosis of dead/dying PMNs by 
macrophages (Scannell, Flanagan et al. 2007), which is central to the restoration of 
tissue homeostasis. The anti-inflammatory properties of this mediator converge 
onto FPR2/ALX, which will be extensively studied in this work using an 
experimental myocardial infarct model in mice. Indeed, human FPR2/ALX exhibits 
homology to 2 mouse genes, termed frp2 (74% of homology) and fpr3 (76% 
homology). 
Here we investigated the role of the receptor FPR2 and its agonist in AMI, 
exploring also damage in secondary organs such as the lung and the kidney. The 
potential anti-inflammatory properties evoked by FPR2 activation appears to play 
an important role in affording protection in ischemia reperfusion injury and may 
lead to potential development of novel therapeutic targets.  
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1.1 INFLAMMATION 
 
1.1.1 Overview  
Inflammation (from latin, inflammare, to set on fire) is the body’s first system of 
alarm signals that are used for the containment and elimination of microbial 
invaders after infection or injury (such us heat or cold exposure, 
ischemia/reperfusion injury, trauma, etc.). The body attempts to restore the tissue 
to its preinjury state. Uncontrolled inflammation has emerged as a pathophysiologic 
basis to many disease such us cardiovascular and neurodegenerative diseases 
and cancer progression. To better manage diagnosis, treatment and prevention of 
these diseases, multidisciplinary research is under way.  
 
The first recorded observation of the inflammatory process was described by 
Aristotele (384-322 BC) as an imbalance of four humours: earth, fire, wet and cold. 
Next, at the time of Hippocrates (460-380 BC), inflammation was also called 
phlegmone’, which translates loosely to “the burning thing”. The Roman Cornelius 
Celsus (30 BC – 38 AD), in the first century, is credited as first documenting the 
four cardinal signs of inflammation: Rubor, Tumor, Calor and Dolor (redness, 
swelling, heat and pain)(Rocha e Silva 1978). In the next years the fifth of the 
cardinal signs of inflammation, the functio laesa (loss of function), was added by 
Galen (129-207 AD), even though the attribution is disputed. It has also been 
ascribed to Thomas Sydenham (1624-1689 AD) and Rudolph Virchow (1821-1902 
AD)(Benaroyo 1994).   
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In 1908, Metchnikoff (1845-1916) described inflammation as a “defensive cellular 
response to pathogens, guided by the vessels rather than an aspect of the 
pathology itself” (Karnovsky 1981). This represented the first basic definition of 
inflammation. Subsequently the biological cell-based definition of inflammation was 
revolutionized by William Harvey (1578-1657), who first described the circulatory 
system in accurate details, and by the discoveries in microscopy and cell biology of 
the 19th century. The biochemical definition of inflammation was brought forward in 
1974, by Rocha and Silva, who described inflammation as a “multi-mediated 
phenomenon, of a pattern type in which all mediators would come and go at the 
appropriate moment, increasing vascular permeability, attracting leukocyte, 
producing pain, local edema and necrosis” (Ryan and Majno 1977). 
 
In 2012, the contemporary definition of inflammation is as follow: 
“Acute inflammation is the immediate defensive reaction of tissue to any injury, 
which may be caused by infection, chemicals or physical agents. It involves pain, 
heat, redness, swelling and loss of function of the affected part. Blood vessels near 
the site of injury are dilated, so that blood flow is locally increased. White blood 
cells enter the tissue and begin to engulf bacteria and other foreign particles. 
Similar cells from the tissues remove and consume the dead cells, sometimes with 
the production of pus, enabling the process of healing to commence. In certain 
circumstances healing does not occur and chronic inflammation ensues”. Concise 
Medical Dictionary. Oxford University Press 
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1.1.2 The inflammatory response 
The inflammatory response consists of an innate system of cellular and humoral 
responses following injury, infection or tissue stress or malfunction (Medzhitov 
2008). The acute inflammatory response begins within seconds to minutes 
following injury. Tissue-resident macrophages upon recognition and activation by 
pathogens generate pro-inflammatory mediators (Ryan and Majno 1977, Nathan 
2002). These include chemokines (Interleukin 8, IL-8), cytokines (Tumour Necrosis 
Factor α, TNF-α and Interleukin 1β, IL-1β), cell adhesion molecules (CAMs), lipid-
derived eicosanoids (prostaglandins and leukotrienes) and vasoactive amines. This 
event leads to endothelial cell activation, stimulating the exposure of adhesion 
molecules on the luminal surface of the endothelium and promoting leukocyte 
migration from the circulation to the damaged sites (Ryan and Majno 1977).   
Neutrophils, the most abundant leukocytes in the blood (Witko-Sarsat, Rieu et al. 
2000), are the first to be recruited from the blood vessels to inflamed tissue. Their 
recruitment requires the canonical steps of rolling, activation, firm adhesion and 
transmigration (Witko-Sarsat, Rieu et al. 2000). The leukocyte interaction with the 
endothelium occurs mostly in the veins (39%) instead of the arteries (0.6%) 
(McEver and Cummings 1997); rolling is characterized by weak adhesion between 
neutrophils or monocytes and the endothelial cell wall. L-selectin, expressed on 
leukocytes, regulates the first step of cell rolling. Inflamed endothelial cells and 
platelets express E and P-selectin. P-selectin interacts with P-selectin glycoprotein 
ligand 1 (PSGL1), located at the tip of leukocyte microvilli (McEver and Cummings 
1997). E-selectin binds to E-selectin ligand 1, which is highly homologous to the 
cysteine-rich FGF receptor located on neutrophil microvilli, and to the proteoglycan 
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CD44 (Hidalgo, Peired et al. 2007). The ‘slow rolling’ phase involves E-selectin and 
β2-integrins. Upon activation, integrins switch from the default low-affinity state to 
the high affinity-state (Jung, Ramos et al. 1998). The most important integrins 
involved in the process of cell adhesion are those of the β2 family such as, for 
example, lymphocyte function-associated antigen 1 (LFA1, αLβ2-integrin) - that 
binds ICAM-1 and ICAM-2 (cell adhesion molecules) and macrophage receptor 1 
(MAC1, also known as CD11b/CD18, α4β1-integrin) that binds ICAM-1 and CD11c.  
There is also the ligand very-late antigen 4 (VLA4; of the β1 family) that binds 
ICAM-1 and promotes chemotaxis (Dunne, Ballantyne et al. 2002). Upon binding to 
their counter-ligand, integrins lead to “inside-out signaling”; in this cellular response, 
β2 integrins migrate from the cytosol to the cell surface and congregate in high-
avidity patches that interact with the leukocyte cytoskeleton through cytosolic 
factors such as talin, α-actinin, kindlin and vinculin (Dustin and Springer 1989, 
Laudanna, Kim et al. 2002). The firm adhesion phase is followed by a shape 
change in migrating leukocytes and endothelial cells that allows the transmigration 
of the leukocytes through the endothelium, a process termed diapedesis. The 
integrin-mediated leukocyte transmigration also requires polarization of the cell 
body, formation of a lamellipodium at the leading edge and a uropod at the tail of 
the leukocyte. This process is mediated by endothelial PECAM-1 (Platelet 
endothelial cell adhesion molecule), JAMs (junctional adhesion molecule) and 
CD99 (Wehrle-Haller and Imhof 2002, Ridley, Schwartz et al. 2003). In the 
interstitial fluid, leukocytes followed by monocytes and lymphocytes, migrate along 
a chemotactic gradient towards the site of injury (Medzhitov 2008). Neutrophils 
release the toxic contain of their granules, composed by reactive oxygen and 
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nitrogen species, proteinase 3, cathepsin G and elastase, to kill the invading agent 
(Nathan 2006). The switch from PMN to mononuclear cells bridges the initial pro-
inflammatory response with the activation of pro-resolution mediators involved in 
clearance, tissue remodeling and repair. Pro-inflammatory prostaglandins switch to 
resolvins, that initiate the tissues repair and lipoxins, able to inhibits neutrophils 
recruitment and promote monocytes infiltration. Monocytes are particularly 
important in this phase thanks to their ability to differentiate into professional 
antigen presenting cells (APC), such as M2 macrophages (Kantari, Pederzoli-
Ribeil et al. 2008, Mills 2012) or dendritic cells that produce an anti-inflammatory 
environment (Bellingan, Caldwell et al. 1996, Schmidt, Nino-Castro et al. 2012). In 
the resolving phase leukocytes are removed either via the lymphatics or by 
apoptosis and phagocytic clearance, and the increased vascular permeability is 
reversed due to closure of the open inter-endothelial junctions. In both vascular 
and extravascular compartments, fibrin deposits are removed by plasminogen.  
 
Following all these steps, the on-going acute inflammation response, which may 
last from 15 minutes to several hours or days, is terminated. If this response is not 
completely removed – or resolved - then chronic inflammation might arise leading 
to a variety of disorders. Examples include rheumatoid arthritis, asthma, chronic 
obstructive pulmonary disease, multiple sclerosis, Crohn’s disease, ulcerative 
colitis and some cancers (e.g., gall bladder carcinoma), acne vulgaris, chronic 
prostatitis, glomerulonephritis, psoriasis, pelvic inflammatory disease and vasculitis 
or myopathies. Also degenerative disease such as atherosclerosis, Alzheimer’s 
and obesity are also characterized by the presence of a chronic inflammation 
process.  
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In summary, acute inflammation is a tissue reaction to injury characterized by 
dilation of blood vessels and consequent cells exudation acting to repair the 
damage. Chronic inflammation, might be defined as the persistence of acute 
inflammation or as the persistent engagement of innate and acquired immune 
response.  
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1.1.2 Lipid mediators in Acute Inflammation and Resolution 
Inflammation triggers the production of different inflammatory mediators that have 
affects on the vasculature, on the recruitment of leukocytes or can alter the 
functionality of tissues and organs. Inflammatory mediators can be classified into 
seven group according to their biochemical properties: vasoactive amines, 
vasoactive peptides, fragment of complement components, lipids mediator, 
cytokines, chemokines and proteolytic enzymes (Medzhitov 2008). Vasoactive 
amines (histamine and serotonin) are released from mast cells and platelets 
degranulation (Spector and Willoughby, 1964). Vasoactive peptides can be stored 
in secretory vesicles (substance P) or generated by proteolytic processing of 
inactive precursors in the extracellular fluid (kinins, fibrinopeptide A or B and fibrin 
degradation products) (Gonzalez-Rey and Delgado 2005). Both vasoactive amines 
and peptide induce mast cells degranulation, an increase in vascular permeability 
and vasodilatation or constriction. The complement fragments, the anaphylatoxins 
(C3a, C4a and C5a), are produced by complement activation and they promote 
granulocyte and monocyte recruitment and mast cells degranulation, thereby 
affecting the vasculature (Haas and van Strijp 2007). Cytokines (e.g. TNFa, IL-6, 
IL-1) are produced by different cell types, especially macrophages and mast cells 
and they have different roles including leukocytes and endothelium activation. 
Chemokines (e.g. neutrophil chemoattractant KC, monocyte chemoattractant 
protein-1 MCP1), produced by many cells in response to inflammation control 
leukocytes chemotaxis towards the affected tissues. Proteolytic enzymes (elastin, 
cathepsins and matrix metalloproteinases) degrading the extracellular matrix 
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(ECM), are important in host defence, tissue remodelling and leukocytes migration 
(Medzhitov, 2008). 
 
There are two classes of lipid mediators: eicosanoids and platelet-activating factors. 
Platelet-activating factors are generated by the acetylation of lysophosphatidic acid 
and activate several processes that occur during the inflammatory response, 
including leukocytes recruitment, vasodilatation and constriction, increase in 
vascular permeability and platelet activation (Yost, Weyrich et al. 2010). 
Eicosanoids are arachidonic acid-derived autacoids, locally acting substance that 
are rapidly synthesized in response to specific stimuli, and are involved in 
inflammation, cardiovascular and reproductive physiology.  
 
Arachidonic acid (AA), an omega-6 PUFA (polyunsaturated fatty acid), is released 
from phospholipids that are present in the inner leaflet of cellular membranes by 
phospholipase A2 (PLA2) that hydrolysed the acyl ester bond. PLA2 can be 
membrane-bound or secretory (sPLA2) and soluble in the cytoplasm (cPLA2). AA 
can also be synthesized from the essential fatty acid precursor linoleic acid, which 
can be obtained only from dietary sources. Next, arachidonic acid is metabolized to 
eicosanoids by cyclooxygenases (COX), lipoxygenase (LOX) or epoxygenase 
(cytP450) enzymes that dictate the class of eicosanoids generated (Figure 1A).  
 
The COX pathway produces prostaglandins, prostacyclin and thromboxane. COX 
(also know as prostaglandin H), exists in two isoform: the constitutive COX1 and 
the inducible COX2. Each COX catalyses the cyclization of AA into prostaglandin 
G2 (PG2) that is reduced to PGH2, the last unstable common mediator of this 
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pathway. Tissue-specific enzyme expression determines the tissues in which the 
various PGH2 are produced. All prostaglandins share the same chemical structure 
characterized by 20-carbon carboxylic acid containing a cyclopentane ring and a 
15-hydroxyl group, and are divided in three groups: PG1, PG2 and PG3 depending 
on the number of double bonds in the molecule. PG2 series is the direct product of 
AA, PG1 series derived from the dihomo-ϒ-linoleic acid (DHGLA) and the PG3 one 
derive from eicosapentaenoic acid (EPA).  
 
Prostaglandins are involved in inflammation and different physiological processes 
(Ricciotti and FitzGerald 2011) (Figure 1B). For example PGD2 induces 
bronchoconstriction and controls the sleep function and PGE2 is a vasodilatator, 
induces inflammatory cells activation and mucus protection. PGF2α is involved in 
the reproductive physiology. Thromboxane (TXA2) is produced in platelet by the 
thromboxane synthase and acts as vasoconstrictor and agonist of platelet 
aggregation. Prostacyclin (PGI2) is the primary product of vascular endothelium 
function as vasodilator and inhibitor of platelet aggregation. It is clear that TXA2 
and PGI2 are critical in the regulation of the blood pressure and thrombogenesis. 
An unbalance of TXA2 and PGI2 can lead to hypertension, ischemia, thrombosis 
and AMI. 
 
The LOX pathway produces leukotrienes and lipoxins through the lipoxygenase 
(LOX) 5, 12 and 15, enzymes able to add a molecular oxygen into arachidonic acid. 
Leukotrienes are biosynthetised by the 5-LOX that convert the AA into 5 
hydroperoxyyeicosatetraenoic acid (HPETE) and further into leukotriene A4 (LTA4). 
LTA4 is then converted to either LTB4 or LTC4 depending on the cells type. LTB4 is 
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produced in neutrophils, erythrocytes, macrophages and monocytes and leads to 
neutrophils chemotaxis, aggregation and transmigration and free radical and 
cytokines production. LTC4, synthetized in mast cells, eosinophils and 
macrophages and it can be cleaved by peptidases to generates the cystenyl 
leukotrienes: LTD4 and LTE4. They cause vasoconstriction, bronchospasm and 
increase in vascular permeability. Lipoxins (LXA4 and LXB4) are important in 
resolution, decreasing neutrophil infiltration and transmigration, inhibiting 
eosinophil recruitment, stimulating vasodilatation through the synthesis of PGI2 
and PGE2 and counteracting pro inflammatory mediators. They are synthesised by 
the 15-LOX and 5-LOX. Both cysteinyl leukotrienes and lipoxins are generated by 
transcellular biosynthesis between neutrophils and platelets or neutrophils and 
endothelial cells (Serhan 1997)(Figure 1B).  
 
The cytP450 is involved in the production of epoxyeicosatetraenoic acids (EET). It 
is important in the regulation of smooth muscle cells, vascular tone and renal 
function.  
 
Recently, two new families of bioactive mediators byosynthesized from omega-3 
essential PUFAs have been discovered, and named the resolvins and the 
protectins (Kohli and Levy 2009).   
Resolvins (resolution phase interaction products) derived from EPA and 
docosahexaenoic acid (DHA) with two different chemicals structure: the E-series 
and D-series (Figure 2). Resolvin E1 and E2 are potent anti-inflammatory 
mediators (decrease neutrophils infiltration and TNF-α activity) thoughts EPA, 18-
HEPE and 5-LOX. D-series resolvins have the same anti-inflammatory role and 
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synthesis but they first derive from DHA (Serhan, Hong et al. 2002). Aspirin 
increase their production (Oh, Vickery et al. 2011, Dalli, Winkler et al. 2013).  
Protectins are biosynthesized via a LOX mechanism that converts DHA to protectin 
D1, an anti inflammatory mediators that blocks T-cell migration and promotes T-cell 
apoptosis.  
 
Research over the past 10 years has demonstrated the physiological benefits of 
increasing dietary consumption of omega-3 PUFAs by promoting the resolution of 
the inflammatory cycle.  Moreover, considerable research supported 
cardiovascular benefits of consuming fish or fish oil containing the omega-3 
eicosapentaenoic acid and docosahexaenoic acid. Both PUFAs reduce ex vivo 
platelet aggregation and are associated with lower risk of fatal cardiac events. DHA 
also modulates LDL and HDL particle sizes and decrease the risk of atrial 
fibrillation (Mozaffarian and Wu 2012). Interesting the American Heart Association 
recommends, after randomized control trials (RCTs), to eat 1g/day of EPA and 
DHA from oily fish or supplements to people with coronary heart disease. 
Consumption of the oily fish twice per week should also be used as prevention 
(<1g/day) (Breslow 2006).  However, higher levels of omega-3 PUFA exert 
suppressive effects on the immune system (Simopoulos 2002). In line with that and 
considering also the dietary sources of omega-6, the omega-6/omega-3 fatty acid 
ratio became important in cardiovascular and other diseases.  
 
Omega-6 fatty acids are found in vegetable oils, nuts and seeds. For example, 
linoleic acid is the primary dietary omega-6 PUFA. After consumption, LA is 
metabolized in γ-linolenic and dihomo-γ-linolenic acids and the latter is converted 
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in the most metabolically important omega-6 PUFA: the arachidonic acid. As said 
before, AA is the substrate for the production of a wide variety of eicosanoids: 
some proinflammatory and some anti-inflammatory (Harris, Mozaffarian et al. 
2009). Excessive amounts of omega-6 PUFA and a very high omega-6/omega-3 
ratio promote the pathogenesis of cardiovascular disease, cancer, and 
inflammatory and autoimmune diseases. On the other hand, as said before, a 
lower omega-6/omega-3 ratio (higher omega-3), exert immune-suppressive effects. 
In the prevention of cardiovascular disease, a ratio of 4/1 of omega6/3 is the 
preferred (70% decrease of mortality). A ratio of 2–3/1 is beneficial in inflammatory 
diseases (Simopoulos 2008).  
 
 
 
 36 
 
 
 
Figure 1: The arachidonic acid pathway 
(A) The arachidonic acid released from the phospholipid by the enzyme PLA2 is the substrate for 
cyclooxygenase, lipoxygenase and epoxygenase. The product of these reactions proceeds through 
a further sequence of enzymatic reactions to produce prostaglandin, prostacyclin and thromboxane 
(COX pathway), leukotrienes and lipoxins (LOX pathway) or epoxyeicosatetraenoic acids (EET) 
(CytP450 pathway). (B) Example of metabolites derived from the COX and LOX pathways with their 
effects of human physiology.  
 
 37 
 
 
 
 
 
 
Figure 2: The resolvins pathway 
Two of the major types of omega-3 fatty acids are the eicosapentaenoic acid (EPA) and the 
docosahexaenoic acid (DHA) precursors, thought enzymatic reactions, for potent anti-inflammatory 
lipids called resolvins (Rvs) and maresins (MaR). 
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1.1.3 “The beginning programs the end” 
The usual outcome of the acute inflammatory response is resolution and repair of 
tissue damage, and it can be divided into three phases: onset, transition and 
resolution (Serhan and Savill 2005). If resolution is not completed acute 
inflammation may became chronic. In the initial onset phase there is a release of 
inflammatory mediators from local tissues and resident cells. This induces 
leukocyte migration to the site of inflammation, which peaks during the transition 
phase (Serhan and Savill 2005). In the early phase pro-inflammatory mediators are 
released, which initiate the acute-phase of the inflammatory response. However, 
this is counterbalanced by endogenous anti-inflammatory signals (Serhan and 
Savill 2005) such as corticosterone (or cortisol in man), which serve to temper the 
severity and limit the duration of the early onset phase.  
 
Besides cortisol and corticosterone, during the progression of the inflammatory 
response some “stop signals” are activated. They are important to prevent further 
leukocyte traffic into the tissue (Serhan and Savill 2005). Examples of stop signals 
are the process of apoptosis and down regulation of pro-inflammatory molecules, 
such as leukotrienes, or desensitization of receptors by high concentration of 
ligands. This phase is also characterized by the release of anti-inflammatory 
molecules such us lipoxins, resolvins (Serhan 2008), IL-10 (Sato, Ohshima et al. 
1999) and prostaglandins (PGs) of the D series (Luster, Alon et al. 2005).  
 
Along this line is the concept that in the resolution phase is not just a passive 
process. The balance of pro-resolving mediators (Lawrence, Willoughby et al. 
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2002) and pathways outweighs the pro-inflammatory, resulting in suppression of 
pro-inflammatory gene expression and cell trafficking, clearance of pathogens and 
apoptotic cells and recovery of homeostasis (Serhan 2004, Serhan and Savill 2005, 
Serhan, Brain et al. 2007), which is lost when this balance is broken. Pro-resolving 
endogenous mediators assure temporal and spatial containment of the host 
reaction (Serhan and Savill 2005, Nathan 2006).  
 
LXA4 and AnxA1, together with the receptor, formyl peptide receptor type 2 
(acronym FPR2/ALX), represent some of the endogenous anti-inflammatory 
mediators involved in the resolution process (Perretti and D'Acquisto 2009, Dufton 
and Perretti 2010).  Moreover, although they are very different in their chemical 
nature, synthetic modalities (produced on demand or stored in cell sources), 
catabolism and half-lives, they share similar pro-resolving properties upon binding 
to the same receptor (Dufton, Hannon et al. 2010). LXA4 and AnxA1 are able to 
stop the process of leukocyte migration (Perretti and D'Acquisto 2009), promote 
macrophage phagocytosis of infective agents and remove apoptotic leukocytes 
(Godson, Mitchell et al. 2000, Oliani, Christian et al. 2000). AnxA1 is also able to 
convey some inhibitory signals to mast cells (Oliani, Christian et al. 2000) which 
are sensitive to fMLF and involved in the pro-inflammatory phase. 
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1.2   ACUTE MYOCARDIAL INFARCT (AMI) 
 
1.2.1 AMI aetiology and pathogenesis 
Ischemic heart disease, stemming from coronary artery disease and Acute 
Myocardial Infarction (AMI), is the largest single cause of death worldwide (Murray 
and Lopez 1997, Bell and Yellon 2011).   
Acute myocardial infarction is an irreversible myocardial injury resulting in necrosis 
of a portion of myocardium bigger then 1 cm causing a reduction of its function. 
Several studies have recognized the high impact that AMI has on patient morbidity 
and mortality through the development of heart failure and arrhythmias (Moens, 
Claeys et al. 2005). 
The necrosis is generally endocardium-based, secondary to occlusion of an 
epicardial artery and located around the occluded vessel with a consequent lack of 
oxygen supply (Burke and Virmani 2007). The lack of blood flow is mainly due to 
acute thrombus overlying atherosclerotic plaque (Arbustini, Dal Bello et al. 1999). 
Atheroma or other obstructions can also be the cause. In the majority of patients, 
there is obstructive coronary disease at angiography. Hearts usually have a left 
coronary dominance (15% of the population). Left main coronary artery occlusion 
results in an anterolateral infarct, whereas occlusion of the left anterior descending 
coronary artery causes are limited to the anterior wall. In hearts with a right 
coronary dominance (with the right artery supplying the posterior descending 
branch), a right coronary artery occlusion causes an inferior infarct. However, 
unusual patterns of vessels supplying of the heart may also result in unexpected 
areas of infarct.  
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Non-reperfusion myocardial infarct, characterized by a permanent occlusion of the 
blood flow, also exists.  
There are many risk factors that predispose to coronary artery disease. These 
include genetic polymorphisms involved in atherogenesis, coagulation, lipid 
metabolism, inflammation and in the renin-angiotensis-aldosterone system 
(Shiffman, Rowland et al. 2006). 
 
The symptoms are chest pain, which may radiate to the arm, sweating, nausea and 
chest tightness or pressure. The diagnosis is based on laboratory findings of 
necrosis of the myocardium, which causes leaking of myocardial enzymes, such us 
troponin, into the circulation. Acute infarcts are divided into ST-elevation 
myocardial infarction (STEMI) and non ST-elevation infarction (non-STEMI). 
STEMI is the result of blockage of a coronary artery with large amount of cardiac 
enzyme in the serum and Q waves in the electrocardiogram (ECG). Modest 
elevation of cardiac enzymes and small or patchy areas of necrosis characterize 
the non-STEMI infarct, often overlapped with the acute coronary syndrome 
unstable angina. 
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1.2.2 The contribution of inflammation to AMI  
AMI is characterized by ischemia and subsequent reperfusion of the myocardium. 
Rapid restoration of blood flow within the first 2-3 h from onset of chest pain (Gersh, 
Stone et al. 2005) is essential to recover the affected area of the myocardium (Fu, 
Goodman et al. 2001). This reperfusion phase, together with the ischemic and 
post-ischemic inflammatory response (Frangogiannis, Smith et al. 2002), enhances 
structural and functional recovery of the heart, preserving left ventricular function, 
and improves survival, preventing the onset of heart failure (Di Napoli, Taccardi et 
al. 2002). However, it is a paradox that reperfusion itself is also responsible for 
myocardial damage. Reperfusion is characterized by ROS release (Kumar, Okuda 
et al. 1990) and intracellular accumulation of calcium (Coetzee and Opie 1992) 
leading to mitochondrial depolarization and breakdown (Lichtig and Brooks 1975), 
ATP depletion, contraction-band necrosis (Rodriguez-Sinovas, Abdallah et al. 
2007) and an extended and increased inflammatory process initiated within the 
ischemia phase (Lefer and Granger 2000, Poon, Ward et al. 2001). Inflammatory 
processes including cytokine production, complement activation (Hill and Ward 
1971) and tissue PMN infiltration (Romson, Hook et al. 1983, Carden and Granger 
2000) play a major role in the extension of myocardial injury.  At 12 hours after the 
onset of the chest pain the myocardium is characterized by hypereosinophilia 
leading to endomyocardial fibrosis, without the presence of the primary causes of 
eosinophilia (Ogbogu, Rosing et al. 2007, Gurgun, Tuluce et al. 2011), followed by 
neutrophil infiltration at 24h. Macrophages begin to appear by day 2-3 post-
ischemia.  
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It is clear that inflammation, in acute myocardial infarct, is a prerequisite for healing 
(Richard, Murry et al. 1995) but it can paradoxically also extend myocardial injury 
leading to the phenomenon called “lethal reperfusion injury”. The infarcted heart 
displays signs of inflammation that, unless resolved, lead to long-term tissue 
damage.   
 
It is for this reason that emerging therapeutics strategies have been focused on the 
inflammatory response. Experimental animal studies with compounds that inhibits 
inflammation such as lipoxygenase inhibitors, LTB4 antagonists (Shappell, Taylor 
et al. 1990), free radical scavengers (Jolly, Kane et al. 1984), anti-neutrophil 
antibodies (Romson, Hook et al. 1983) or neutrophil depleting antimetabolites 
(Mullane, Read et al. 1984) have demonstrated statistical reduction of ischemia 
reperfusion injury.  However, in some cases anti-inflammatory drugs have 
produced critical results in clinical investigations. For example, administration of 
corticosteroids was shown to decrease leukocyte infiltration and infarct size (Libby, 
Maroko et al. 1973, Versaci, Gaspardone et al. 2002) but also lead to ventricular 
arrhythmias and collagen deposition delaying the healing process (Roberts, 
DeMello et al. 1976, Kloner, Fishbein et al. 1978, Solomon, Schneeweiss et al. 
2004, Hippisley-Cox and Coupland 2005, Nussmeier, Whelton et al. 2005).  
 
Thus, there is a need for a better understanding of the mediators involved in the 
inflammatory response after myocardial infarct in order to develop more specific 
interventions that could mitigate inflammatory injury during early reperfusion 
without interfering with myocardial healing. It is now appreciated that the acute 
inflammatory response is not simply a passive process, but relies on the active 
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involvement of pro-resolving mediators which assure the containment of the host 
reaction (Serhan and Savill 2005, Serhan, Brain et al. 2007), in line with the 
concept that “the beginning programs the end”, recently put forward (Serhan and 
Savill 2005). Hence, promoting endogenous anti-inflammatory mediators may 
represent an alternative approach to the treatment of the ischemic diseases; where 
the pro-resolving mediators of the inflammatory response can be targets to reduce 
myocardial ischemia and reperfusion injury (Steffens, Montecucco et al. 2009).  
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1.2.3 The cardioprotective IL-6/JAK/STAT3 pathway 
Plasma levels of pro-inflammatory cytokines, such us IL-6, TNF-α and IL-1β are 
elevated after myocardial infarct (Munkvad, Gram et al. 1991, Guillen, Blanes et al. 
1995, Manginas, Bei et al. 2005). These cytokines play an important role in the 
modulation of the inflammatory response after AMI and are associated with left 
ventricle remodelling (Ono, Matsumori et al. 1999, Hayashidani, Tsutsui et al. 2003, 
Dewald, Zymek et al. 2005). Among these cytokines IL-6 plays an important role in 
AMI. 
 
IL-6 is only one of the members of a large IL-6 family that includes leukaemia 
inhibitory factor (LIF), cardiotrophin 1 (CT-1), oncostatin M (OSM), cilliary 
neurotrophic factor (CNTF), IL-11 and IL-27 which share the common receptor 
subunit gp130 for signalling.  
 
IL-6 secreted by macrophages, T cells (Hagiwara, Abbasi et al. 1995) and cardiac 
neutrophils (Neumann, Ott et al. 1995) levels are upregulated in both plasma and 
heart after AMI (Deten, Volz et al. 2002, Kaminski, Kozuch et al. 2009) and are 
also prognostic markers for morbidity and mortality. Administration of IL-6 
antagonists affords beneficial effects on the development of left ventricular 
remodelling after AMI (Kobara, Noda et al. 2010).  IL-6 activates cells by binding to 
the α-subunits of the membrane-bound receptor (mIL-6R) and the soluble form sIL-
6R and inducing homodimerization of signal-transducing gp130 molecules (Taga, 
Hibi et al. 1989). In the infarcted myocardium, the major IL-6R expressing cells are 
neutrophils and monocytes. Moreover, plasma levels of sIL-6R in patients with AMI 
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are elevated, leading to activation of gp130-expressing cells including cardiac 
myocytes (Kimura, Kanda et al. 2000). 
Homodimerization of the gp130 receptor β-subunits or heterodimerization of gp130 
with either the LIF or OSM receptor subunits leads to the activation of intracellular 
signalling cascades including the Janus kinase/signal transducer and activator of 
transcription (JAK/STAT), Ras/mitogen-activated protein kinase (MAPK) and 
phosphatidylinositol-3-kinase pathways (Fischer and Hilfiker-Kleiner 2008). The  
protein-tyrosine phosphatase/extracellular-signal-regulated kinases (SHP2/ERK) 
and STAT pathways play an important roles in cardiac development, hypertrophy, 
protection and remodeling in response to physiological and pathophysiological 
stimuli (Fischer and Hilfiker-Kleiner 2008). 
 
The contribution of ERK1/2, PI3K/Akt and JAK/STAT signalling to cardiomyocyte 
hypertrophy and survival is complex. ERK1/2 and PI3K play an important role in 
regulating hypertrophic gene expression and aspects of myofilament remodelling, 
whereas JAK/STAT activation may be important in myofilament organization 
(Fischer and Hilfiker-Kleiner 2008). However, although new evidence suggests that 
ERK1/2 and PI3K activation by IL-6 are sufficient for cardioprotective activity (Bolli, 
Stein et al. 2011), the JAK/STAT3 pathway, with a particular role for STAT3, is the 
most recognized for its beneficial role in AMI (Negoro, Kunisada et al. 2000). 
 
Four JAKs and seven STATs have been identified. JAK1, JAK2 and TYK2 
(Tyrosine Kinase 2) are present in cardiomyocytes, JAK3 in the thymus (Pan, 
Fukuda et al. 1999). All seven STATs (STAT1, STAT2 STAT3, STAT4, STAT5A 
STAT5B and STAT6) are expressed in, endothelial cells smooth muscle cells, 
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cardiac fibroblast and cardiomyocytes (Xuan, Guo et al. 2001). STAT3 is the more 
likely to be involved in cardioprotection, especially after ischemia reperfusion injury. 
STAT3 activation has positive effects on infarct size, since it leads to anti-apoptotic 
activity and up-regulates the COX-2 enzyme (Xuan, Guo et al. 2003), which 
confers protection. STAT3 also induces heme oxygenase-1, which has been 
recognized as a major cardioprotective and anti-apoptotic enzyme (Vulapalli, Chen 
et al. 2002). In addition, various anti-apoptotic proteins, involved in the 
mitochondria-mediated pathway of apoptosis, are known to be transcriptionally 
regulated by STAT1/3 (Fujio, Kunisada et al. 1997, Haga, Terui et al. 2003).  
 
Upon activation, STATs are also able to bind to the promoter region of SOC genes 
(suppressors of cytokine signalling) and up-regulate the transcription of target 
genes (Cooney 2002). Importantly, SOC3 down regulates IL-6 (Croker, Krebs et al. 
2003) and modulate its ability to increase infiltrated cells that represent an 
exacerbating factor in left ventricle remodelling after AMI. Indeed, IL-6 induces 
intracellular adhesion molecule-1, resulting in the adhesion of neutrophils and 
increase in tissues myeloperoxidale (MPO) levels, and MCP1 expression and 
monocytes infiltration. Recent data suggest that IL-6/gp130 signalling through 
STAT3 might also mediate the anti-inflammatory effects of IL-10 (Williams, Sarma 
et al. 2007). 
 
A recent publication (Pupjalis, Goetsch et al. 2011) showed that the AnxA1 peptide 
Ac2-26, released by apoptotic cells, is able to activate the JAK/pTyrSTAT3/SOCs3 
signalling pathway reducing IL-6 signalling and release of TNFα from endotoxin-
challenged monocytes. The FPR2/ALX agonist WKYMVm can promote STAT3 
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serine, but not tyrosine, phosphorylation via ERK activation, blocking hydrogen 
peroxide-induced STAT3 activity, without concomitant JAK activation (Jo, Lee et al. 
2004). This is in line with the ability of chemokine and other agonists to induce the 
JAK/STAT signalling binding to seven-transmembrane G-protein-coupled receptors 
(Pelletier, Duhamel et al. 2003, Soriano, Serrano et al. 2003, Wu, Lo et al. 2003).  
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1.2.4 Current treatment for AMI 
Several approaches are being investigated for the prevention of cardiovascular 
diseases. Current therapies are antiplatelet agents, anticoagulants, vasodilators, 
diuretics, calcium-channel blockers, beta-blockers, angiotensin-converting enzyme 
(ACE) inhibitors and cardiac glycosides (Ryan, Antman et al. 1999, Siddiqui, 
Tandon et al. 2001, Braunwald 2012). However, there remains no effective 
therapeutic agent for preventing lethal myocardial reperfusion injury. 
 
During acute myocardial infarct the treatment is aimed to restore the balance 
between the oxygen supply and the demand to prevent further ischemia and the 
prevention and treatment of complications. Pain relief is also considered. 
According to the 2013 guidelines from the American College of Cardiology 
Foundation/American Heart Association (ACCF/AHA), the first approach is the use 
of aspirin to inhibit thrombolosis (Hennekens and Dalen 2013) and the supplement 
of oxygen (to maintain oxygen saturation >90%) to prevent hypoxemia. Then, 
STEMI and NSTEMI patients are treated in different way.  
 
Patients with STEMI are treated with thrombolysis or primary percutaneous 
transluminal coronary angioplasty (PTCA). NSTEMI patients receive anti-ischemic 
therapy (Antman, Anbe et al. 2004).  
 
Beta-adrenergic blockers, like metoprolol and atenolol, are a benefit for both. They 
reduce the rates of reinfarction and recurrent ischemia. ACE inhibitors are useful 
for long-term therapy: they reduce the mortality rates after myocardial infarction. A 
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combination of beta-adrenergic blockers and ACE inhibitors improve the balance 
between myocardial oxygen supply and demand and limit infarct size.  
 
Calcium channel blockers such as diltiazem and verapamil are used, in the 
absence of pulmonary edema, in patients where beta-adrenergic blockers are 
contraindicated. Recent studies showed that L-carnitine is able to limit the infarct 
size and to stabilize the cardiomyocyte membrane. L-carnitine reduces the 
mortality (27%) and ventricular arrhythmias (65%) (DiNicolantonio, Lavie et al. 
2013).  
 
In all cases morphine sulfate may be administered to relieve pain and anxiety. 
 
Even if inflammation play a major role during AMI and during the no-reflow 
phenomenon where good myocardial perfusion is not achieved despite drug 
treatments, only the anti-inflammatory drugs aspirin cited above is used in coronary 
artery diseases.  The effect of aspirin is due to an irreversible inhibition of COX-1 
and TXA2, a platelet aggregation factor, and to a reduction of the C-reactive protein, 
a clinical biomarker of risk of myocardial infarction (Ridker, Cushman et al. 1997). 
Inhibition of COX-2 in macrophages has been also suggested as another potential 
mechanism (Baker, Hall et al. 1999). 
 
However, non-steroidal anti-inflammatory drugs (NSAIDs) are associated with an 
increased risk of reinfarction, hypertension, heart failure, and myocardial rupture 
(Antman, Hand et al. 2008). Diclofenac and other NSAIDs, with the exception of 
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Naproxen, increase the risk of cardiovascular events in patients with established 
CHD (Schjerning Olsen, Fosbøl et al. 2011).  
 
For these reasons there is need for a better understanding of the role(s) of 
inflammation during reperfusion injury and a development of novel therapeutic 
approaches to the treatment of AMI. 
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1.2.5 Experimental models of AMI: relevance to humans 
Animal models of myocardial ischemia reperfusion mimic the clinical scenario 
where a period of ischemia is followed by the restoration of myocardial blood flow. 
U-shaped constrictors, ring-shaped hydraulic occluders or intracoronary balloon 
catheters are used in large animals (pigs, dogs). In mice, two methods are used to 
induce myocardial ischemia. One is to create cryo-infarction using a cryo-pen on 
the surface of the heart. This technique is somewhat inaccurate as the ischemia is 
not guaranteed and it leads to side effects that are not related to myocardial 
infarction (Atkins, Hueman et al. 1999, Kolk, Meyberg et al. 2009). The second 
method consists in ligation of the left anterior descending coronary artery (LADCA) 
(Michael, Entman et al. 1995) and has several advantages. The surgery is 
extremely fast, with a duration ranging only from 3 to 5 minutes. By occluding the 
LADCA, the ischemia can be detected immediately as no further blood flow is 
permitted in the left ventricle, while the surrounding myocardial tissue is almost 
unaffected. It allows induction of myocardial infarctions of varying degrees and 
long-term survival as needed (Michael, Entman et al. 1995). The mortality within 
the first 24 hours after surgery is 37 to 50%. Among the causes of death, at the 
beginning the main factors are related to the surgical procedure and they are 
pneumothorax and respiratory depression (Klocke, Tian et al. 2007). However, 
65% of deaths happens between 1.5 and 9 hours after LADCA occlusion and are 
caused by arrhythmias like ventricular tachycardia and ventricular fibrillation (Opitz, 
Mitchell et al. 1995).  
The LADCA model is preferred because it is generally accepted as the model that 
better shares the clinical and pathological features of AMI. Moreover, this protocol 
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allows comparative and quantitative studies on the pathobiological and 
pathophysiological aspects occurring in infarction-related myocardial ischemia. The 
studies of the mechanisms involved in coronary artery occlusion and reperfusion 
are essential to develop and optimize future treatment for this pathology. 
 
Here, the procedure of ischaemia and reperfusion is performed as described 
previously (Di Filippo, Rossi et al. 2004). Briefly, under anesthesia (Ketamine 
100mg/Kg and Xilazina 16mg/Kg) a midline cervical incision separating the skin, 
muscle and tissue covering the trachea is performed. Subsequently a hole is made 
between two cartridge rings below the glottis of the trachea - of mice kept at a body 
temperature by a homeothermic blanket – allowing cannulation to maintain artificial 
ventilation. The tidal volume of the respirator is set a 1.0 ml/min, with the rate set at 
110 strokes/min, and supplemented with 100% oxygen with no evidence of lungs 
or cardiovascular injury (Figure 3). 
 
 
 
Figure 3: Photograph of open-chest mouse with trachea canulation. 
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After an equilibration period of 10 min, the mouse is turned on its right side and a 
left thoracotomy is performed (between the fourth and the fifth ribs ~3 mm from the 
sternum) and the pericardium is removed to expose the heart. Subsequently a silk 
ligature (7-0) is placed around the LADCA, located between the pulmonary artery 
and the left auricle, for 30 minutes. Both ends of the ligature around the coronary 
artery are threaded through a small polythene button placed in contact with the 
heart. Coronary artery occlusion is achieved by applying tension to it and clamping 
the ligature against the button with a rubber-sheathed artery clip. After the 2h hours 
of reperfusion, blood and tissues are harvested and used for further analysis. 
 
Mice have a different septal coronary artery (Salto-Tellez, Yung Lim et al. 2004, 
Kumar, Hacker et al. 2005) but the ligation of the left coronary artery as it emerges 
from under the left atrium results in reproducible large infarctions (Salto-Tellez, 
Yung Lim et al. 2004, Kumar, Hacker et al. 2005) (Figure 4). The origin of the left 
coronary artery from the aorta up to 1-2 mm posterior to the left atrium is identical 
between C57BL/6 mice (Salto-Tellez, Yung Lim et al. 2004). 
 
The infarct size resulting from the coronary occlusion can be up to the 65% of the 
area perfused from the coronary (Pfeffer, Pfeffer et al. 1979). When the occlusion 
is too close to the origin, with a septal artery involvement, the infatct size can be 
higher than 65% with a 100% of mortality (Pfeffer, Pfeffer et al. 1985). 
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Figure 4: Photograph of open-chest mouse with silk ligature on left anterior descending 
coronary artery. 
The left anterior coronary artery of the mice originates between the pulmonary artery sulcus and the 
left atrium. The proximal region is intramyocardial, returning to the surface after 3 to 4 mm.  
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1.3 FORMYL PEPTIDE RECETOR 2  
 
1.3.1 Overview of the Formyl Peptide Receptor family 
G protein coupled receptors (GPCRs) are the largest group of receptors coded by 
the human genome. These seven transmembrane (7TM) receptors are involved in 
a variety of biological response like visual signal transduction, mood and 
behavioural regulation, olfactory modulation and control of cardiac function. Since 
they also transduce the action of chemokines and other inflammatory signals they 
are very important in the regulation of the body’s defence system. For example, 
GPCR signalling is required for leukocyte transmigration into the inflamed area. 
They ensure appropriate arrival of the leukocyte at the site of infection where they 
are capable to kill, engulf and digest xenobiotics or infective agents (Yona, Lin et al. 
2010). One family of GPCRs involved in the inflammatory response is the formyl 
peptide receptor family (FPRs). 
Schiffman, in 1975, showed that synthetic N-formyl peptides, particularly the N-
formyl-methionyl-phenylalanine (fMLF) derivatives, were potent neutrophil 
chemoattractants. The discovery that N-formyl peptides could stimulate chemotaxis 
at very low concentrations (Schiffmann, Corcoran et al. 1975, Zigmond 1977) 
provided strong evidence for the presence of a functional receptor for these 
molecules. Indeed, the human formyl peptide receptor (FPR) was subsequently 
defined pharmacologically as a high affinity-binding site on the surface of 
neutrophils for the peptide fMLF by Showell (1976) and Freer (1980, 1982). fMLF is 
the smallest formyl peptide that display full agonist activities and it is able to 
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stimulate chemotaxis, lysosomal enzyme release and superoxide generation 
(Schiffmann, Corcoran et al. 1975, Showell, Freer et al. 1976). 
 
The human FPRs were first defined using radioisotope- and fluorescence-labeled 
peptide ligands. In 1977 Aswanikumar and William demonstrated that neutrophils 
express specific and saturable binding sites for fMLP (Williams, Snyderman et al. 
1977). In 1979 Niedel demonstrated that fMLP retained full biological activity in 
human neutrophil chemotaxis assays. He also observed fMLP internalization and 
aggregation suggesting existence of a phenomenon of receptor binding followed by 
a receptor-mediated uptake of the ligand. Vitkauskas in 1980 and Donabedian and 
Gallin in 1981 showed deactivation and the internalization of the fMLP receptor. 
These approaches paved the way for the discovery and characterization of the 
neutrophil FPR, which was cloned by François Boulay in 1980 (Ye, Boulay et al. 
2009). FPR (or FPR1 according to more recent nomenclature) is a glycoprotein of 
57-70 kDa formed by a polypeptide of 350 aminoacids assembled as 7 
hydrophobic trans-membrane domains. It maintains a three-dimensional structure 
by the presence of ionic bridges between the positively charged amino acids 
arginine and lysine and the negative charges of phosphates (Niedel and 
Cuatrecasas 1980, Dolmatch and Niedel 1983, Niedel and Dolmatch 1983, Allen, 
Jesaitis et al. 1986). Throughout the 1980s the FPR receptor was characterised as 
a pertussis toxin sensitive G-protein coupled receptor (GPCR) (Bokoch and Gilman 
1984, Lad, Glovsky et al. 1985, Lad, Olson et al. 1985), which means it is coupled 
with to a Gi protein (Gierschik, Sidiropoulos et al. 1989, Uhing, Gettys et al. 1992, 
Lavigne, Murphy et al. 2002).  
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In 1992, several laboratories reported the identification of a 7TM receptor that 
shared significant sequence homology to human FPR (Bao, Gerard et al. 1992, 
Murphy, Ozcelik et al. 1992, Perez, Holmes et al. 1992, Ye, Cavanagh et al. 1992): 
the related FPR2/ALX receptor was therefore identified.  The human pertussis 
toxin sensitive GPCR family of FPRs was completed (Boulay, Tardif et al. 1990) 
with three genes encoding FPR1, FPR2/ALX and FPR3 clustered on chromosome 
19q13.3-19q13.4 (Ye, Boulay et al. 2009), whilst the murine Fpr gene family is 
located on chromosome 17 and consists of seven members. Human FPR1 has a 
direct orthologue in mouse Fpr, termed Fpr1 (76% of homology), with high affinity 
for N-formylated peptides (He, Liao et al. 2013). Human ALX/FPR2 exhibits 
homology to 2 mouse genes, termed frp2 (74% of homology) and fpr3 (76% 
homology) (Figure 5). Fpr2 binds the synthetic FPR2/ALX agonists WKYMVm, 
compound 43 and Quin-C1 (He, Liao et al. 2013). Other related murine genes, 
designated from fpr-rs3 to fpr-rs7, have also been identified but remain orphan 
receptors (Ye, Boulay et al. 2009). 
 
FPR3, a 7TM receptor with 352 amino acids, shares 56% homology with human 
FPR1 (Ye, Boulay et al. 2009) although it is not activated by fMLP. FPR3 has no 
current orthologues in the mouse and has only one high affinity endogenous ligand, 
the heme-binding derived F2L peptide (Migeotte, Riboldi et al. 2005). 
 
FPR1 and FPR2/ALX receptors are expressed on PMN and mononuclear cells, 
both myeloid and lymphoid (Schiffmann, Corcoran et al. 1975, Showell, Freer et al. 
1976, Aswanikumar, Corcoran et al. 1977, Zigmond 1977). The FPR3 receptor is 
not expressed in neutrophils (Murphy, Ozcelik et al. 1992) but is found on 
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monocytes and dendritic cells. Immature DC expresses FPR1, FPR2/ALX and 
FPR3, however only FPR3 is retained in mature cells (Yang, Chen et al. 2002, 
Migeotte, Riboldi et al. 2005, Devosse, Guillabert et al. 2009). FPR2/ALX 
expression remains unchanged during monocyte differentiation into macrophages 
(Ye, Boulay et al. 2009), even if with a limited function in resident tissue 
macrophages (Hashimoto, Murakami et al. 2007).  
 
The distribution of the human FPR1 and FPR2/ALX receptor is also mirrored by 
their murine orthologues, suggesting that they might maintain physiological roles 
across the species (Fu, Karlsson et al. 2006). The FPR1 receptor has also been 
found, using immuno-histochemical methods, in several organs and tissues, 
including epithelial cells (Rotrosen, Malech et al. 1987), endocrine cells (including 
follicular cells of the thyroid and cortical cells of the adrenal gland), platelets, liver 
hepatocytes and Kupffer cells, gut epithelial cells,  smooth muscle cells, brain, 
spinal cord and both sensory and motor neurons (Lacy, Jones et al. 1995, McCoy, 
Haviland et al. 1995, Becker, Forouhar et al. 1998, Le, Hu et al. 2000, Czapiga, 
Gao et al. 2005, Leoni, Alam et al. 2013). However, tissues and cellular distribution 
of the human FPR gene family members remains, for the moment, a partially 
explored field.  
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Figure 5: Schematic representation of the FPR receptors in human and mouse and Homology 
between human and mouse FPRs. 
The FPR receptor family comprises seven homologues in mouse and three in humans with identified 
of highly conserved regions. 
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FPRs receptor signalling is regulated by agonist-induced internalization. Following 
binding with their agonists, the receptors undergo rapid phosphorylation in a 
concentration- and time-dependent manner (Ali, Richardson et al. 1993). This 
leads to conformational change to allow functional interaction with Giα1, Giα2 and 
Giα3 and association with G0, Gz and Gα16 (Migeotte, Communi et al. 2006). This 
interaction triggers activation of a variety of signaling pathways (Figure 6) including 
fluxes in intracellular calcium concentration, activation of phospholipase C and D 
(PLC and PLD), PI3K and MAPK (Selvatici, Falzarano et al. 2006). PLC, involved 
in both PI3K and MAPK pathways via protein kinase (PKC), is responsible for 
receptor desensitization and internalization (Le, Wetzel et al. 2001). The MAPK 
pathway, in particular ERK 1/2, regulates chemokinesis (Wenzel-Seifert, Hurt et al. 
1998). It has also been shown that PI3K, in neutrophils after interaction with fMLP, 
is able to regulate oxidative burst and actin relocation, essential for cell polarization 
(Dufton, Hannon et al. 2010).  
 
As described above, FPR receptor signalling is followed by receptor 
desensitization (Ali, Richardson et al. 1999). For example, after activation of FPR1 
with fMLP, the receptor reduces its responses to a secondary stimulation with the 
same agonist, a process referred to as homologous desensitization. FPR1 is also 
susceptible to heterologous desensitization, and has been shown to desensitize 
following activation of the complement receptor (C5aR), the interleukin-8 receptor 
(Ali, Richardson et al. 1999). 
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Figure 6: FPRs receptor signalling 
Fprs agonists binding induce activation of different signalling pathways like MEKK/P38-MAPK, 
MEK-ERK1/2, PLC, PKC and Pi3K.  
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1.3.2 The Formyl Peptide Receptor 2 (FPR2/ALX) 
The FPR2/ALX receptor was originally characterized as the low-affinity fMLF 
receptor (Murphy, Ozcelik et al. 1992, Ye, Cavanagh et al. 1992, Quehenberger, 
Prossnitz et al. 1993) and then identified also as the receptor for the LXA4 (Fiore 
and Serhan 1995).  FPR2/ALX is a 7TM receptor with 351 amino acids and share 
69% identity with human FPR1 (Ye, Boulay et al. 2009). FPR2/ALX receptor has 
two different related murine genes, called Fpr2 and Fpr-rs2 (Hartt, Barish et al. 
1999). Fpr2 showed closer sequence homology with FPR2/ALX, but Fpr3 showed 
more functional homology (Gao, Chen et al. 1998). Indeed mFpr3 is a low affinity 
receptor for fMLP (Hartt, Barish et al. 1999) and responds to several FRP2/ALX 
agonists like the amyloidogenic proteins serum amyloid A (SAA) (Liang, Wang et al. 
2000) and amyloid β(1-42) (Le, Gong et al. 2001) . Following the recent nomenclature 
guidelines from IUPHAR (Ye, Boulay et al. 2009) we can name the two genes, 
Fpr2 and Fpr3, as both being orthologues of human FPR2/ALX (Table 3). Mouse 
Fpr2 shares 81% of protein sequence with the mouse Fpr1 and 58% with the 
human FPR1 (Gao, Chen et al. 1998).  Mouse Fpr2 and Fpr3 share the first exon, 
whereas the second exon that completes the transcription sequence differs 
between the two genes (Ye, Boulay et al. 2009). 
 
FPR2/ALX expression is induced by both pro-inflammatory stimuli like TNF-α (Cui, 
Le et al. 2002) and pattern recognition receptors (Chen, Huang et al. 2009) as well 
as anti-inflammatory molecules, such as the glucocorticoids (Sawmynaden and 
Perretti 2006, Hashimoto, Murakami et al. 2007). FPR2/ALX is associated with 
host defence but, unlike FPR1, it seems to be involved in both pro and anti-
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inflammatory processes. As an anti-inflammatory receptor it can induce 
deactivation, detachment and apoptosis of leukocytes, increase phagocytosis of 
apoptotic cells, and can also regulate COX-2 expression (El Kebir, Jozsef et al. 
2007). FPR2 is also involved in the homeostasis and epithelial repair in the colon 
(Chen, Liu et al. 2013) and anti tumour activity (Liu, Chen et al. 2013). Most of the 
anti-inflammatory effects of FPR2/ALX are related to its endogenous ligands 
(Perretti, Chiang et al. 2002), like LXA4, AnxA1, the neuroprotective peptide 
humanin and heme-binding protein-deriving peptide F2L.  
 
Recent work from our lab, published during the completion of this thesis, indicates 
that FPR2/ALX follows ligand-biased pharmacology paradigms. Thus, it is 
activated by an array of different ligands resulting in different conformational 
changes and the ensuing intracellular responses: AnxA1 and LXA4, but not the pro-
inflammatory protein serum amyloid A, induce FPR2 homodimerization. This event 
led to a p38/MAPK-activated protein kinase/heat shock protein 27 signalling with 
generation of IL-10. The same study revealed that the pan-agonist peptide Ac2-26 
induces FPR2/FPR1 heterodimerization and this activates a JNK-mediated 
proapoptotic path (Cooray, Gobbetti et al. 2013). 
 
The versatility of FPR2/ALX is demonstrated by its interaction with the CC 
chemokine receptor 2 (CCR2) mediating monocyte-derived dentritic cells 
recruitment in allergic airway inflammation (Chen, Liu et al. 2013).  
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1.3.3 FPR2/ALX agonists  
It is now known that FPR2/ALX can bind to a range of ligands, with putative pro 
and anti-inflammatory properties, and all of different natures, that is lipids, proteins 
and peptides. For example this receptor binds the glucocorticoids-modulated anti-
inflammatory protein AnxA1 (Perretti, Getting et al. 2001 - FPRs KO mice and 
FPRs antagonists employed in the study) and the pro-inflammatory protein SAA 
(Su, Gong et al. 1999 - using HEK-FPRs transfected cells and antagonists). Other 
endogenous ligands include the mitochondrial peptides, the vasoactive intestinal 
peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP)-27 
(Cattaneo, Parisi et al. 2013 - using HEK-FPRs transfected cells and antagonists). 
FPR2 and in this case, FPR3, also bind the Hp(2-20) peptide derived from H. pylori, 
accelerating wound healing of gastric mucosa thought stimulation of eosinophil 
migration and vascular endothelial growth factor-a (VEGF-A) and transforming 
growth factor-beta (TGF-beta) production (Prevete, Rossi et al. 2013 - FPRs KO 
employed). 
 
Screening of libraries of peptides has allowed the identification of various 
FPR2/ALX binding molecules, such as the synthetic peptide Trp-Lys-Tyr-ValD-Met, 
also termed W-peptide or WKYMVm (He, Tan et al. 2000 - in vitro studies), that 
induces post-receptor Ca2+ flux, promotes cell chemotaxis (Le, Gong et al. 1999 - 
in vitro studies) and has therapeutic effects in ulcerative colitis (Kim, Kwon et al. 
2013 - FPRs antagonists used). The small molecule pyrazolone-derived, the 
compound 43 (C43, designed by Amgen), represents another example of a 
synthetic FPR2/ALX agonist. C43 has anti-inflammatory activity by inhibiting fMLF 
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and IL-8 mediated chemotaxis in vitro and oedema formation in vivo (Burli, Xu et al. 
2006 - in vitro studies).  
The synthetic Quin-C1, a substituted quinazolinone, induces neutrophil calcium 
mobilization and chemotaxis (Nanamori, Cheng et al. 2004 - in vitro studies) and 
displays an anti-inflammatory effect in bleomycin-induced lung injury (He, Cheng et 
al. 2011). 
 
Lipoxin A4 (LXA4) is part of the family of the lipoxins, eicosanoids generated from 
arachidonic acid via 5-, 12- and 15 LOX after interaction of leukocytes with 
platelets or epithelial cells (Chiang, Hurwitz et al. 2006, Chiang and Serhan 2006). 
The anti-inflammatory LXA4 reduces PMN activity (Pouliot, Clish et al. 2000), 
promotes detachment of adherent leukocytes from mesenteric circulation (Gavins, 
Yona et al. 2003) and induces apoptosis and phagocytosis (Mitchell, Thomas et al. 
2002) through FPR2/ALX (FPRs KO and receptor antagonists used). LXA4 also 
binds to other receptors, including a receptor shared with cysteinyl leukotriene 
receptor type 1 (CysLT1) (Chiang, Serhan et al. 2006) and the aryl hydrocarbon 
receptor (AhR) (Schaldach, Riby et al. 1999). 
 
 
AnxA1 (Wallner, Mattaliano et al. 1986) is a 37kDa protein (consisting of 346 
amino acids) and is one of the most studied anti-inflammatory FPR2/ALX agonists 
(Perretti, Getting et al. 2001, Gavins, Sawmynaden et al. 2005, Babbin, Lee et al. 
2006, Hayhoe, Kamal et al. 2006 - (FPRs KO and receptor antagonists employed). 
Initially discovered as a mediator of glucocorticoid-induced inhibition of PLA2 and 
called macrocortin or lipomodulin (Flower, 1979), these proteins were subsequently 
 67 
shown to be identical and renamed under the unified name of lipocortin 1 
(Pepinsky, Sinclair et al. 1986, Wallner, Mattaliano et al. 1986). Subsequent 
studies categorized it as a member of the annexin super-family (Pepinsky, Sinclair 
et al. 1986, Wallner, Mattaliano et al. 1986).  The term annexin, from the Greek 
annex “hold together”, describes the ability of these proteins to bind negatively 
charged phospholipids in a calcium-dependent manner. AnxA1 is abundant in 
neutrophils, where it is mostly packaged within gelatinase granules (Perretti, 
Christian et al. 2000) but is also present in the cytosol (Ernst, Hoye et al. 1990). 
Upon neutrophil adhesion to endothelial cell (Perretti, Croxtall et al. 1996) or 
interaction with FPR2/ALX agonists (Brancaleone, Dalli et al. 2011) AnxA1 can be 
externalized and, by interacting with FPR2/ALX, is able to induce neutrophil 
detachment, apoptosis hence promoting the resolution of inflammation (Perretti 
and D'Acquisto 2009).  Antiflammin 2 (AF2) is a nonapeptide corresponding to 
region 246-254 in the third repeat of the AnxA1 core (Miele, Cordella-Miele et al. 
1988). Once the crystal structure of AnxA1 was resolved, it was noted that the AF2 
sequence was exposed on the outer side of the protein (Rosengarth, Gerke et al. 
2001). It was therefore proposed that this portion of the whole protein might be 
available to interact, in conjunction with the N-terminal region (Rosengarth and 
Luecke 2003), with specific molecular targets. Of interest, AF2 displays anti-
inflammatory activities by inhibiting PMN activation, chemotaxis and adhesion to 
endothelial cells (Zouki, Ouellet et al. 2000). In some cases, these effects are 
through FPR2/ALX (Kamal, Hayhoe et al. 2006). 
 
AnxA1 plays an anti-inflammatory role in arthritis (Patel, Kornerup et al. 2012), 
uveitis (Girol, Mimura et al. 2013), leukemic cells (Tsai, Lai et al. 2013), sepsis 
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(Gavins, Hughes et al. 2012), ulcerative colitis (Vong, Ferraz et al. 2012) and 
inflammatory pain modulation where can be a target for developing anesthesia and 
analgesic drugs (Chen, Lv et al. 2013). 
 
Resolvin D1 (RvD1) is an omega-3 polyunsaturated fatty acids derived lipid 
mediators transcellular produced in human leukocytes and endothelial cells 
(Serhan, Hong et al. 2002) by sequential oxygenations by 15 LOX and 5-LOX. 
Omega-3 derivate are known to bestow protective clinical effects in the 
cardiovascular system and inflammatory disorders (De Caterina 2011). Specifically, 
RvD1 exhibit potent anti-inflammatory action in vivo (Hong, Gronert et al. 2003) 
and it limits neutrophil recruitment during acute inflammation through FPR2 and the 
orphan receptor G-protein-coupled receptor 32 (GPR32) (Norling, Dalli et al. 2012 - 
Receptor-specific antibodies and FPRs KO mice used). 
 
As mentioned before, FPR2/ALX also binds pro-inflammatory molecules (as seen 
by both in vivo and in vitro studies using KO mice and receptors antagonists) and 
becomes involved in pro-inflammatory pathways. For example, binding the Serum 
Amyloid A (Liang, Wang et al. 2000), the peptide-derivative beta-amyloid-A (Aβ42) 
(Yazawa, Yu et al. 2001) or the prion peptide PrP106-126 (Le, Yazawa et al. 2001), 
FPR2/ALX might be involved in amyloidosis (Munishkina and Fink 2007), 
atherosclerotic plaques (Wilson, Thompson et al. 2008), Alzheimer’s disease (Cui, 
Le et al. 2002) and rheumatoid arthritis (Koga, Torigoshi et al. 2008, Nakamura 
2008).   
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SAA is an inducible component of the acute phase and it is particularly abundant in 
chronic diseases: SAA serum levels increase up to 1000-fold after experimental or 
clinical inflammation (Kushner 1982). SAA is predominately secreted from the liver 
(Meek, Urieli-Shoval et al. 1994) and transported in the circulation primarily in 
association with high density lipoprotein (HDL) (Malle, Steinmetz et al. 1993). 
Besides systemic synthesis and delivery, SAA can also be produced at local 
inflammatory site (Vreugdenhil, Dentener et al. 1999) from endothelial cells, 
macrophages, adipocytes, and smooth muscle cells (Meek, Urieli-Shoval et al. 
1994). SAA also interact with TLR4 (Sandri, Rodriguez et al. 2008) RAGE, TANIS, 
and CLA-1/hSR-B1 (Lakota, Mrak-Poljsak et al. 2013).  
Through FPR2, SAA mediates a chemotactic response in human monocytes (Su, 
Gong et al. 1999) and is also able to induce neutrophil chemotaxis (Liang, Wang et 
al. 2000) and neutrophil adhesion to endothelial cells (Badolato, Wang et al. 1994). 
All these properties are associated with FPR2/ALX binding. SAA is also involved in 
the inflammatory ROS burst and production of inflammatory chemokines such as 
IL-8 (He, Sang et al. 2003) in the macrophage foam cell formation in atherogenesis 
(Lee, Kim et al. 2013) and in rheumatoid arthritis (Satomura, Torigoshi et al. 2013). 
 
Aβ42 is an enzymatic cleavage fragment of the amyloid precursor protein and is 
the major component of senile plaques in Alzheimer’s disease. Through 
engagement of FPR2/ALX, Aβ42 may cause neurodegeneration and pro-
inflammatory responses in glial cells (Yazawa, Yu et al. 2001, Cui, Le et al. 2002). 
PrP106-126 causes monocyte FPR2/ALX internalization and release of pro-
inflammatory mediators (Miele, Cordella-Miele et al. 1988). 
 
 70 
1.3.4 The role of FPR2/ALX in AMI 
Increasing evidence suggests that the FPR family, and their agonists, might have 
an important functions in the pathophysiology of I/R injury (Gavins 2010). In 
particular, studies showed that AnxA1 (D'Amico, Di Filippo et al. 2000) and AnxA1-
derived peptides - including short sequences derived from the N-terminal region, 
termed peptide Ac2-12 and Ac2-26 (La, D'Amico et al. 2001, Qin, Buxton et al. 
2012, Qin, Buxton et al. 2013) - are able to exert protective effects in an 
experimental model of myocardial ischemia-reperfusion. Ac2-26 reduced 
myeloperoxidase activity and IL-1β levels in infarcted murine hearts (La, D'Amico 
et al. 2001). Boc-2, a pan-FPRs antagonist (able to antagonize FPR1 and 
FPR2/ALX in human cells, and Fpr1, Fpr2 and Fpr3 in the mouse) reversed the 
cardioprotective actions of AnxA1 and its N-terminal peptides (La, D'Amico et al. 
2001), demonstrating the involvement of the FPRs receptors in the cardioprotective 
properties of these molecules.  
 
A recent publication (Qin, Buxton et al. 2013) showed that Ac2-26 is able to 
improve recovery of left ventricle function through activation of the FPR1 receptor. 
The pan-antagonist Boc-2 and the FPR1-selective antagonist CysH blocked this 
effect. However other insights were obtained with the use of Fpr1 null mice (Gao, 
Lee et al. 1999). In this study peptide Ac2-26 retained its cardioprotective 
properties in this transgenic colony (Gavins, Kamal et al. 2005) providing evidence 
for the involvement of other BOC-2 sensitive receptors. Real time PCR revealed 
expression of Fpr2 in the infarcted heart (Gavins, Kamal et al. 2005). Congruent 
with this hypothesis is the observation that FPR2/ALX ligands like LXA4 (Chen, Wu 
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et al. 2013) and the Compugen peptide CGEN-855A (Gavins, Yona et al. 2003), 
and AnxA1 derived peptide CR-AnxA1(2-50) (Dalli, Consalvo et al. 2013) afford 
protective effects in rat and murine myocardial infarct models.  Whilst these studies 
indicate the protective nature of FPR2/ALX in AMI, they do not shed light on the 
site of action and/or expression, that is, whether the leukocyte or the 
cardiomyocyte are the main cellular target bearing this receptor. There is evidence 
that peptides derived from the AnxA1 N-terminal can directly affect cardiomyocyte 
and exhibit protective effects against endotoxin-induced cardiac depression 
(Ritchie, Sun et al. 1999, Ritchie, Sun et al. 2003). Also, FPR2 is expressed in 
human coronary artery endothelial cells (HCAEC) where it can bind SAA inducing 
a pro-inflammatory phenotype like phosphorylation of ERK1/2, NF-κB and JNK, as 
well as release of IL-6, IL-8, G-CSF, GM-CSF, ICAM-1 and VCAM-1 (Lakota, 
Mrak-Poljsak et al. 2013). 
 
Human AMI and other surgically based clamping procedures are also well known 
to cause aberrant PMN activation and infiltration (Goldman, Welbourn et al. 1992, 
Chiang, Gronert et al. 1999), giving rise to second-organ injury and subsequently 
longer hospitalization (Gelman 1995). Also, the delayed fall in flow in the ischemic 
areas - the “no reflow phenomenon” - has been directly linked to neutrophil 
localization (Frangogiannis, Smith et al. 2002).  LXA4 is able to modulate this PMN 
response (Serhan 1997, Chiang, Gronert et al. 1999) and its formation within 
ischemic tissue, and elevation by reperfusion (Chiang, Gronert et al. 1999), might 
represent an endogenous compensatory and protective role to limit PMN trafficking 
and PMN-mediated damage. This is not unique to LXA4 as other FPR2/ALX 
agonists, like the synthetic analogue 15-epi-lipoxin (Leonard, Hannan et al. 2002, 
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Bannenberg, Moussignac et al. 2004), have a protective role in I/R-induced 
second-organ kidney and lung injury. AnxA1, for example, can reduce tissue-
damage associated with ischemia-reperfusion as shown in the mesentery (Gavins, 
Yona et al. 2003), brain (Gavins, Dalli et al. 2007) and kidney (Facio, Sena et al. 
2011). However, its potential effect on distant organ injury has yet to be determined.  
What is interesting, though, is the description of a non-genomic relationship 
between LXA4 and AnxA1, with the short-lived lipid being able to rapidly mobilize 
the protein in human and mouse PMN, the end-point being reduced activation and 
trafficking (Brancaleone, Dalli et al. 2011). 
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1.4 HYPOTHESIS & AIMS 
 
Taken together these observations lead us to propose that FPR2/ALX (or Fpr2/3 in 
the mouse) and its agonists may represent a novel therapeutic target to prevent 
damage caused by AMI in the heart and secondary injury organs. 
 
For this reason the aims of this studentship are to: 
 
1. Understand if the cardioprotective property of AnxA1 is Fpr2/3 mediated. 
2. Study role and modulation of Fpr2/3 in myocardial infarct, focusing on the 
heart. 
3. Study role and modulation of Fpr2/3 in secondary organ damage following 
myocardial infarct, focusing on lungs and kidneys.  
4. Study the effects of Fpr2/3 pro-resolving agonists in myocardial infarct.  
5. Understand the distinct domains required by pro and anti Fpr2/3 agonists 
to induce downstream associated signalling. 
 
Understanding the potential biological functions of Fpr2/3 in myocardial infarct, and 
how it could be modulated during on-going local and systemic inflammation, may 
represent a key step towards unveiling its biology and potentially exploiting it for 
drug discovery programs for novel AMI treatments. The study of the domains 
required only by pro-resolving Fpr2/3 agonists for the activation of the receptor 
help to synthetises selective and specific anti inflammatory molecules.  
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We postulate that exploitation of targets activated by endogenous anti-
inflammatory mediators could lead to molecules effective for I/R diseases 
burdened by fewer side effects as their effect would be similar to mechanisms used 
by the body to sequester inflammation. 
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2.1 Chemical and reagents 
Human recombinant AnxA1 was produced as published previously (Pederzoli-
Ribeil, Maione et al. 2010). SAA was purchased from PeproTech Laboratories 
(London, UK), and C43 was a generous gift from Amgen (Thousands Oaks, CA). 
N-tert-butoxycarbonyl-L-Phe-D-Leu-L-Phe-D-Leu-L-Phe (Boc2) was bought from 
Tocris (UK). The JAK/STAT inhibitor Tyrphostin AG 490 was obtained from Sigma-
Aldrich (USA). The MEK1 inhibitor PD98059 and the calcium inhibitor BAPTA-AM 
were obtained from Cell Signaling Technologies (Hertfordshire, UK) and 
Calbiochem, respectively. F1, B11 and GB4 primers were synthesized by Thermo 
Electron, MA. 
 
 
2.2 Fpr2/3 KO colony 
Male Fpr2/3 KO mice and wild type (WT) littermate controls (6-7 weeks old) were 
maintained on a standard chow pellet diet and had free access to water, with 12 
hours light dark cycle. Animal work was performed in accordance with the U.K. 
Home Office Animals (Scientific Procedure) Act 1986.  
Our Fpr2/3 KO mice are generated by the deletion of both the murine Fpr2 and 
Fpr3 genes (Figure 3). Of interest, the Fpr1 gene is transcribed from a different 
strand to Fpr2 and Fpr3 and was not modified.  
The transcription of the Fpr2 and Fpr3 genes was prevented with the insertion of a 
GFP PGK-Neo cassette (Figure 7) creating a transgenic colony characterised by 
an in-frame green fluorescence protein (GFP) gene ‘knocked-in’ (Dufton, Hannon 
et al. 2010). The PGK-Neo is a vector that contains the phosphoglycerate kinase I 
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(PGK) promoter and a neomycin resistance gene (neo). Using the PGK-Neo 
recombinase-mediated cassette exchange the genetic modification is permitted by 
by exchange of a pre-existing gene cassette with an analogous cassette carrying 
the "gene of interest" (GFP). 
The GFP is a 238 amino acid protein with a MW of 26.9kDa. It is able to exhibit 
bright green fluorescence when exposed to blue light (Tsien 1998). The GFP from 
the jellyfish Aequorea victoria has a major excitation peak at the wavelength of 
395 nm and a minor one at 475 nm. Its emission peak is at 509 nm, which is in the 
lower green portion of the visible spectrum (Prendergast and Mann 1978). In cell 
and molecular biology, the GFP gene is a marker used for example to monitor 
physiological processes or visualize protein localization. 
The genotype of the Fpr2/3 KO mice was confirmed by PCR screening of ear clip 
DNA using the Extract-N-Amp Tissues kit (Sigma-Aldrich, XNAT2-1KT). The 
primers used are F1 (Fpr2 forward – TGAGTGTCATGTCAGAAGGAGCC), B11 
(Fpr2 reverse for WT – CGGAATCCAGCTACCCAAATC) and GB4 (Fpr2 reverse 
for KO –ATAACCTTCGGGCATGGCACT). The F1/B11 pair produces a band of 
233 bp from the wild type allele, whereas F1 and GB4 produce a band of 351 bp 
for the allele of Fpr2/3 KO mice. Cycling condition were 94°C for 5min, 35 cycles of 
94°C for 30min, 55°C for 30min, 72°C for 15min and 72°C for 7min.  
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Figure 7: Schematic representation of the Fpr2/3 GFP KO mice genome. 
The construct of our transgenic Fpr2/3 KO mice were characterised by deletion of the Fpr2 and 
Fpr3 gene and the insertion. (A) The Fpr2 gene was transcribed from exon 1 (not coding exons) 
and exon 2 (coding exon). Fpr3 was transcribed by exon 1 and exon 3 (coding exon). Exon 2 was 
excluded. (B) The GFP PGK-Neo cassette was inserted in reverse orientation into intron 1 of Fpr2 
and fused in-frame (vector shown in grey) with the ATG start codon.  
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2.3 Quantification of myocardial tissue injury 
Unlike after permanent occlusion of a coronary artery where there is necrosis of 
the entire coronary territory, infarctions with ischemia and reperfusion of the heart 
is variable. Therefore there is a need to clearly demarcate the area perfused by the 
occluded artery and quantify the infarct size in that area. For this reason at the end 
of the 2 hours of reperfusion period the LADCA was re-occluded and 100 µl of 
Evans Blue dye (1% w/v) (Sigma-Aldrich, USA) was injected into the left ventricle 
to distinguish between perfused and non-perfused areas of the heart, the Area At 
Risk (AAR). The Evans Blue dye stains the perfused myocardium, while the 
occluded vascular bed remains uncoloured. Next the mice were killed and the 
heart excised and excess dye was washed with saline. 
After the removal of the atria and the right ventricular wall the AAR (non perfused – 
pink) was separated from the rest of the left ventricle (perfused – blue). Both 
tissues were weighed and the AAR was expressed as a percentage of the left 
ventricle. The AAR was then cut into small pieces and incubated with the reducing 
agent p-nitroblue tetrazolium (NBT, 0.5 mg/ml) (Sigma-Aldrich, USA) for 10 
minutes at 37°C. This technique relies on the ability of dehydrogenase enzymes 
and cofactors in health tissue to react with tetrazolium salts to form a dark blue 
color. Infarcted tissue lack in dehydrogenase activity and fail to stain. Not stained 
pieces were weighted to determine the infarct size expressed as percentage of the 
weight of the area at risk. 
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2.4 Histology 
2.4.1 Tissues collection and paraffin embedding process 
After collection, tissues were washed in PBS and fixed with 10% formalin (buffered 
with 0.1M NaH2PO4 and 0.1M Na2HPO4) for 24h at 4°C before the paraffin 
embedding procedure was processed. Embedded tissues were then cut in serial 
paraffin sections (5µm) using a standard microtome. Sections were then mounted 
on slides, dried overnight in an oven (45°C) and stored at room temperature until 
required. All sections were used for the experiments within 2 days from cutting.  
 
2.4.2 Hematoxylin/Eosin staining – GFP 
Formalin fixed paraffin embedded tissue sections were deparaffinized through two 
seven-minutes changes in Histoclear™ and rehydrated with 100% ethanol for two 
washes of five minutes followed by five minutes in distilled water. Next the tissues 
were immersed for 10-30 seconds in Haematoxylin, washed with running tap water. 
Tissues were then immersed in 1% Acid/Alcohol (70% EtOH, 1% HCl, 29% dH2O) 
for 10 seconds and washed and differentiated under running tap water. Afterwards 
tissues were immersed in eosin for 5 minutes, washed in tap water, and 
dehydrated by treatment for 5 minutes with 70% ethanol, 90% ethanol, 100% 
ethanol and twice with Histoclear™. Lastly the slides were covered with a coverslip 
and mounted with DPX.  
 
To allow GFP detection the tissues were exposed to blue light for the intensity 
indicated. ImageJ software was used to quantify the fluorescence intensity. 
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2.4.3 Immunohistochemistry – Immunoenzyme method (HRP) 
Formalin fixed paraffin embedded tissue sections were deparaffinized and 
rehydrated with Histoclear and ethanol as described before. Once hydrated, 
sections were rinsed with dH2O followed by 5 minutes of TBS 1X (Tris HCl, Tris 
Base, NaCl).  To counteract the antigen masking effects of formalin fixation, 
epitope retrieval was performed by heating the tissue sections for 20 minutes at 
95°C followed by 5 minutes at room temperature in pre-warmed Buffer Retriever 
(Dako, UK) using as a source of heat a hot water bath. After antigen retrieval the 
sections were treated with Peroxidase blocking (Dako, UK) followed by Avidin and 
Biotin (Vector, UK) for 10 minutes each to block the endogenous corresponding 
biotin that may result in high and non-specific background staining. The sections 
were then washed for two times for two minutes with Tris-Buffered Saline (TBS) 
and incubated for 10 min. at room temperature with Protein Block Serum Free 
(Dako) to reduce non-specific staining blocking.  
Subsequently the tissues were incubated with the primary antibody (Anti rabbit 
polyclonal Fpr2 – Santa Cruz) for 1 hour in humidified chambers. Next the sections 
were washed three times in TBS with 5 minutes between each wash and incubated 
with the biotinylated secondary Ab (1:200, Swine anti-rabbit - Dako) for 1 hour at 
room temperature. The secondary antibody was rinsed off by three 5-minutes 
washes in TBS and sections were further incubated with a preformed Avidin and 
Biotinylated horseradish peroxidase Complex (ABC Kit – Vector, UK) for 30 
minutes. The ABC substrate solution was prepared using 1µl of Avidin and 1µl of 
the Biotinylated enzyme in 1 ml of TBS and allowed to react 30 minutes at room 
temperature before use. Sections were then washed three times in TBS (5 minutes 
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per wash) and developed using the Liquid DAB+Substrate Chromogen System 
(Dako, UK). The substrate working solution was prepared adding 1 drop (20µl) of 
the DAB Chromagen per mL of Sustrate Buffer. This substrate-chromagen system 
is a system suitable for peroxydase-based immunohistochemical (IHC) staining 
methods. Upon oxidation, DAB forms a brown end-product at the site of the target 
antigen. The development reaction was stopped in distilled water. Sections were 
then counterstained with hematoxylin for 30 seconds and hydrated through graded 
ethanol solutions (70%, 90%, 100%, 5 minutes each) and Histoclear™ twice, for 5 
min each. To finish the sections were mounted using a coverslip and a mounting 
DPX. 
 
Primary and secondary antibodies were diluted in ready-to-use Antibody diluent 
with Background Reducing Components (Dako, UK). Negative staining control 
experiments were performed omitting the primary antibody. 
 
 
2.5 Cell culture 
Stably transfected FPR1 and FPR2/ALX HEK-293 cells (Human Embryonic Kidney 
cells) were available in the laboratory – and been described by (Hayhoe, Kamal et 
al. 2006); cells were maintained in culture with DMEM F-12 supplemented with 
10% FCS, gentamicin (50 µg/ml), Non-essential Amino Acids (500 µg/ml) and 
geneticin (200 µg/ml) solution. The HEK-293 cells transfected with the chimaeric 
FPR1/FPR2 receptors were obtained with distinct domains of the FPR1 receptor 
replaced with FPR2/LAX amino acid sequences (Le, Ye et al. 2005). These cells 
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were cultured in DMEM with 10% FCS, L-glutamine (500 µg/ml), Penicillin-
Streptomycin mix (500 µg/ml), Hepes 1M and geneticin solution (800 µg/ml).  
 
 
2.6 Cells and tissues lysis and Protein Assay 
Protein content (aliquots diluted 1:100) was determined using the Pierce BCA 
Protein Assay Kit (Thermo Scientific, Rockford, USA) that measure the total protein 
concentration compared to a protein standard (Figure 8). The assay combines the 
reduction of Cu2+ to Cu1+ by protein in an alkaline medium with the colorimetric 
detection of the cuprous cation (Cu1+) by bicinchoninic acid. Briefly, the first step is 
characterized by the chelation of copper with protein in an alkaline environment 
(with sodium potassium tartrate) to form a light blue complex. Subsequently, 
bicinchoninic acid (BCA) reacts with the reduced (cuprous) cation that was formed 
resulting in an intense purple-colored reaction product. The BCA/copper complex 
exhibits a linear absorbance at 562 nm with increasing protein concentrations.  
 
Cell and tissue lysis. Cells and tissues were lysed in lysis buffer containing Tris 
HCl, 1% Triton and the protease inhibitors aprotinin (1mM), Leupeptin (10µM), 
PMSF (200µM), β-GP (1mM) and DTT (1mM) and phosphatase inhibitors NaF 
(1mM), Na3VO4, (1mM). Tissues were treated with lysis buffer (100µl/10µg tissue) 
in round-bottom microfuge tubes and subjected to centrifugation in the 
homogenizer (Precellys 24 – Stretton Scientific LTD, UK) at 5,000 rpm for 50 
seconds twice, followed by a centrifugation at 10,000 rpm for 10 minutes. Cells 
were resuspended in 100µl of the lysis buffer followed by a mechanical lysis by 
syringe.   
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Figure 8: Standard curve of bovine serum albumin (BSA). 
A series of dilutions of known concentration of BSA were prepared and assayed alongside the 
unknown protein. A standard curve of BSA was prepared by plotting the measurement of BSA 
standard vs. its concentration. The concentration of each unknown protein was then determined 
and reported with reference to the standard curve of the BSA. Each sample was analysed in 
triplicate and the average was blank-corrected. Equation and R2 value (Pearson Coefficient of 
Determination) are shown. 
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2.7 Enzyme-linked immunosorbent (ELISA) assay 
ELISA uses a solid-phase enzyme immunoassay (EIA) to detect the presence of 
an antigen in a sample. There are different types of ELISA. Here the “Sandwich” 
ELISA was used.  Briefly, a 96 wells plate was coated with a known quantity of 
capture antibody. Subsequently any nonspecific binding sites on the well were 
blocked and the samples and the standards were added to the plate allowing any 
antigen present in the sample to bind to the capture antibody. The plate was then 
washed to remove unbound antigen and a detecting antibody, whose bind to the 
antigen, was added. Enzyme-linked secondary antibodies were then applied to 
bind to the detecting antibody. The detection antibody was conjugated with an 
avidin-horse radish peroxidase (HRP) and visualized with a 3,3’,5,5’-
tetramethylbenzidine (TMB), an HRP substrate solution, resulting in the 
development of blue. The colour development was stopped by addition of 2N 
H2SO4 changing to yellow. The absorbance of the plate wells was measured at 
450nm to determine the presence and quantity of antigen. The sample values were 
read off the standard curve (Figure 5). 
 
IL-6, TNFα, IL-1β, IL-10 and CCL2 were measured by murine Ready-Set-Go 
ELISA kit according to manufactures instructions (eBioscience). Tissues were 
diluited 1:20 and plasma 1:2 (Figure 9) 
Keratinocyte-derived Cytokine (KC) ELISA. Mouse KC levels in plasma (1:2 
dilution) and tissues (1:20 dilution) were measured using the Mouse CXCL1/KC 
Elisa Kit (R&D System).  
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Mouse Serum Amyloid A (SAA) ELISA. Levels of SAA were measured using a 
mouse SAA Elisa kit (immunological Consultants Laboratory, Newburg, OR). 
Samples were diluted 1:20 for tissues and 1:2 for plasma. 
Regulated upon activation, Normal T cell expressed and presumably secreted 
(RANTES) ELISA. Mouse RANTES levels were measured in tissues (1:20 dilution) 
using the Mouse RANTES Instant ELISA (eBioscience).  
Troponin I ELISA. Troponin-I levels were measured using a mouse cardiac 
troponin-1 elisa kit (Life Diagnostics). The high sensitivity cTnl Elisa recognizes an 
epitope on mouse cTnl that is resistant to preoteolysis in mouse plasma. Plasma 
samples were diluted four-fold (Figure 9). 
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Figure 9: Standard curve of IL-6 and mouse cTnl Elisa kit 
Examples of standard curve made with eBioscience Ready-Set-Go (IL-6) and Life Diagnostics 
(mouse cTnl) ELISA kit. Standards were prepared in serial dilution and assessed, in duplicate, 
together with the samples according to manufacturing instructions. Equation and R2 value (Pearson 
Coefficient of Determination) are shown. 
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2.8 Measurement of myeloperoxidase (MPO) activity 
MPO enzyme activity, index of granulocyte infiltration, was assayed by measuring 
hydrogen peroxide dependent oxidation of 3,3',5,5'-tetramethyl-benzidine (TMB). 
Blood-free tissue samples were homogenised in cell lysis tubes (Peqlab, UK) 
containing a solution of 0.5% hexadecyltrimethylammonium bromide (HTAB) 
dissolved in phosphate buffer solution (pH 6.0). The homogenized tissues were 
centrifuged at 15000rpm for 5 min. Supernatants were added to a buffer containing 
distilled water, 1% hydrogen peroxide, and O-dianisidine dihydrocholoride solution. 
Optical density readings were taken for 1 min at 30 s intervals at 450 nm. 
 
 
2.9 Western Blot analysis 
HEK-293 transfected with FPR1, FPR2/ALX and the chimeric receptors, HEK-293-
GFP cell lysates, murine bone marrow cells, bone marrow derived macrophages 
and mouse tissue lysates were analyzed using the SDS-PAGE technique. Samples 
were boiled in 6x Laemmli buffer for 5 min, and analyzed by standard SDS-
polyacrylamide gel electrophoresis (10% or 12% acrylamide gels) for 90 minutes at 
110V. The separated proteins were then electrophoretically transferred to 
polyvinylidene difluoride membranes at 4°C for 75 minutes using 100V.  
 
Membranes with AMI samples were then incubated with the mouse Phospho-Stat3 
(Tyr705) (1:1000, Cell Signalling, MA) and the Stat3 (79D7) antibodies  (1:2000, 
Cell Signalling, MA). All the antibodies were diluted in Tris-buffer saline solution 
containing 0.1% Tween 20 (TBST) and 1% non-fat dry milk or TBST with 5% BSA 
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(phosphorylated proteins) overnight at 4°C. Membranes were then washed for 30 
min with TBST with the solution being changed at 10-min intervals and incubated 
with the secondary antibody  (HRP-conjugated goat anti-rabbit 1:2000, Dako, 
Cambridge, UK), for 1h and 30 minutes at room temperature.  
 
HEK-293 FPR1, FPR2/ALX and cell clones were incubated with rabbit anti-
phospho-p44/42 MAP kinase (1:1000 dilution) and anti-total-p44/42, clone 137F5, 
(Cell Signalling, Cambridge, USA, 1:1000 dilution) diluted in Tris-buffer saline 
solution containing 0.1% Tween 20 (TBST) and 1% BSA overnight at 4°C. 
Membranes were washed for 30 min with TBST and incubated with secondary 
antibody  (HRP-conjugated goat anti-rabbit 1:2000, Dako, Cambridge, UK), for 2 h 
at room temperature. After stripping, membranes were also incubated with anti-β-
actin (1:10,000; SigmaAldrich) in TBST and 5% non-fat dry milk.  Human actin was 
detected with HRP-conjugated goat anti-mouse (1:5000). 
 
In all cases proteins were then detected using enhanced chemiluminescence 
(ECL) detection kit and visualized on Hyperfilm (GE Healthcare, Little Chalfont, 
UK). 
 
 
2.10 Caspase 3 activity assay 
The activity of caspase 3 was analyzed using the Caspase 3 Assay Colorimetric Kit 
(Abcam). Caspase 3 cleaves the Poly(ADP-ribose)polymerase and its derived 
tetrapeptide DEVD during cells death by apoptosis. Derivatives of DEVD 
conjugated with a chromophore used as substrate for enzyme activity assay of 
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caspase 3. This assay is based on spectrophotometric detection of the 
chromophore p-nitroaniline (p-NA) after cleavage from the labeled substrate 
DEVD-p-NA. The p-NA light emission is quantified at 405nm.  
 
 
2.11 Quantitative Real Time PCR 
The assay was processed as previously shown (Renshaw, Montero-Melendez et al. 
2010). Briefly, RNA was extracted using an RNeasy Kit (Qiagen, 74104) according 
to the manufacturer’s instructions. Total RNA was normalized at 5ug/reaction. 
cDNA was produced using SuperScript III (Invitrogen Ltd, Paisley, UK). Samples 
were normalized to 100ng of cDNA per well and loaded in duplicate for each gene 
using a Power SYBR Green PCR Master Mix (AB 4367659). Specific QuantiTect 
primer assays (Qiagen Ltd, UK) were used. GAPDH was used as endogenous 
control. PCR ramping protocols were standardized for QuantiTect primer assay 
sets at 95°C for 15min followed by 40 cycles of 15 sec at 94°C, 30 sec at 55°C and 
30 sec at 72°C. Data were analysed using the relative quantification method 
(Schmittgen and Livak 2008). Following this method the response produced in 
control mice (NO AMI) was taken as 1 and all the data represent the upregulation 
(>1) or downregulation (<1) of the mRNA expression in mice after AMI. 
 
 
2.12 Human polymorphonuclear leukocyte isolation 
Peripheral blood was collected from healthy volunteers by intravenous withdrawal 
in 3.2% sodium citrate solution (1:10). All healthy volunteers gave oral and written 
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consent and cell separation was covered by ethical approval 05/Q0603/34 (East 
London and The City Research Ethics). Granulocytes (PMNs) were isolated from 
blood via density centrifugation on Histopaque 1119/1077 (Sigma-Aldrich, Poole, 
UK) gradient according to the manufacturer’s instructions and suspended in PBS 
containing 0.5% BSA. Contaminating erythrocytes were removed by lysis with cold 
milliQ water.  
 
 
2.13 Peritoneal cells isolation – Biogel method 
The peritoneal cavity is a unique compartment where several immune cells reside 
and from where resident macrophages are commonly collected for functional 
studies.  The cavity of Fpr2 KO and WT mice was lavaged with PBS with 10% 
ethylenediaminetetraacetic acid (EDTA).  
 
Biogel method. One milliliter of sterile Biogel (2% Biogel solution in PBS) was 
injected in the peritoneal cavity of the mouse. After 4 days, mice were sacrificed by 
cervical dislocation and the cells were collected using PBS with 10% EDTA. The 
cells were then filtrated with 70-µm strainer and centrifuged at 1200 rpm for 10 
minutes. Subsequently cells were re-suspended in RPMI medium with 10% heat-
inactivated fetal calf serum (FCS) and 0.5 ng/ml gentamicin. 
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2.14 Culture of Bone Marrow Macrophages 
2.14.1 Generation of conditioned medium 
L929 fibroblasts were plated in T75 cm2 flasks containing DMEM supplemented 
with 10% FCS and maintained in an incubator with 37°C, 5% CO2 and 95% O2. 
When the cells became confluent, after a wash with sterile PBS, they were 
detached with Trypsin and plated in T175 cm2 flasks with 100ml of fresh medium. 
On day 3 of culture, the supernatant medium was collected, centrifuged, filtered 
through a 0.22 µm filter and used as conditioned medium for the direction of bone 
marrow pre-cursor cells towards a mature macrophage phenotype. The 
conditioned medium was made with DMEM medium containing 20% FCS, 30% 
L929 supernatant and 50µg/ml gentamicin.  
 
2.14.2 Harvest of bone marrow cells 
Young (4-6 week old) Fpr2/3 KO and WT male and female mice were sacrificed by 
cervical dislocation. To dissect away the skin and expose the hind limbs a 
transverse cut through the abdomen skin was performed and, in order to expose 
the femurs and tibia, the muscles attaching the hind limbs to the pelvis were 
dissected. Subsequently the femurs and the tibia were washed in a Petri dish with 
70% ethanol for 1 minute and then moved to another Petri dish containing sterile 
PBS. After the cutting of the bones epiphyses a 25-gauge needle, connected with a 
5 ml syringe containing sterile PBS, was placed into the bone shaft and the bone 
marrow was flushed out in a 50 ml falcon tube. The cells were then filtered through 
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a 70µm strainer and centrifuged for 5 minutes at 1200 rpm. All of the protocol was 
performed in a sterile flow cabinet. 
 
2.14.3 Bone marrow cells differentiations 
The cells, counted using a Neubauer haemocytometer, were plated at a 
concentration of 2x106ml in 10cm sterile Petri dishes with 10ml of conditioned 
medium. They were incubated in a humidified incubator for 5 days to allow 
proliferation and differentiation. 6ml of fresh conditioned medium was added on 
day 3. On day 5, non-adherent cells were removed by washing with PBS and 
adherent cells were harvested using a cell scraper. The bone marrow which was 
flushed from the femurs and the tibia gave approximately 50-80 x 106 cells per 
mouse and resulted in approximately 40 x 106 macrophages following 5 days of 
differentiation. The differentiation of macrophages was confirmed by flow cytometry 
using the F4/80 antigen staining that revealed 83% of macrophages at day 5 
(Figure 10) (Weischenfeldt and Porse 2008). F4/80 is a mature mouse cell surface 
glycoprotein expressed at high levels on various macrophages (Austyn and 
Gordon 1981).  
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Figure 10: Differentiation of bone marrow cells in macrophages. 
Bone marrow cells have been differentiated using L929 conditioned medium for 5 day. The 
differentiation was confirmed by flow cytometry using the F4/80 antigen staining that revealed 83% 
of macrophages at day. During each day of differentiation the FSC/SSC plot revealed the gradual 
increase of the macrophages population.  
 
 
 
 
 
Macrophage differentiation 
F4/80 APC 
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2.15 Flow cytometry analysis  
2.15.1 HEK293 transfected cells  
HEK293 FPR1 and FPR2/ALX cell surface expression was measured by 
incubation with anti-FPR1 or anti-FPR2/ALX mAb (1:100 dilution in both cases; 
from R&D System, Abingdon, UK and Genovac, Brussels, Belgium, respectively); a 
final staining with a rabbit antimouse IgG (1:200 dilution, clone STAR9B; Serotec) 
was then conducted. Flow cytometry analysis was performed analyzing ≥10,000 
events using a FACScalibur flow cytometer (Becton Dickinson, San José, CA) 
equipped with CellQuest software (Becton Dickinson) and analysed using FlowJo 
(Version 9.2, Treestar Inc, Stanford, CA). Results are reported as median 
fluorescence intensity (MFI) units.  
 
2.15.2 GFP detection  
Whole blood, peritoneal cells, bone marrow cells and bone marrow derived 
macrophages were analyzed by flow cytometry (FACS). The FACS analysis was 
used to monitor the fluorescent properties of the Green Fluorescence Protein. GFP 
expression was measured in the FL1 channel (natural fluorescence). To amplify 
the signal, a rabbit polyclonal anti-GFP antibody (Invitrogen, Molecular probes) and 
a PE-conjugated donkey anti-rabbit IgG secondary (1:200 dilution, eBioscience) 
were used. When the anti GFP antibody was used a cell membrane 
permeabilization with Saponin was performed to allow an intracellular staining.  
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Extracellular staining: cells were resuspended in round-bottom 96-well plate 
(400.000 cells/well) with 100µl ice-cold PBS containing 0.2% bovin serum albumin 
(BSA) and 1.3mM Cacl2 (PBC). Cells were washed (400g, 30s) before non-specific 
binding was blocked with 16mg/ml human immunoglobulin g (IgG) for 5 min at 4°C. 
Cells were then washed and incubated with the primary antibody for 40 min at 4°C 
followed, after 3 washing, by the secondary antibody for 20 min at 4°C. Cells were 
then washed prior to fixation with 4% formaldehyde (PFA) (10 min; 4°C) and 
resuspended in 200µl PBC for analysis.  
Intracellular staining: cells, incubated with 16mg/ml human immunoglobulin g 
(IgG) for 5 min at 4°C to block non-specific binding were then fixed with 4% PFA 
for 10 min at 4°C. Cells where then washed with PBC containing 0.1% saponin 
(From Saponaria species – Sigma) to allow permeabilization of the cell membrane. 
Then, the staining with the primary and the secondary antibody diluted in PBC 
supplemented with 0.1% saponin was performed as described for the extracellular 
staining. Cells were washed with PBC/0.1% saponin between each staining step. 
Finally cells were washed twice in PBC without saponin before being re-suspended 
in 200µl PBC for analysis. 
 
Whole blood staining: blood aliquots (0.5-1 ml of mouse blood) were collected by 
cardiac puncture using 3.2% tri-sodium citrate, from both WT and Fpr2/3 KO mice 
under terminal anesthesia. Aliquots were diluted to 4ml with PBC, centrifuged at 
400g for 5min and the cell pellets obtained stained, as above, in 15-ml tubes. 
Following staining the cell pellets were washed twice and lysed using 500µl/tube of 
Whole Blood Immuno-Lyse to allow the lysis of the red blood cells. Cells were then 
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washed twice, fixed with 2% PFA and resuspended in 250µl PBC for analysis. To 
monitor the nature of the cells an extracellular staining with APC conjugated Ly6G 
(GR-1, Granulocytes) and APC or PE conjugated F4/80 (Monocytes/Macrophages) 
was also performed.  
Flow cytometry analysis was performed analyzing ≥10,000 events using a 
FACScalibur flow  cytometer (Becton Dickinson, San José, CA), CellQuest 
software (Becton Dickinson) and analysed using FlowJo analysis software (Version 
9.2, Treestar Inc, Stanford, CA). Results are reported as % of positive cells and/or 
as median fluorescence intensity (MFI) units for specific fluorescence. 
 
 
2.16 Calcium mobilization assay 
HEK-293 cells or freshly prepared PMNs were incubated with 2µM Fura 2-AM 
(Molecular Probes, Invitrogen, Paisley, UK) and 1µM Pluronic Acid F127 
(Molecular Probes, Invitrogen, Paisley, UK) in extracellular solution (13mM glucose, 
10mM HEPES, 147mM NaCl, 2mM KCl, 1mM MgCl2, 2mM CaCl2 at pH 7.3) at 
37°C for 1 h in the dark. Subsequently, cells were washed x3 with the extracellular 
solution, added to 96-well plates prior to stimulation with agonists at indicated 
concentrations. Ionomycin (1µM), a Ca2+ ionophore, was used as a positive control. 
Mobilization of intracellular calcium was measured by recording the ratio of 
fluorescence emission at 510 nm after sequential excitation at 340 nm and 380nm 
using the NOVOstar microplate reader (BMG Labtech, Aylesbury, UK) (Figure 11). 
 
 
 99 
 
 
               A. 
 
 
 
B. 
 
 
 
 
Figure 11: Calcium mobilization induced by Ionomycin in HEK-293 cells 
Fura-2AM loaded HEK-293 cells were stimulated with ionomycin and calcium flux was recorded 
using the NOVOstar microplate reader (BMG Labtech, Aylesbury, UK). (A) Fura-2, a cell-permeable 
acetoxymethyl (AM) ester form of Fura-2, is excited at 340 nm and 380 nm of light. (B) The ratio of 
the emissions at those wavelengths is directly correlated to the amount calcium mobilization 
induced by Ionomycin. Buffer was used as negative control.  
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2.17 Liquid chromatography/tandem mass spectrometry 
measurement 
The liquid chromatography mass spectrometry assay has been performed by the 
laboratory of Prof. Natalie Vergnolle in Tolouse (France) using plasma samples 
rapidly frozen in liquid nitrogen and stored at -70 degrees. 
 
2.17.1 Lipid extraction 
Plasma samples were submitted to solid-phase extraction using HRX-50 mg 96-
well (Macherey Nagel, Hoerd, France). Briefly, the plate was conditioned by 
successive washing with MeOH (2 mL) and H2O/MeOH (90:10, 2 mL). The sample 
was loaded at flow rate of 0.1 mL/min. After complete loading, the plate was 
washed with H2O/MeOH (90:10, 2 mL). After drying under aspiration, lipid 
mediators were eluted with MeOH (2 mL). Solvent was evaporated under nitrogen 
and samples were dissolved with MeOH and stored at -80 °C for Liquid 
chromatography/tandem mass spectrometry measurements. 
 
2.17.2 Measurement 
6kPGF1a, TXB2, PGE2, PGA1, 8-isoPGA2, PGE3, LxA4, LxB4, RvD1, RvD2, 7-MaR1, 
LTB4, LTB5, Pdx, 18-HEPE, 5,6-DiHETE, 15-HETE, 12-HETE, 8-HETE, 5-HETE, 
17-HDoHE, 14-HDoHE, 14,15-EET, 11,12-EET, 8,9-EET, 5,6-EET and 5-oxo-ETE 
were quantified in plasma samples. To simultaneously separate 27 lipids of interest 
and 3 deuterated internal standards (LxA4-d5, LtB4-d4, 5-HETE-d8) LC-MS/MS 
analysis was performed on UHPLC system (Agilent LC1290 Infinity) coupled to 
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Agilent 6460 triple quadrupole MS (Agilent Technologies) equipped with electro-
spray ionization operating in negative mode. Reverse-phase UHPLC was 
performed using ZorBAX SB-C18 column (2.1 mm, 50 mm, 1.8 µm) (Agilent 
Technologies) with a gradient elution. Mobile phase A consisted of water, ACN and 
FA (75:25:0.1;v/v/v); Solvent B: ACN, FA (100:0.1, v/v). Compounds were 
separated with a linear gradient to 85 % B in 8.5 min and then to 100 % B in one 
more minute. Isocratic elution continued for 1 min at 100 % B then 100 % A was 
reached in 1 min and maintained for 1 min. The flow rate was 0.35 mL/min. The 
autosampler was set at 5 °C and the injection volume was 5 µL. Data were 
acquired in Multiple Reaction Monitoring (MRM) mode with optimized conditions 
(fragmentors and collision energy). Peak detection, integration and quantitative 
analysis were done using Mass Hunter Quantitative analysis software (Agilent 
Technologies). Mass Hunter quantitative (MH Quant) analysis software was used 
to generate calibration lines. For each standard, the validity of the calibration line 
was evaluated by comparing the deviation between back-calculated amounts and 
nominal amounts of standards. For the calibration curve, a linear regression with a 
weight factor of 1/X was applied for each compound. By the use of this factor, 
calibration line with a coefficient of correlation over 0.998 and an accuracy ranging 
from 85 % to 115 % was obtained. The limit of detection (LOD) and the limit of 
quantification (LOQ) were determined for the 13 compounds using signal to noise 
ratio (S/N). All values under the LOQ were not considered. Importantly, blank 
samples were evaluated, and their injection showed no interference (no peak 
detected), during the analysis 
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2.18 Assessment of cardiac function 
Basal cardiac function of WT and Fpr2/3 KO mice in normal condition was 
measured by Ken Suzuki laboratory at the William Harvey Research Institute, Barts 
and The London School of Medicine and Dentistry, Queen Mary, University of 
London, London, United Kingdom. Briefly, cardiac function of WT and Fpr2/3 K0 
mice was measured by using echocardiography (Vevo−770, VisualSonics) as 
previously described (Fukushima, Varela-Carver et al. 2007). Diastolic and systolic 
LV endocardial areas at the papillary muscle level were measured from parasternal 
short-axis views, from which LV fractional area change (LVFAC) was calculated. 
Hemodynamics parameters were measured by catheterization 
(SRP−320/PVAN3.2, Millar Instruments and Chart 5 software, ADInstruments) as 
described previously (Narita, Shintani et al. 2013). 
 
 
2.19 Statistics 
Experiments were performed with group of at least 5 mice and results expressed as 
mean ± SEM (Standard error of the mean). Statistical differences between 2 groups 
were determined with the unpaired Student t test; more than 2 groups were analysed 
using one- or two-way analysis of variance (ANOVA) upon satisfaction of homogeneity 
of variances. Intergroup analyses were assessed with the Dunnett or Bonferroni tests, 
as appropriate.  
 
The unpaired Student t test compares one variable: the means of two groups. We 
used the unpaired test because the samples were collected from two different 
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populations or from randomly selected individuals from the same population at 
different times. The test follows a Gaussian distribution; a theory that tells the 
probability that an observation would fall between any two real numbers. The null 
hypothesis is that the means of the samples are equal for the two groups.  
 
In an experiment with more than two groups, a multiple two-sample t-tests would 
increase the chance to have a type I error: a rejection of the null hypothesis. For this 
reason to compare the data of two or more group the analysis of variance was used. 
The ANOVA tests the null hypothesis that samples in two or more groups have the 
same mean values using the F-distribution, an asymmetric distribution characterised 
only by a minimum value of 0. Samples must be normally distributed. The one-way 
ANOVA analyses the effect of one independent variable, the two-way ANOVA the 
effect of more than one independent variable and multiple observations for each 
independent variable. Indeed, the two-way ANOVA measures the effect of 
contributions of each independent variable and also if there is an interaction effect 
between the independent variables.  
 
One- or two-way ANOVA test were followed by Dunnett or Bonferroni post tests. The 
Dunnett test compares each treatment with a control value. The Bonferroni test 
compare selected pairs of means. 
 
In all the experiment, a p<0.05, described the p value as the probability of getting the 
results given that the null hypothesis is true, was taken as a threshold for rejecting the 
null hypothesis.  All analyses were performed using GraphPad Prism 5.0 software. 
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3.1 Rationale 
The FPR2/ALX pathway is part of an endogenous counter-regulatory circuit crucial 
for the resolution phase of the inflammatory response. Whereas the levels of its 
agonists are often quantified in several experimental and clinical inflammatory 
states, the potential modulation of specific receptors is almost over-looked and 
partially unexplored.  Related to the FPR2/ALX pathway, AnxA1 gene promoter 
activity was studied in a spatial and temporal fashion during experimental 
inflammatory and septic settings (Damazo, Yona et al. 2006). Another link between 
these pathways is represented by the fact that expression of FPR2/ALX can be 
induced by glucocorticoids in leukocytes (Sawmynaden and Perretti 2006) and in 
experimental dermatitis (Hashimoto, Murakami et al. 2007). 
 
We propose that receptor modulation could also occur in disease and/or after 
therapeutic treatment.  
 
To understand how FPR2/ALX is involved in the inflammatory response we thought 
it was important to investigate how its expression could be regulated in vivo. For 
this reason we have generated a novel Fpr2/3 null mouse which bears an in-frame 
green fluorescence protein (GFP) gene ‘knocked-in’ (Dufton, Hannon et al. 2010) 
and we developed novel analytical protocols to monitor GFP expression as a 
reporter for Fpr2/3 gene promoter activity. Specifically, we used biochemical and 
imaging protocols aimed at determining cell-associated GFP expression in cells 
and tissues harvested from the Fpr2/3 null colony.  
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These techniques helped to understand if and how inflammation could modulate 
FPR2/ALX expression and this achievement would provide important knowledge 
on the biology of this receptor and on the opportunity that selective agonists may 
be relevant as novel anti-inflammatory therapeutics. 
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3.2 Genotyping of Fpr2/3 KO mice 
The genotype of Fpr2/3 KO mice, on a C57BL/6 WT background, was confirmed. 
Mice were screened by PCR of ear clip DNA for the transmission of the Fpr2/3 
allele (Figure 12). Using our strategy the deletion of the Fpr2 gene also deleted the 
Fpr3 gene since it incorporates exon 1 of Fpr2. 
 
The primers used were F1 (Fpr2 forward – TGAGTGTCATGTCAGAAGGAGCC), 
B11 (Fpr2 reverse for WT – CGGAATCCAGCTACCCAAATC) and GB4 (Fpr2 
reverse for KO –ATAACCTTCGGGCATGGCACT). The F1/B11 pair produced a 
band of 233 bp from the wild type allele, whereas F1 and GB4 produced a band of 
351 bp for the allele of Fpr2/3 KO mice. A double band identified the heterozygous 
mice. 
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Figure 12: Genotyping of Fpr2/3 KO and C57BL/6 WT mice. 
Ear clips DNA were removed from mice and screened by PCR. The genotyping was confirmed by 
southern blotting analysis. The F1 (Fpr2 forward), B11 (Fpr2 reverse for WT) and GB4 (Fpr2 
reverse for KO) primers were used to identify the wild type allele (F1/B11 pair at 233 bp), the Fpr2/3 
KO allele (F1/GB4 pair at 351 bp) and heterozygous mice (double band). Example of blot of 15 
different mice is shown.   
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3.2 GFP expression of tissues harvested from Fpr2/3 KO  
mice. 
The natural fluorescence of tissues harvested from the Fpr2/3 KO mice was 
identified and quantified by immunohistochemistry.  
 
The tissues that exhibited GFP positivity were: aorta, heart, lung, spleen, liver and 
kidney (Figure 13 A). Using the imaging software ImageJ, the extent of GFP 
expression was also quantified finding the kidney as the tissue with the highest 
expression of the green fluorescent protein. Thus, taking the kidney as 100% of 
GFP expression, green fluorescence protein of the other tissues was quantified 
and compared as shown in Figure 13 bottom panel.  
 
It is noteworthy to mention that to quantify GFP expression across all tissues 
identical conditions were kept: they were all stained with hematoxylin and eosin 
and observed using a 20x magnification applying an exposure of 56 milliseconds to 
the blue light.  
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Figure 13: GFP expression in tissues harvested from Fpr2/3 KO mice. 
(A) Natural fluorescence of tissues (from left: kidney, aorta, heart, lung, liver and spleen) harvested 
from the Fpr2 KO mice. The tissues were stained with haematoxylin and eosin and observed using 
a 20x magnification and an exposure of 56 seconds to the blue light. (B) Using the imaging 
software ImageJ the GFP expression was quantified in terms of fluorescence intensity. Data were 
calculated taking the values of the kidney as 100%. Data are expressed as mean ± SEM of at least 
5 different slice of each tissue harvested from 6 to 15 mice (**p<0.01, ***p<0.001 vs. kidney).  
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3.2.1 Auto-fluorescesce of WT tissues: validation of GFP 
expression in the Fpr2/3 KO mouse 
To validate the specificity of the green fluorescence of the Fpr2/3 KO mice the 
fluorescence of WT mice was also observed subjecting tissue slices to the same 
condition used for the Fpr2/3 KO mice (20x, 56milliseconds). No fluorescence was 
detected in any of the WT tissue samples (Figure 14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Green fluorescence of tissues harvested from WT mice. 
Kidney, Aorta, Heart, Lung, Liver and Spleen (From Left to Right) harvested from WT mice were analysed 
using a 20x magnification after 56sec of exposure to the blue light. Pictures are representative of at least 5 
different slice of each tissue harvested from 6 to 15 mice. 
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3.2.2 HRP staining with the anti mouse Fpr2 antibody  
To compare – at least qualitatively – expression of Fpr2 in WT mice with the results 
obtained, and presented above for the GFP expression in the Frp2/3 KO tissues, 
an antibody against mouse Fpr2 (Santa-Cruz) was also used in WT mice. The 
antibody was tested in two tissues, selected because of their different degree of 
fluorescence, the kidney (Figure 15) and the lung (Figure 16).  
 
The HRP staining was performed using different concentrations of the primary 
antibody. Examples of antibody titrations are shown. Negative controls for the 
staining procedures were also conducted, omitting the primary antibody or staining 
in the absence of any antibody (Panels A and B in both Figure 15 and Figure 16). 
Another important control for the specificity of the primary antibody was the use 
Fpr2/3 KO mice, which tissues I tested only with the optimal dilution (1:200 for 
Kidney and 1:100 for Lung). The anti-Fpr2 antibody did not give any staining in the 
null mouse tissue samples (Panels F,G and H of Figures 15 and 16). 
 
That the anti-Fpr2 antibody worked in the WT mice and not in the Fpr2/3 KO 
emphasized the specificity of the antibody for the Fpr2 receptor. Therefore, the 
results obtained with the GFP staining in tissues prepared from Fpr2/3 KO mice 
could be considered genuine, and the protocol used further, since there was at 
least a qualitative match and validation with WT tissues using the anti-Fpr2 
antibody.  
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Figure 15: Fpr2 staining on kidneys harvested from WT and Fpr2/3 KO mice. 
The staining with the anti-mouse Fpr2 antibody was performed on WT mice at different dilutions of 
1:50 (C), 1:100 (D) and 1:200 (E). Images of WT tissue not-stained (negative control; A) and 
stained with the 2°Ab (B) are shown. As a further control the staining was performed in Fpr2/3 KO 
tissue samples. Picture of not-stained (F), and stained with the 2° antibody (G) and the Fpr2 
antibody at 1:200 dilutions (H) are shown. Images are representative of at least 6 different slices of 
each tissue harvested from 5 to 15 mice. 
 
  
 
A: WT not stained B: WT 2Ab only 
C: WT 1:50 
D: WT 1:100 
E: WT 1:200 
F: Fpr2/3 KO  
Not-stained 
G: Fpr2/3 KO 2Ab H: Fpr2/3 KO 1:200 
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Figure 16: Fpr2 staining on lungs harvested from WT and Fpr2/3 KO mice. 
The staining with the anti-mouse Fpr2 antibody was performed on WT mice at different dilutions of 
1:50 (C), 1:100 (D) and 1:200 (E). Images of WT tissue not-stained (negative control; A) and 
stained with the 2°Ab (B) are shown. As a further control the staining was performed in Fpr2/3 KO 
tissue samples. Picture of not-stained (F), and stained with the 2° antibody (G) and the Fpr2 
antibody at 1:200 dilutions (H) are shown. Pictures are representative of at least 6 different slices of 
each tissue harvested from 5 to 15 mice. 
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3.2.3 Western Blotting Analyses. 
We have also established whether Western blotting could also be a valid method to 
‘chase’ GFP expression, hence potential modulation of Fpr2/3 gene activity. To do 
this, we have tested different anti-GFP antibody: 
1. Invitrogen – GFP ABfinity recombinant rabbit monoclonal (G10362) 
2. Invitrogen – Anti-GFP chicken (A10262) 
3. AbD Serotec – Goat Anti Green Fluorescent Protein (AHP975) 
4. Clontecg – Living Colours A.v. Peptide Antibody (632377) 
and tested them in bone marrow cells (Figure 17 A) and kidney’s lysate harvested 
from the Fpr2/3 KO mice (Figure 17 A,B) 
 
Kidney was used as the tissue with the highest expression of the GFP. 
 
As a positive control and, to test the validity of the antibodies, we have used HEK-
293 cells stable transfected with the green fluorescence protein (Figure 17 A). In 
other experiment we also used kidney of KO mice treated with LPS, an 
inflammatory stimuli able to induce Fpr2/3 (Figure 17 B). Unfortunately we have 
been not able to detect the presence of GFP in any of the Fpr2/3 KO cells and 
tissues using this technique.  
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Figure 17: Western Blot analysis. 
Representative blots of HEK-GFP cells, Fpr2/3 KO Bone Marrow Cells (BMC) and Fpr2/3 KO 
Kidney lysates from sham surgery mice or mice after 30 min or 3h or ischemia/reperfusion injury, 
incubated with anti-GFP Ab (1:1000) and beta-actin antibody (A). Beta-actin of kidney lysate from 
sham surgery WT and Fpr2/3 KO mice or Fpr2/3 KO treated for 6h and 24h with LPS (10mg/kg i.p). 
No GFP signals were detected (B).  
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3.2.3 GFP expression on cells of Fpr2/3 KO mice 
FPR2/ALX is expressed on a variety of immune cells, including neutrophils, 
mononuclear cells and lymphocytes.  To validate the GFP expression in these cell 
types blood, bone marrow derived cells and peritoneal cells of Fpr2/3 KO mice 
were analysed.  
 
Blood was collected by cardiac puncture from both WT and Fpr2/3 KO mice and, 
after lysis of red blood cells, was analyzed by flow cytometry. To monitor the 
natural GFP fluorescence the FL-1 channel was used and to amplify the GFP 
signal, an intracellular staining with an anti-GFP antibody was performed. As 
shown in Figure 18, neutrophils exhibit ~6% of natural green fluorescence that is 
amplified up to ~20% value using an anti-GFP antibody at a final dilution of 1:50 
(titration of the antibody was performed as showed in figure 18 B). Performing the 
Ly6G staining procedure the GFP fluorescence was covered and lost. To avoid this 
problem neutrophils were gated in the FSC/SSC plot (Figure 18 A) and GFP 
expression of this specific population was then quantified. 
 
GFP expression in bone marrow cells was detected without the use of specific anti-
GFP antibodies. Indeed, Fpr2/3 KO mice showed ∼14% of GFP positive cells in the 
FL-1 channel (against a background of ∼2% in WT mice - Figure 19 A). Deeper 
phenotyping of the FL-1 positive population with markers for macrophages and 
neutrophils revealed that ~25% of events corresponded to F4/80+ve cells whilst 
~40% Ly6G+ve cells could be found (Figure 19 B).   
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Bone marrow derived cells were also differentiated into macrophages over a 5-day 
culture protocol in L929 conditioned medium. Fpr2/3/GFP expression was 
monitored over this time course (Figure 20 B,C). Already at Day 1, cells harvested 
from Fpr2/3 KO mice (Figure 20 A-blue line) showed a detectable GFP+ve 
population, which was clearly not present in WT mice (Figure 20 A-red line). As 
can be seen in Figure 20 B, the percentage of GFP positive cells remained 
unchanged up to Day 3 whilst it underwent a major increase on Day 4 (Figure 20 
D,E,F). A more gradual increase in GFP expression could be monitored in terms of 
MFI units, i.e. intensity of GFP expression at the single cell level. Indeed, the 
median of MFI united changed from a value of 5 at Day 2 to a value of ~20 at Day 
5 (Figure 20 C).  
 
Finally, peritoneal cells were also studied. Out of the total peritoneal cells 
harvested from the Fpr2/3 KO mice, ~5% of GFP positive cells (with a 10 units for 
MFI) and ≥50% GFP positive cells (with a median intensity of 25 units) were 
revealed using an anti-GFP antibody (Figure 21 A,B). Further detailing with specific 
cell markers indicated presence of ≤1% of Ly6G positive cells in the pool of GFP 
positive peritoneal cells prepared from naïve cavities (Figure 21 C) whilst 30% of 
cells were F4/80 positive (Figure 21 D). WT mice were used as a negative control.  
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Figure 18: Fpr2/GFP expression in Neutrophils. 
Whole blood was collected by cardiac puncture from Fpr2/3 KO mice and analysed by Flow 
Cytometry after lysis of the red blood cells. (A) Representative FSC/SSC plot. (B) Analysis of the 
gated neutrophils, revealed a 6% (MFI 6%) of natural green fluorescence that was amplified to a 
20% value using an anti-GFP antibody at 1:50 concentration. Data, analysed with FlowJo software 
and reported as % of positive cells, are expressed as mean ± SEM of 10 to 20 mice. * p<0.05, 
**p<0.01, ***  p<0.001 vs FL1. 
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Figure 19: Fpr2/GFP expression in Bone Marrow Cells. 
Bone marrow cells collected from femurs and tibia of WT and Fpr2/3 KO mice were analysed by 
flow cytometry. (A) Analysis of the FL-1 channel revealed an exclusive population of 13.7% GFP 
positive cells in Fpr2/3 KO mice. WT mice showed 1.5 % of FL-1 positive cells. (B) The Fpr2 
KO/GFP population was characterised by 25% of F4/80 positive cells and 40% of Ly6G positive 
cells. Data have been analysed using the FlowJo software and are reported as % of positive cells. 
Data are expressed as mean ± SEM of 10 to 20 mice. 
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Figure 20: GFP expression in bone marrow derived macrophages. 
WT and Fpr2/3 KO bone marrow cells have been collected and differentiated into macrophages for 
5 days in L929 conditioned medium. (B,C) Monitoring of GFP expression, expressed in terms of % 
of positive cells (B) and MFI (C), during the 5 days of differentiation. (A) Fpr2/3 KO and not WT cells, 
were positive for the GFP already at day 1 and increase in numbers until day 4 (E,F). (D) GFP 
expression in WT mice also at day 4 is inexistent. Results, analysed with the FlowJo software, are 
reported as % of positive cells and as median fluorescence intensity (MFI) units for specific 
fluorescence. Data are expressed as mean ± SEM of 10 to 15 mice (**p<0.01, *** p<0.001 vs Day 4 
in figure B and Day 5 in figure C). 
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Figure 21: GFP expression in peritoneal cells. 
Peritoneal cells from the cavity of Fpr2/3 KO were collected with a lavage of PBS and EDTA and 
analysed by flow cytometry. (A,B) Fpr2 KO peritoneal cells showed a 5% of FL-1 positive cells with 
a 10% of MFI increased up to 50% of GFP positive cells with a 25% of MFI using an anti-GFP 
antibody (1;50). Other concentrations of anti-GFP antibody were also used (1:200, 1:100). (C,D) 
The GFP positive population is composed by 1% of Ly6G positive cells and 30% of F4/80 positive 
cells. Results have been analysed using the FlowJo software and reported as % of positive cells 
and as median fluorescence intensity (MFI) units for specific fluorescence. Data are expressed as 
mean ± SEM of 10 to 15 mice (* p<0.05, **p<0.01, *** p<0.001). 
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3.2.4 Conclusion 
FPR1 and FPR2/ALX cellular and tissue distribution is mirrored by their murine 
orthologues, suggesting the important information that they might maintain 
physiological roles and functions across the species (Fu, Karlsson et al. 2006).  
FPR1 and FPR2/ALX receptors are expressed on PMN and mononuclear cells, 
both myeloid and lymphocytes (Schiffmann, Corcoran et al. 1975, Showell, Freer et 
al. 1976, Aswanikumar, Corcoran et al. 1977, Zigmond 1977). Human and rodent 
FPR1 receptor display quiet a widespread distribution since it has been found, 
using immunohistochemical methods, in tissues that include epithelial cells 
(Rotrosen, Malech et al. 1987), endocrine cells (including follicular cells of the 
thyroid and cortical cells of the adrenal gland), platelets, liver hepatocytes and 
Kupffer cells, smooth muscle cells, brain, spinal cord and both sensory and motor 
neurons (Lacy, Jones et al. 1995, McCoy, Haviland et al. 1995, Le, Hu et al. 2000, 
Czapiga, Gao et al. 2005, Fu, Karlsson et al. 2006). The localization of FPR2/ALX 
has not yet been investigated, though it is expressed by endothelial cells (Fierro, 
Colgan et al. 2003) and epithelial cells (Leoni, Alam et al. 2013). However, the 
tissues distribution of the human FPR gene family members remains a partial 
unexplored field.  
 
GFP expression was studied in Fpr2/3 KO tissues using fluorescence microscopy. 
Using this approach we were able to identify Fpr2/3 localization around the body: 
the quantification of the fluorescence revealed that the Fpr2/3 genes may be more 
active (or expressed by a higher number of positive cells) in the kidney, followed by 
the heart, aorta, heart, lung, liver and spleen (Figure 13,14). It was important to 
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corroborate the findings obtained by GFP fluorescence with the anti-Fpr2 staining 
in WT tissue (Figure 15,16).  
 
GFP expression has also been studied in cells harvested from the Fpr2/3 KO mice. 
In the first 24 hours of the inflammatory reaction, the infiltration is predominantly 
composed by PMNs (Witko-Sarsat, Rieu et al. 2000, Kantari, Pederzoli-Ribeil et al. 
2008). During on-going inflammatory reactions the profile of infiltrated cells change 
from PMNs to monocyte and macrophages. The number of the latter cells 
increased more slowly becoming the major cells type between 48 and 72 hours 
(Bellingan, Caldwell et al. 1996, Kantari, Pederzoli-Ribeil et al. 2008). The great 
relevance of neutrophils and macrophages in the resolving phase of an acute 
inflammatory process (Nathan 2002, Luster, Alon et al. 2005) led us to focus our 
work on these two populations.  To monitor the GFP expression of neutrophils and 
macrophages we used the flow cytometry; the FL-1 channel was used for the 
green natural fluorescence and to amplify the signal, an intracellular staining with 
an anti-GFP antibody was performed. 
 
We started off by trying to quantify the GFP expression in the whole blood however, 
even when we added an anti-GFP antibody, we could not obtain a strong enough 
fluorescent signal. Then, we stained neutrophils with the Ly6G marker in a mixed 
population of blood cells after removal of erythrocytes by lysis; however, the double 
staining masked the GFP fluorescence. To avoid this problem we used the scatter 
characteristics to gate the neutrophils in the FSC/SSC plot and quantify the GFP 
expression of this population (Figure 18 A). Using this method, the neutrophils of 
the Fpr2/3 KO mice exhibited ~5% of GFP +ve signal (with a value of MFI units of 
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6), and this was increased to 20% (with MFI units of 9%) value using an anti-GFP 
antibody at 1:50 concentration (Figure 18 B). 
 
I have also tried other techniques and protocols for separation and analysis of 
neutrophils from the whole blood. We tried different protocols with Histopaque of 
different density, the protocol that we used for the isolation of human neutrophils or 
we attempted to sort neutrophils from the whole blood using a sorting machine. 
None of these protocols gave positive results. I conclude that the more appropriate 
method is using a mixed population of cells (e.g. peripheral blood cells after lysis of 
the red blood cells), gating PMN using their forward and side scatter profile, and 
analyse their degree of GFP expression. All in all I am not fully confident that this 
protocol can be consistently used for this cell type.  
 
We obtained better results when macrophage expression was investigated. Firstly, 
we started with bone marrow cells, which gave a clear signal in the FL1 channel 
when prepared from Fpr2/3 KO mice (~10% of GFP positive cells) (Figure 19). 
Deeper phenotyping of the FL-1 positive population with markers for macrophages 
and neutrophils revealed that ~25% of events corresponded to F4/80+ve cells 
whilst ~40% Ly6G+ve cells could be found (Figure 19 B). Following analysis on the 
presence of GFP staining in the bone marrow, we moved on to bone marrow 
derived macrophages, prepared over a 5-day culture protocol (see Figure 10: bone 
marrow cells differentiation using L929 conditioned medium). Since it has been 
published that FPR2/ALX expression remains unchanged during monocyte 
differentiation into macrophages (Ye, Boulay et al. 2009) we monitored GFP 
expression daily. Already only after 1 day of differentiation the bone marrow cells 
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harvested from Fpr2/3 KO mice showed a GFP positive population which was 
obviously absent in WT mice. During the 5 days of differentiation, as can be seen 
in figure 20 B and C, the percentage of GFP positive cells remained unchanged 
during the first three day and had a significant increase on day 4. Instead, in terms 
of MFI, we detected a gradual increase. It changes from 5 at day 2 to 18 at day 5. 
On figure 20 D,E and F it is shown the FL-1 expression in WT (Figure 20 D, F-red 
line) and Fpr2/3 KO mice (Figure 20 E, F-red line) at day 4. It is evident that the FL-
1 positive population is specific for the Fpr2/3 KO mice and that, during the 
differentiation into macrophages the GFP positive cells increase in terms of 
number (Figure 20).  
 
We have also analysed peritoneal macrophages. The peritoneal cavity is a unique 
compartment within which a variety of immune cells reside, and from which 
macrophages are commonly collect for functional studies. Peritoneal cells 
harvested from the Fpr2/3 KO mice showed 5% of FL-1 positive cells with a 10% of 
MFI and 50% of GFP positive cells with a 25% of MFI using an anti-GFP antibody 
(Figure 21 A,B). In the peritoneal cells we founded 1% of Ly6G positive cells 
(Figure 21 C) and 30% of F4/80 positive cells (Figure 21 D).  
 
We also tried do quantify the GFP expression by Western blotting using different 
anti-GFP antibody. Unfortunately we have been not able to detect the presence of 
GFP in any of the Fpr2/3 KO cells and tissues using this technique (Figure 17).  
 
In conclusion we have monitored the pattern of expression of Fpr2/GFP in murine 
tissues and cells. We are not confident that we will be able to quantify the GFP 
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expression as a report for Fpr2/3 gene promoter activity but we will use these 
techniques to localize Fpr2/3 in our model. Also, Fpr2/3 is expressed in the organs 
of our interest (heart, lung and kidney) and in infiltrating cells that characterize the 
inflammatory response during acute myocardial injury, all in all increasing our 
interest in studying the role of this receptor in AMI in the heart and in secondary 
injury organs. 
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4.1 Echocardiography in WT and Fpr2/3 KO sham mice: 
evaluation of left ventricle function 
To confirm that WT and Fpr2/3 KO mice have the same left ventricle function in 
physiological condition echocardiography was performed in sham mice. Both WT 
and Fpr2/3 KO mice showed the same heart function and contractility as 
expressed in terms of heart rate, interventricular septal thicknesses, left ventricle 
internal dimensions, posterior wall thicknesses, ejection fraction, fractional 
shortening and posterior wall thickening (Table 1). 
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Table 1: Left ventricle (LV) function of sham WT and Fpr2/3 KO mice. 
Echocardiography data of WT and Fpr2 KO mice in normal condition with correlated heart rate (HR) 
value. At diastole (d) and systole (s): LV interventricular septal thicknesses (IVS), LV internal 
dimensions (LVID), Posterior wall thicknesses (LVPW), Ejection fraction (EF), Fractional shortening 
(FS), Posterior wass thickening (PWT). Data (mean ± SEM) of 6 mice. *P<0.05 between WT and 
Fpr2 KO. 
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4.2 Role of Annexin A1 and Formyl Peptide Receptors in 
Acute Myocardial Infarct 
AnxA1 (1 µg per mouse ~ 27 pmol (Gavins, Dalli et al. 2007)) was injected 
intravenously in WT mice and the infarct size was quantified. The AMI procedure 
led to necrosis of ~55% of the area at risk (AAR) (Figure 22 A). Administration of 
AnxA1 before LADCA occlusion afforded significant cardioprotection (~30% 
reduction of infarct size, p<0.01) as compared to vehicle (PBS). AnxA1 
administration at the beginning of reperfusion afforded a much lower degree of 
protection (~10%) (Figure 22 B,C). To evaluate the involvement of the Formyl 
Peptide Receptor (Fpr) 1 and 2 in AnxA1 mediated cardioprotection, similar 
experiments were performed in Fpr1 and Fpr2/3 KO mice using an i.v injection of 
AnxA1 prior to ischemia. Deletion of Fpr1 did not significantly alter the 
cardioprotective effect of AnxA1, whilst the protein less effective in Fpr2/3 KO mice 
(p<0.05) (Figure 23). 
 
Analysis of mRNA expression in hearts of WT mice after AMI revealed a marked 
increase in Fpr2 mRNA during ischemia (Figure 24 A) and an increase in AnxA1 
mRNA during reperfusion (Figure 24 B). Upregulation of Fpr1 mRNA occurred in 
both ischemia and reperfusion (Figure 24 C). Exogenous AnxA1 administration at 
the beginning of ischemia also induced an upregulation in the expression of Fpr2 
mRNA after AMI (p<0.01 vs. Vehicle) (Figure 24 D). 
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Figure 22: AnxA1 cardioprotection in vivo. 
WT mice were injected intravenously with vehicle (PBS) or AnxA1 as shown. AMI procedure of 
30+90 min I/R was applied, through occlusion of the LADCA, and area at risk and infarct size 
analysed. (A) Occlusion of the artery blocked the oxygen to a ~55% of the left ventricle (Area at risk 
- AAR). Necrosis of this area are is referred as infarct size (B) and the left ventricle (C). I.v. injection 
of AnxA1 (1 µg) before ischemia afforded significant cardioprotection (~30% reduction of infarct size, 
p<0.01) as compared to vehicle (PBS). AnxA1 administration at the beginning of reperfusion 
afforded a less degree of protection (~10%). Data are expressed as mean ± SEM of 8 to 10 mice 
per group. 
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Figure 23: Role of Fprs on AnxA1 cardioprotection in vivo. 
WT, Fpr1 and Fpr2/3 KO mice were subjected to 30 min of ischemia through occlusion of the 
LADCA and 90 min of reperfusion. All mice were injected intravenously with vehicle (PBS) or AnxA1 
(1 µg) prior ischemia. At the end of reperfusion the area at risk and the infarct size were analysed. 
(A) LADCA occlusion induced ~55% necrosis of the AAR in WT, Fpr1 and Fpr2/3 KO mice. (B) 
AnxA1 cardioprotective activity decreased in both Fpr2/3KO and Fpr1 KO mice (p<0.05). (C) The 
decrease of infarct size induced by AnxA1 was significantly less in the Fpr2/3 KO mice compared to 
WT mice (p<0.05). Data are showed as mean ± SEM of 8 to 10 mice per group. 
 
 
 
 
 
. 
 
 
 
 134 
 
 
 
 
 
Figure 24: AnxA1, Fpr2 and Fpr1 mRNA modulation during AMI. 
WT mice were subjected to AMI. At indicated time points hearts were collected and RNA and cDNA 
extracted and analysed with specific primers. mRNA regulation of (A) Fpr2, (B) AnxA1 and (C) Fpr1 
is shown. (D) WT mice were treated i.v. with vehicle (PBS) or AnxA1 (1 µg) prior ischemia. After 
30+90 min I/R Fpr2 mRNA upregulation was higher in mice treated with the protein (p<0.01). 
According to the relative quantification method the response produced in control mice (no AMI) was 
taken as 1 and data represent the upregulation (>1) or downregulation (<1) of mRNA expression. 
GAPDH was used as endogenous control. Data are showed as mean ± SEM of 8 to 10 mice per 
time point.  
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 4.2.1 The role of Fpr2/3 in AnxA1 cardioprotection 
Immunofluorescence of Fpr2/3 (GFP) and AnxA1 showed that the Fpr2/3 and 
Annexin A1 are expressed, and co-localized, in cardiomyocytes and in the 
neutrophils (Ly6G positive cells) of heart subjected to acute myocardial infarct 
(Figure 25).  
 
To evaluate the damage induced by AMI and the role of AnxA1 during this patology, 
plasma troponin I levels and caspase 3 activity in the heart were evaluated. 
Troponin I is a contractile regulatory protein that controls calcium-mediated 
interactions between actin and myosin in cardiac and skeletal muscles, and, 
importantly, is released into circulation in response to myocardial necrosis 
whereupon it can be used as a clinical biomarker of cardiac injury. Caspase 3 is a 
member of the cysteine-aspartic acid protease family. Caspases exist as inactive 
proenzymes that undergo proteolytic processing to produce two subunits that 
dimerize to form the active enzyme. Caspase 3 activation plays a central role in 
cell apoptosis. 
 
AMI was able to induce Troponin I (p<0.01) in WT mice. The levels were 
significantly decreased (p<0.01) by an i.v injection of AnxA1 (1 µg) prior too 
ischemia (Figure 26 A). The effect of AnxA1 was lost in Fpr2/3 KO mice (p<0.01 
WT AnxA1 AMI vs. KO AnxA1 AMI) (Figure 26 A). Also Caspase 3 activity was 
induced by AMI (p<0.001) and decreased after AnxA1 injection (Figure 26 B) only 
in WT mice (p<0.001) and not in Fpr2/3 KO mice (p<0.001 WT AnxA1 AMI vs. KO 
AnxA1 AMI) (Figure 26 B).  
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To study the inflammatory response the levels of the neutrophils chemokine KC 
and TNFα were evaluated. AMI significantly increased the levels of KC (p<0.001) 
that were decreased by AnxA1 (p<0.001) in WT and KO mice (Figure 27 A). AnxA1 
injection also decreased the levels of TNFα, in this case only in WT mice (p<0.05) 
and not in KO mice (p<0.001) (Figure 27 B).  Interesting the Fpr2/3 KO mice had a 
decrease (p<0.05) of the cardioprotective AnxA1 after AMI (Figure 28). 
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Figure 25: Immunofluoresce staining of heart of Fpr2/3 KO mice after AMI. 
Hearts harvested from Fpr2/3 KO mice after AMI and subjected to immunofluorescence after 
staining with the AnxA1 antibody (in red, 1:1000) and the Ly6G antibody (in purple, 1:1000). Slides 
were also exposed to the blue light to allow the detection of the Fpr2/3 receptors expressed by the 
natural GFP fluorescence. The tissues were observed using a 20x magnification after 
immunofluorescence compensation. 
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Figure 26: The cardioprotective effects of AnxA1 during AMI in WT and Fpr2/3 KO mice. 
AMI procedure of 30+90 min I/R, through occlusion of the LADCA, was applied on WT and Fpr2/3 
KO mice. At the end of reperfusion plasma and heart were collected and analysed. In WT mice 
(white bar), AnxA1 (1 µg) administrated i.v prior ischemia, decreased the plasma levels of Troponin 
I (p<0.01) induced by AMI (p<0.01 vs. sham). The effect of AnxA1 was lost in Fpr2/3 KO mice 
(black bar) (p<0.01 AnxA1 WT vs. AnxA1 Fpr2/3 KO). (B) The role of AnxA1 on caspase 3 activity 
induced by acute myocardial infarct (p<0.001 vs. sham mice) in hearts was also evaluated.  AnxA1 
injection decreased the augmented levels of Caspase 3 in WT mice (p<0.001) and not in Fpr2/3 KO 
mice (black bar) (p<0.001 AnxA1 WT vs. AnxA1 Fpr2/3 KO). Data are expressed as mean ± SEM 
of 8 to 12 mice per group. 
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Figure 27: AnxA1 decrease the inflammatory response induced by AMI in the heart. 
WT and Fpr2/3 KO were subjected to AMI after an i.v. injection of AnxA1 (1 µg)  prior ischemia. 
Hearts were excised at the end of reperfusion and analysed.  (A) AnxA1 decreased the levels of KC 
(p<0.001) induced by AMI (p<0.001) in WT (white bar) and Fpr2/3 KO mice (black bar). (B) AnxA1 
injection also decreased the levels of TNFα (p<0.05) and the effect was lost in Fpr2/3 KO mice 
(black bar) (p<0.001). Data are mean ± SEM of 8 to 12 mice per group. 
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Figure 28: AnxA1 expression in WT and Fpr2/3 KO mice after AMI in the heart. 
AnxA1 expression in hearts of WT and Fpr2/3 KO sham mice or subjected to acute myocardial 
infarct through 30 min of occlusion of the LADCA and 90 min of reperfusion was analysed. AnxA1 
was decreased in Fpr2/3 KO mice after AMI (p<0.05 vs. WT AMI). Protein expression was 
monitored by western blot analysis using an AnxA1 antibody (1:1000, Cell Signalling) an anti-β-
actin antibody (1:10,000; SigmaAldrich) as loading control. Representative blots from ≥3 
experiments with distinct cell preparations are shown. 
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4.3 Effects of Acute Myocardial Infarct in Fpr2/3 KO mice 
 
4.3.1 Survival and Infarct size of WT and Fpr2/3 KO mice 
A significant proportion (~40%) of Fpr2/3 KO mice perished during the procedure 
of experimental AMI (Figure 29 A), and those that did survive up to 90 min post-
reperfusion (Figure 29 A) exhibited a larger infarct size (~15%, p<0.05) than WT 
animals (Figure 29 C,D).  
 
Congruently, Fpr2/3 KO mice showed an increase in plasma troponin I after AMI 
(p<0.001), and moreover, these levels were significantly higher in the Fpr2/3 KO 
mice than in WT animals (p<0.05) (Figure 30 A). Heart tissue from both WT and 
Fpr2/3 KO mice showed an increase in Caspase 3 activity after AMI (p<0.001) 
(Figure 30 B). 
 
The expression of Fpr1, Fpr2 and AnxA1 mRNAs was up regulated in hearts of WT 
and Fpr2/3 KO mice after acute myocardial infarct (Figure 31 A). AnxA1 mRNA 
upregulation was significantly higher in Fpr2/3 KO mice compared with WT 
(p<0.001), whilst in contrast Fpr1 mRNA expression was upregulated similarly in 
the two different strains of mice (Figure 31 B,C). Interesting, the Fpr2 mRNA 
induction in the heart, during LADCA occlusion (Figure 24 A and Figure 32 A) were 
not connected with an increase in neutrophils infiltration, as seen by CXCL1 mRNA 
and KC quantification (Figure 32 C). During ischemia, the levels of KC were 
increased only in the plasma (Figure 32 B). 
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Figure 29: The impact of AMI on Fpr2/3 KO mice. 
In WT and Fpr2/3 KO mice the LADCA was occluded for 30 min and re-opened for 90 min. Survival 
was monitored and recorded over all the AMI procedure. At the end of reperfusion the area at risk 
and infarct size were valuated. (A) 39% of Fpr2/3 KO mice and no WT mice died during the surgery. 
WT mice survived over all the reperfusion period (120h), Fpr2/3 KO were dying after 90 min. (B) 
AMI caused ~55% necrosis of the left ventricle (Area at risk) to both WT and Fpr2/3 KO mice. (C) 
Fpr2/3 KO mice showed a higher infarct size in comparison with WT mice (p<0.05). Infarct sizes are 
shown related to the area at risk. Data are expressed as mean ± SEM of 8 to 15 mice per group. 
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Figure 30: Troponin I expression and Caspase 3 activity in WT and Fpr2/3 KO mice. 
AMI procedure characterised by 30+90 min I/R was applied to WT and Fpr2/3 KO mice. At the end 
of reperfusion plasma and hearts were collected and analysed. (A) WT (p<0.05) and Fpr2/3 KO 
mice (p<0.001) showed an increase in Troponin I expression in plasma after AMI. The increase in 
Troponin I levels (Sham mice vs. AMI mice) was significantly higher in the Fpr2/3 KO mice 
compared with WT mice (p<0.01). (B) Hearts from both WT and Fpr2 KO mice had an increase in 
Caspase 3 activity after AMI (p<0.001). Bars are representative of Sham mice (white bar) or mice 
where AMI has been induced (grey bar). Data are mean ± SEM of 8 to 15 mice per group. 
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Figure 31: Upregulation of Fpr2, Fpr1 and AnxA1 mRNA expression in hearts of WT and 
Fpr2/3 KO mice after AMI. 
mRNA analysis of WT and Fpr2/3 KO subjected to ischemia and reperfusion through sequential 
occlusion (30 min) and reopening (90 min) of the LADCA. Hearts were collected and RNA and 
cDNA extracted and analysed. (A, B) AMI induced an upregulation of Fpr2 in WT mice and Fpr1 in 
both WT and Fpr2/3 KO mice. (C) AnxA1 mRNA increased in both WT and Fpr2/3 KO mice with 
higher levels in Fpr2/3 KO mice (p<0.001). Using the relative quantification method the response 
produced in control mice (no AMI) was considerated as 1 and the data were expressed as an 
upregulation (>1) or downregulation (<1) of mRNA expression after AMI. GAPDH was used as 
endogenous control. Data are showed as mean ± SEM of 8 to 15 mice per group.  
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Figure 32: Fpr2 upregulation in the heart during ischemia is not connected with an increase 
in neutrophils.  
AMI (30+90 min I/R) was induced in WT mice. At indicated time points hearts and plasma were 
collected and analysed by RT-PCR following the relative quantification method or ELISA. (A) Fpr2 – 
reused from figure 20 A for comparative purpose (C) CXCL1 mRNA modulation by AMI in the heart. 
KC induction in plasma (C) and in heart (D). The response produced in control mice (no AMI) was 
taken as 1 and data represent the upregulation (>1) or downregulation (<1) of mRNA expression. 
GAPDH was used as endogenous control. Data are showed as mean ± SEM of 8 to 15 mice per 
time point.  
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4.3.2 Effects of AMI in Fpr2/3 KO mice – Heart analyses  
Hearts excised from WT and Fpr2/3 KO mice after acute myocardial infarct were 
studied and compared with the corresponding hearts of sham mice.  The cardiac 
muscle of WT and Fpr2/3 KO mice, after AMI, showed an alteration of the classical 
structure as compared with the hearts of respective sham-operated mice. The 
classical cardiac morphology characterized by cross-striations formed by 
alternating segments of thick (myosin) and thin (actin) protein filaments (myofibril) 
was damaged (Figure 33).   
 
In term of cell infiltration CXCL1/KC, CCL2/MCP1 and MPO levels were quantified. 
AMI induced an increase of the neutrophil chemoattractant chemokine CXCL1/KC 
(at both gene and protein level) in WT and Fpr2/3 KO mice (p<0.001 vs. 
corresponding sham). After AMI, CXCL1/KC levels were significant higher in 
Fpr2/3 KO mice when compared with WT mice (p<0.05) (Figure 34 A). The level of 
the MPO, expressed at high abundance in neutrophils (Figure 35), was also 
evaluated. No significant changes were observed between sham and AMI mice in 
both WT and Fpr2/3 KO mice (Figure 35). The AMI protocol induced an increase of 
CCL2 mRNA, with higher expression in the KO in comparison with WT mice 
(p<0.01). CCL2 is also referred to as monocyte chemotactic protein-1 (MCP1). 
CCL2/MCP1 recruits monocytes, memory T cells and dendritic cells to the sites of 
inflammation. No significant changes of the corresponding MCP1 protein were 
however observed (Figure 35 B). 
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Levels of pro- and anti-inflammatory cytokines and other chemokines were also 
measured (Table 2). Moreover, the pro-inflammatory protein serum amyloid A 
(SAA) was studied in view of its ability to activate Fpr2. TNFα, IL-6, IL-1β, IL-10 
and SAA mRNA expression were upregulated after AMI in both WT and Fpr2/3 KO 
mice. TNFα mRNA upregulation was significantly higher in Fpr2/3 KO mice 
compared with WT mice (p<0.05). CCL5 mRNA expression was downregulated in 
WT mice and upregulated in KO mice (p<0.001). In terms of protein expression 
only Fpr2/3 KO mice showed an increase of TNFα and IL-6 after acute myocardial 
infarct (p<0.05) (Figure 36, 37).  
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Figure 33: Morphology of Heart of WT and Fpr2/3 KO mice after AMI. 
Representative images of H&E staining of heart removed from WT and Fpr2/3 KO mice, in sham 
condition or after 30 minutes of LADCA occlusion and 90 minutes of reperfusion. Pictures are 
representative of at least 6 different slices of heart harvested from 5 to 8 mice. 
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Figure 34: Analysis of cells infiltration in heart of WT and Fpr2/3 KO mice after AMI: 
CXCL1/KC and CCL2/MCP1 expression. 
Genes and proteins expression of CXCL1/KC and CCL2/MCP1 in hearts of WT and Fpr2/3 KO 
mice subjected to 30 minutes of LADCA occlusion and 90 minutes of reperfusion. (A) AMI induced 
an increase of CXCL1 mRNA and KC protein (p<0.001 vs. sham mice) in WT and Fpr2/3 KO mice. 
After AMI, the upregulation of CXCL1 and KC levels was significant higher in Fpr2/3 KO mice 
compared with WT mice (p<0.05). (B) AMI up regulated the levels of CCL2 mRNA in both WT and 
Fpr2 KO mice with higher effect in the KO (p<0.01 vs. WT). No significant changes in MCP1 levels 
were detected. mRNA was quantified using the relative quantification method. Data were expressed 
as an upregulation (>1) or downregulation (<1) of mRNA compared to the levels in control mice (no 
AMI) taken as 1. GAPDH was used as endogenous control. Data are mean ± SEM of 8 to 15 mice 
per group.   
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Figure 35: Analysis of cells infiltration in Heart of WT and Fpr2/3 KO mice after AMI: MPO 
levels.  
Myeloperoxidase quantification and localization in hearts of WT and Fpr2/3 KO mice where the AMI 
procedure characterised by 30+90 min I/R of the heart was applied. (A) AMI induced a not 
significant increase in MPO levels in both WT and Fpr2/3 KO mice. (B) MPO was detected in fixed 
paraffin-embedded slides of WT and Fpr2/3 KO mice hearts in sham condition (left panel) or after 
AMI (right panel). The Anti-Myeloperoxidase antibody (Abcam, ab9535, 1:50) was used and 
representative pictures of at least 6 different slices of hearts harvested from 5 to 8 mice are shown. 
Data are showed as mean ± SEM of 8 to 15 mice per group.   
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Figure 36: Screening of cytokines in hearts of WT and Fpr2/3 KO mice after AMI. 
Levels of mRNAs (left panel) and proteins (right panel) of TNFα, IL-6 and IL-1β in hearts of WT and 
Fpr2/3 KO mice after acute myocardial infarct. (A) AMI upregulated TNFα mRNA in both WT and 
Fpr2/3 KO mice. The relative mRNA expression was higher in Fpr2/3 KO mice compared with WT 
mice (p<0.05). TNFα protein levels were upregulated by AMI in Fpr2/3 mice (p<0.05 vs. Fpr2/3 
sham mice and WT AMI). (B) IL-6 protein expression was increased by AMI only in Frp2/3 KO mice 
(p<0.05). (C) No significant changes in IL-1β mRNA and protein expression were detected. Data 
are representative as mean ± SEM of 6 to 10 mice per group.   
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Figure 37: Screening of cytokines, chemokines and inflammatory mediators in hearts of WT 
and Fpr2/3 KO mice after AMI. 
mRNAs (left panel) and proteins (right panel) quantification of IL-10, CCL5/RANTES and SAA in 
hearts of WT and Fpr2/3 KO mice after ischemia/reperfusion through LADCA occlusion. 
(A) AMI increased the levels of IL-10 mRNA in both WT and Fpr2/3 KO mice. Fpr2/3 KO sham mice 
were characterized by higher expression of IL-10 compared with WT mice (p<0.05). (B) CCL5 
mRNA was downregulated in WT mice and upregulated in KO mice (p<0.001 WT vs. Fpr2/3 KO) by 
AMI. No changes in protein expression were induced by LADCA occlusion. (C) No significant 
changes in SAA mRNA and protein levels were detected. Data are expressed as mean ± SEM of 6 
to 10 mice per group.   
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Heart (pg/mg) 
 Sham 
(Mean±SEM) 
AMI 
(Mean±SEM) 
P value 
(Sham vs AMI) 
P value 
(AMI: WT vs KO) 
KC  WT 0.621±0.5 101.548±24.02 p<0.01  p<0.05 
 
KO: Higher CXCL1 
mRna upregulation 
Fpr2 KO 15.57±9.53 219.50±53.43 p<0.001 
MCP1 WT 76.625±17.34 72.91±15.89 p>0.05 p>0.05 
 
KO: Higher CCL2 
mRna upregulation 
Fpr2 KO 76.17±18.91 67.83±24.41 p>0.05 
TNFα WT 31.731±3.66 49.02±6.23 p>0.05 p<0.001 
 
KO: Higher TNFα  
mRna upregulation 
Fpr2 KO 53.015±6.42 94.19±11.07 p<0.01  
IL-1β WT 19.907±0.86 19.98±0.74 p>0.05 p>0.05 
Fpr2 KO 19.772±0.8 28.128±5.73 p>0.05 
IL-10 WT 392.68±65.24 453.35±70.26 p>0.05 p>0.05 
Fpr2 KO 811.89±123.41 863.008±97.24 p>0.05 
   
 
 
 
Table 2: Summary of chemokines and cytokines modulation induced by AMI in heart 
harvested from WT and Fpr2/3 KO mice. 
Summary of proteins and mRna modulation of KC/CXCL1, MCP1/CCL2, TNFα, IL-1β and IL-10 in 
hearts of WT and Fpr2/3 KO mice after ischemia/reperfusion through LADCA occlusion. 
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4.2.4 Effects of AMI in Fpr2/3 KO mice – plasma analyses  
At the end of the 90 minutes of reperfusion, plasma cytokine/chemokine profiles 
from WT and Fpr2/3 KO mice was also analysed. The AMI procedure upregulated 
CXCL1/KC levels in both WT (p<0.001) and Fpr2/3 KO mice (p<0.05). No 
significant changes in MCP1 were detected (Figure 38).  
 
Many endogenous mediators are released into the plasma by cells that infiltrate the 
site of challenge, especially during ischemia reperfusion injury. Using cyclo-
oxygenases or lipoxygenase, leukocytes rapidly biosynthesize mediators from 
membrane-derived arachidonic acid or its derivates. In order to study the levels of 
activation of inflammation, PUFAs (Polyunsaturated fatty acid, ω3 – ω6) 
metabolites derived from the cyclooxygenase (COX) and lipooxygenase (LOX) 
pathway and from auto oxidation were monitored during AMI (Table 3). COX is an 
enzyme responsible for the formation of biological mediators called prostanoids 
catalysing the conversion of free essential fatty acids to prostaglandins, 
prostacyclin and thromboxane. COX converts arachidonic acid (AA, a ω-6 PUFA) 
to prostaglandin H2 (PGH2), the precursor of the series-2 prostanoids. Here we 
analyzed different COX’s metabolites (Table 3) and detected significant modulation 
of PGE2, TXB2, PGA1 and PGI2, with data showed in Figure 39.  
 
Prostaglandin E synthase generates prostaglandin E2 (PGE2). PGE2 is synthesized 
in inflammation where it acts as a vasodilator. Synergistically with other mediators 
such as histamine and bradykinin, PGE2 is also able to cause an increase in 
vascular permeability and oedema. It is a central mediator of febrile response 
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triggered. AMI was able to induce PGE2 only in Fpr2/3 KO mice (p<0.01 vs. KO 
Sham and p<0.05 vs. WT AMI) (Figure 39).  
 
Thromboxane-A synthase generates thromboxane A2 from PGH2, and then this 
leads to downstream generation of the inactive metabolite/product TXB2. TXA2 is 
produced by activated platelets and possesses prothrombotic properties: it is 
involved in platelet activation and aggregation. Also in this case, only Fpr2/3 KO 
mice displayed increased TXA2 levels both during ischemia (p<0.01) and at the 
end of AMI (p<0.05) (Figure 39).  
 
The potent anti-inflammatory PGA1, derived from dihomo-γ-linolenic acid 20:3 
(DGLA), has been shown to cause renal vasodilation, stimulates renin release, 
inhibit NFκB activation and induce thermo-tolerance through modulation of heat 
shock protein 70. Fpr2/3 KO mice, after AMI, genereated less PGA1 compared to 
WT mice (p<0.05) (Figure 39).  
 
Prostacyclin is produced in endothelial cells from prostaglandin H2 (PGH2) by the 
action of the enzyme prostacyclin synthase. Prostacyclin I2 (PGI2) prevents 
formation of the platelet by inhibiting platelet activation. It is also vasodilator. In this 
case, Fpr2/3 KO mice had higher PGI2, in ischemia (p<0.05) and at the end of 
reperfusion (p<0.01), when compared to sham mice (Figure 39). 
 
Lipoxygenases are a family of iron-containing enzymes that catalyses the 
dioxygenation of PUFA in lipids containing a cis,cis-1,4-pentadiene structure. The 
metabolism of arachidonic acid (AA) and eicosapentaenoic acid (20:5(n-3), EPA) 
 156 
through the lipoxygenase pathways leads to the generation of various biologically 
active eicosanoids like the proresolving mediator and FPR2/ALX agonist lipoxin A4 
(LXA4) or the pro inflammatory leukotriene B4 (LTB4). LTB4 induces adhesion and 
activation of leukocytes on the endothelium and induces the formation of reactive 
oxygen species. Fpr2/3 KO mice had a lack of LXA4 after AMI (p<0.05). Both WT 
(p<0.05) and Fpr2/3 KO mice (p<0.01) had an increase of LTB4 during ischemia 
but only WT mice showed a decrease in LTB4 during reperfusion (p<0.01 KO AMI 
vs. KO Sham) (Figure 40). Also the pro-inflammatory 12-hydroxyeicosatetraenoic 
acid (12-HETE), a metabolite of AA produced by the enzyme 12-lipoxygenase (12-
LOX), was significant increased only in Fpr2/3 KO both during ischemia (p<0.05) 
and at the end of reperfusion (p<0.01) (Figure 40). Analysing some of the 
intermediates of the lipoxygenase pathway such as the 5-hydroxyeicosatetraenoic 
acid (5-HETE) and 15-hydroxyeicosatetraenoic acid (15-HETE), we observed no 
changes for 5-HETE whereas an increase of 15-HETE was only detected in Fpr2/3 
KO after ischemia (p<0.05; Figure 40).  
 
Resolvins are lipid mediators synthesized from the essential omega 3 fatty acids 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (22:6(n-3), DHA). They 
are induced in the resolution phase following acute inflammation. After AMI, Frp2/3 
KO mice had higher levels of the resolvin D precursor 17-hydroxy 
docosahexaenoic Acid (17-HDoHE) (p<0.05) but less resolvin D2 (RvD2) (p<0.05) 
(Figure 41). In WT mice, AMI induced an increase of RvD2 (p<0.05) (Figure 41). 
Only WT mice displayed an increase in the resolvin E precursor 18-HEPE after 
ischemia (p<0.05) (Figure 41). 
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The 14-hydroxy docosahexaenoic Acid (14-HDoHE), an autoxidation product of 
DHA, is a marker of oxidative stress. 14-HDoHE was produced by ischemia in both 
WT and Fpr2/3 KO mice (p<0.05). In Fpr2/3 KO mice the levels remained high 
even at the end of the reperfusion (p<0.05) (Figure 41).  
 
A summary on the modulation of all mediators analysed during acute myocardial 
infarct can be recapitulated with the heat map of ω3 and ω6 metabolites as 
measured at the end of acute myocardial infarct (Figure 42). 
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Figure 38: KC and MCP1 plasma levels in WT and Fpr2/3 KO mice after AMI. 
Acute myocardial infarct procedure characterised by 30+90 min I/R of the heart was applied to WT 
and Fpr2/3 KO mice. At the end of reperfusion whole blood was collected by cardiac puncture and 
plasma obtained by centrifugation and analysed. AMI upregulated WT (p<0.001) and Fpr2/3 KO KC 
levels (p<0.05). No significant changes in MCP1 expression were detected. Data are expressed as 
mean ± SEM of 6 to 10 mice per group.   
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Table 3: Summary of the metabolites analysed in plasma of WT and Fpr2/3 KO. 
Plasma of WT and Fpr2/3 KO mice were collected after ischemia or after reperfusion of the heart 
and analysed by liquid chromatography and mass spectrometry. Selected metabolites from the 
COX, LOX, Cyp pathways and from autooxidation were studied, as detailed here with indication of 
their precursors. 
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Figure 39: Plasma metabolites derived from the COX pathway. 
Plasma collected from WT and Fpr2/3 KO mice in sham condition (white bar), at the end of 
ischemia (grey bar) or at the end of reperfusion (black bar) has been analysed. AMI was able to 
induce, only in Fpr2/3 KO mice, PGE2 (p<0.01 vs. KO Sham and p<0.05 vs. WT AMI) and TXA2. 
TXA2 was increased during ischemia (p<0.01) and at the end of AMI (p<0.05). Fpr2/3 KO mice, 
after AMI, had less PGA1 compared with WT mice (p<0.05) and higher PGI2, in ischemia (p<0.05) 
and at the end of reperfusion (p<0.01). Data are showed as mean ± SEM of 10 mice per group. 
(*p<0.05, **p<0.01 vs. respective sham or comparison indicates with connectors). 
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Figure 40: Plasma metabolites derived from the LOX pathway.  
Plasma collected from WT and Fpr2/3 KO mice in sham condition (white bar), at the end of 
ischemia (grey bar) or at the end of reperfusion (black bar) has been studied. Fpr2/3 KO mice had a 
lack of LXA4 after AMI (p<0.05). LTB4 was increased during ischemia in both WT (p<0.05) and 
Fpr2/3 KO mice (p<0.01). In Fpr2/3 KO mice, LTB4 was significant higher also after AMI (p<0.01). 
Fpr2/3 KO mice had an increase of 12-HETE after ischemia (p<0.05) and at the end of reperfusion 
(p<0.01). 15-HETE increased in Fpr2/3 KO after ischemia (p<0.05). Data are expressed as mean ± 
SEM of 10 mice per group. (*p<0.05, **p<0.01 vs. respective sham or indicated comparison). 
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Figure 41: Plasma metabolites derived from the omega 3 pathways and from autoxidation. 
Plasma collected from WT and Fpr2/3 KO mice in sham condition (white bar), at the end of 
ischemia (grey bar) or at the end of reperfusion (black bar) has been analysed. After AMI, Frp2/3 
KO mice had higher levels of 17-HDoHE (p<0.05) but less RvD2 (p<0.05). AMI induced RvD2 after 
ischemia and reperfusion (p<0.05) and 18-HEPE after ischemia (p<0.05) only in WT mice. 14-
HDOHE was induced by ischemia in both WT and Fpr2/3 KO mice in ischemia (p<0.05) and only in 
Fpr2/3 KO mice at the end of the reperfusion (p<0.05). Data are showed as mean ± SEM of 10 
mice per group. (*p<0.05, **p<0.01 vs. respective sham or indicated comparison). 
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Figure 42: Heat map of ω3 and ω6 metabolites induced after AMI in WT and Fpr2/3 KO mice. 
Summary of metabolites modulated by AMI in the plasma of WT and Fpr2/3 KO mice at the end of 
ischemia and reperfusion (30 min + 90 min, respectively). Red bars represent higher levels of the 
metabolites (WT vs. KO). Changes to different intensity of green ending to black bars represent 
lower levels of the metabolites studied. Metabolites are divided in 3 groups: 
1. Metabolites higher in Fpr2/3 KO vs Fpr2/3 KO sham mice or WT AMI mice, after AMI.  
2. Metabolites decreased in Fpr2/3 KO mice after AMI in comparison to WT AMI mice.  
3. Metabolites higher in WT AMI in comparison to Fpr2/3 KO mice post-AMI.  
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4.3 Role of Fpr2/3 in secondary organs injury after AMI 
As reported in Chapter 3, Fpr2/3 are expressed in the lungs and in the kidneys. In 
order to study injury in secondary organ these tissues of WT and Fpr2/3 KO mice 
were removed at the end of acute myocardial infarct and examined. 
 
4.3.1 Lung 
The Fpr2 receptor is expressed in epithelial and endothelial cells of sham-operated 
WT mice (Figure 43 top panel). After acute myocardial infarct, Fpr2 is also 
expressed in infiltrated neutrophils (Figure 43 bottom panel). These representative 
pictures matched with biochemical data that showed that AMI was able to up-
regulate lung mRNA expression of Fpr2 together with AnxA1 and Fpr1 mRNA 
(Figure 44 A). Both AnxA1 and Fpr1 mRNA were significantly higher in Fpr2/3 KO 
mice compared to WT mice (p<0.001) (Figure 44 A). AnxA1 and Fpr2, after AMI, 
were expressed and co-localized in the epithelial cells of the lung (Figure 44 B). 
 
To evaluate tissue injury, the Koksel’s protocol of lung injury evaluation was used 
(Ozdulger, Cinel et al. 2003, Koksel, Kaplan et al. 2005, Koksel, Ozdulger et al. 
2005, Koksel, Yildirim et al. 2005, Koksel, Yildirim et al. 2005). Tissue oedema 
formation, infiltration of inflammatory cells and the integrity of the pulmonary 
architecture were evaluated. The injury was classified into four grades (Figure 45 
A). After AMI, Fpr2/3 KO mice showed higher interstitial congestion, destruction of 
pulmonary structure and infiltration compared with WT mice (p<0.01) (Figure 45 
B,C).  
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In terms of cell infiltration, the lungs of both WT and Fpr2/3 KO mice showed an 
increase in CXCL1/KC protein (p<0.001), however only WT mice had an increase 
of CXCL1/KC. Fpr2/3 KO mice showed decreased CXCL1/KC mRNA expression 
(p<0.001 vs. WT) (Figure 46 A). MPO expression significantly increased after AMI 
only in Fpr2/3 KO mice (p<0.01 vs. KO Sham, p<0.05 vs. WT AMI) (Figure 47). 
AMI was also able to increase CCL2 mRNA, with higher expression in KO tissue 
samples when compared to WT ones (p<0.001). No significant changes of MCP1 
levels were observed in either strain of mouse (Figure 46 B). Also levels of 
CCL5/RANTES were quantified noting that only WT mice displayed an increase of 
RANTES after AMI (p<0.01 vs. CTL or KO AMI). In contrast, CCL5 mRNA 
expression was down regulated in both WT and Fpr2/3 KO mice (p<0.01; Figure 
46 C). 
 
Other cytokines and pro inflammatory molecules including TNFα, IL-6, IL-1β, IL-10 
and SAA were also measured (Figure 48, 49). Only IL-6 and IL-10 protein levels 
were modulated by the ischemia/reperfusion injury of the heart. Specifically, Fpr2/3 
KO mice had an increase of IL-6 (p<0.05) (Figure 48 B) whilst WT mice had an 
increase of IL-10 (p<0.01) (Figure 49 C) after AMI. In terms of mRNA expression, 
both WT and Fpr2/3 KO mice had an increase in IL-6 and IL-1β, with higher IL-1β 
mRNA levels in KO mice in comparison with WT (p<0.001) (Figure 48). Only WT 
mice had an increase in IL-10 mRNA (p<0.05) (Figure 49). No significant changes 
of TNFα and SAA were detected (Figure 48, 49).  
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Figure 43: Fpr2 expression in lungs of sham or mice subjected to acute myocardial infarct.  
Fpr2 expression (brown staining) was detected in lungs fixed paraffin-embedded slides from WT 
and Fpr2/3 KO mice lungs in sham condition (top panel) or after AMI (bottom panel). Slides were 
stained with the anti-Fpr2 antibody (1:100). A negative control is shown. Pictures are representative 
of at least 6 different slices of hearts harvested from 6 to 10 mice.   
 
 
 
 167 
                                                                                  
 
 
 
B.                                                                                  
 
 
 
Figure 44: AnxA1, Fpr1 and Fpr2 expression in Lung of WT and Fpr2/3 KO mice after AMI. 
WT and Fpr2/3 KO mice were subjected to 30 min of LADCA occlusion and 90 min of reperfusion. 
Lungs were then excised and analysed by RT-PCR for AnxA1, Fpr1 and Fpr2 mRNA expression 
and by IHC for AnxA1 and Fpr2 localization. (A) Upregulation of Fpr2, AnxA1 and Fpr1 mRna 
expression in WT and Fpr2/3 KO mice after AMI with higher levels of AnxA1 and Fpr1 mRna in 
Fpr2/3 KO mice in comparison with WT (p<0.001). The response produced in control mice (no AMI) 
was considerated as 1 and the data were expressed as an upregulation (>1) or downregulation (<1) 
of mRNA expression after AMI. GAPDH was used as endogenous control. (B) Co-localization of 
AnxA1 (Red) and Fpr2 (Green-GFP) in epithelial cells of the lung of Fpr2/3 KO mice after I/R of the 
heart. Fixed paraffin-embedded slides were stained with DAPI (Blue) and AnxA1 antibody (1:1000). 
Fpr2 expression was detected thought the GFP fluorescence in the FL-1 channel. Images are 
representative of at least 6 different slices of lungs harvested from 5 or more mice. Data are 
showed as mean ± SEM of 8 to 15 mice per group 
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Figure 45: Lung injury evaluation of WT and Fpr2/3 KO mice after acute myocardial infarct. 
30 minutes of LADCA occlusion followed by 90 minutes of reperfusion were applied to WT and 
Fpr2/3 KO mice. At the end of reperfusion lungs were collected, fixed in PFA and paraffin-
embedded. Haematoxylin and eosin were used to stain the slides (pictures representative of 6 
different slices of lungs harvested from 5 mice are shown) and the staining analysed following the 
grades of the Koksel’s protocol of lung injury evaluation. Fpr2/3 KO mice showed higher lungs 
damage, after AMI, in comparison with WT mice (p<0.01). Data are mean ± SEM of 5 mice per 
group. 
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Figure 46: Analysis of cells infiltration in lungs of WT and Fpr2/3 KO mice after AMI. 
Genes and proteins expression of CXCL1/KC, CCL2/MCP1 and CCL5/RANTES in lungs of WT and 
Fpr2/3 KO mice subjected to 30 min of ischemia and 90 min of reperfusion of the heart. (A) CXCL1 
mRNA was up regulated in WT mice and down regulated in Fpr2/3 KO mice (p<0.001). KC was 
increased, by AMI, in both WT and Fpr2/3 KO mice (p<0.001). (B) AMI induced CCL2 mRNA, with 
higher values in KO mice compared with WT (p<0.001). No changes in MCP1 levels were detected 
(C) CCL5 mRna expression was down regulated in both WT and Fpr2/3 KO mice (p<0.01 WT vs. 
KO). WT mice had an increase of RANTES after AMI (p<0.01 vs. CTL or KO AMI). Following the 
relative quantification method the response induced in control mice (sham mice) was taken as 1. 
AMI data were expressed as upregulation (>1) or downregulation (<1) compared with sham mice. 
GAPDH was used as endogenous control. Data are showed as mean ± SEM of 6 to 10 mice per 
group. 
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Figure 47: Analysis of cells infiltration of lungs of WT and Fpr2 KO mice after AMI: MPO 
levels.  
30 min of ischemia of the heart, through LADCA occlusion, followed by 90 min of reperfusion were 
induced in WT and Fpr2/3 KO mice. At the end of reperfusion, lungs where excised and MPO levels 
analysed. AMI induced a significant increase in MPO only in Fpr2/3 KO mice (p<0.01 vs. KO Sham, 
p<0.05 vs. WT AMI). Data are showed as mean ± SEM of 8 to 10 mice per group. 
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Figure 48: Screening of inflammatory mediators in lungs of WT and Fpr2/3 KO mice after 
AMI: TNFα, IL-6 and IL-1β. 
Levels of gene (left panel) and proteins (right panel) expression of TNFα, IL-6 and IL-1β in lungs of 
WT and Fpr2/3 KO mice after acute myocardial infarct (30+90 min I/R). (A) No significant changes 
in TNFα were detected. (B,C) Both WT and Fpr2/3 KO mice had an increase in IL-6 and IL-1β 
mRNA, with higher levels of IL-1β in KO mice in comparison with WT (p<0.001). Fpr2/3 KO mice 
had also an increase of IL-6 after AMI (p<0.05). mRNA data are expressed as upregulation (>1) or 
downregulation (<1) of sham mice taken as 1, following the relative quantification method. GAPDH 
was used as endogenous control. Data are showed as mean ± SEM of 6 to 10 mice per group. 
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Figure 49: Screening of inflammatory mediators in Lungs of WT and Fpr2/3 KO mice after 
AMI: IL-10 and SAA. 
Levels of gene (left panel) and proteins (right panel) expression of IL-10 and SAA in lungs of WT 
and Fpr2 KO mice after 30+90 min I/R of the heart through LADCA occlusion. (A) IL-10 was 
upregulated in WT mice by AMI both in terms of mRNA (p<0.05 vs. Fpr2/3 KO) and protein 
expression (p<0.01 vs. WT sham) (B) No significant changes in SAA levels were observed. 
Following the relative quantification method, mRNA data are expressed as upregulation (>1) or 
downregulation (<1) of sham mice taken as 1. GAPDH was used as endogenous control. Data are 
showed as mean ± SEM of 6 to 10 mice per group. 
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4.3.2 Kidney 
As another organ prone to secondary injury, we examined the kidney of WT and 
Fpr2/3 KO mice following sham operation or acute myocardial infarct. AMI was 
able to up-regulate kidney expression of Fpr2 as seen by immunohistochemistry 
(Figure 50) and by quantifying mRNA expression (Figure 51). AMI also upregulated 
AnxA1 and Fpr1 mRNA. Fpr1 mRNA was significantly higher in Fpr2/3 KO mice in 
comparison to WT mice (p<0.001) (Figure 51).  In terms of cytokines/chemokines, 
kidneys of Fpr2/3 KO mice contained increased levels of KC after AMI (p<0.05 vs. 
KO Sham, p<0.01 vs. WT AMI) (Figure 52 A). In contrast, kidneys harvested from 
WT mice had an increase in RANTES (p<0.05 vs. WT Sham, p<0.01 vs. KO AMI) 
(Figure 52 C). No significant changes in MCP1 (Figure 52 B) and MPO (Figure 52 
A) expression were induced, with AMI, in both WT and Fpr2/3 KO mice. 
 
After AMI, kidney samples of WT and Fpr2/3 KO mice displayed higher levels of IL-
6 (Figure 53 A) and SAA (Figure 54 B) mRNA, with more pronounced values of IL-
6 mRNA in the Fpr2/3 KO compared to WT mice (p<0.001). IL-1β mRNA was 
upregulated in both genotypes (p<0.05 WT vs. KO) (Figure 53 C). TNFα (Figure 53 
A) and IL-10 (Figure 54 A) mRNA were down regulated in WT mice and 
upregulated in Fpr2/3 KO mice (p<0.01). In terms of protein expression only IL-10 
was upregulated by AMI in Fpr2/3 KO mice (p<0.05 vs. KO SHAM and WT AMI) 
(Figure 54 A).   
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Figure 50: Fpr2 expression in kidneys of WT mice subjected to acute myocardial infarct.  
Fpr2 staining (1:200) on fixed paraffin-embedded kidneys harvested from WT mice after sham 
operation (left panel) or acute myocardial infarct (30+90 I/R of the heart) (right panel). Images are 
representative of at least 6 different slices of kidney from 5 to 10 mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 175 
 
 
 
 
 
 
Figure 51: AnxA1, Fpr1 and Fpr2 expression in kidneys of WT and Fpr2/3 KO mice after AMI. 
mRNA analysis of kidney excised from WT and Fpr2/3 KO mice after 30 min of LADCA occlusion 
and 90 min of reperfusion using the relative quantification method. Fpr2, AnxA1 and Fpr1 mRNA 
were upregulated by AMI. Fpr1 mRNA was significantly higher in Fpr2/3 KO mice compare with WT 
mice (p<0.001). The response induced in control mice (no AMI) was taken as 1 and the AMI data 
expressed as upregulation (>1) or downregulation (<1) of mRNA expression. GAPDH was used as 
endogenous control. Data are showed as mean ± SEM of 6 to 10 mice per group. 
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Figure 52: Cells infiltration in kidneys of WT and Fpr2/3 KO mice after AMI. 
Kindneys of WT and Fpr2/3 KO mice were subjected to acute myocardial infarct (30+90 min I/R) 
were analysed by RT-PCR for mRNA expression and ELISA for protein expression. (A) Fpr2/3 KO 
mice, and not WT mice, had an increase of KC levels after AMI (p<0.05 vs. KO Sham, p<0.01 vs. 
WT AMI). No changes in MPO expression were observed. (B) No significant changes in 
CCL2/MCP1 were detected. (C) Kidneys of WT mice had an increase in RANTES (p<0.05 vs. WT 
Sham, p<0.01 vs. KO AMI) No changes in CCL5 mRNA were detected. mRNA data are expressed 
as upregulation (>1) or downregulation (<1) of sham mice taken as 1, following the relative 
quantification method. GAPDH was used as endogenous control. Data are showed as mean ± SEM 
of 6 to 10 mice per group 
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Figure 53: Inflammatory mediators in kidneys of WT and Fpr2/3 KO mice after AMI: TNFα, IL-
6 and IL-1β. 
WT and Fpr2/3 KO mice were subjected to sham or myocardial infarct surgery (30+90 min I/R of the 
heart). At the end of reperfusion kidneys were collected and analysed by RT-PCR, using the 
relative quantification method, for mRNA analyses and by ELISA for protein expression. (A) TNFα 
mRNA was down regulated in WT mice and upregulated in Fpr2/3 KO mice (p<0.01). (B, C) IL-6 
and IL-1β mRNA were increased by AMI in both WT and Fpr2/3 KO mice. IL-6 mRNA was higher in 
the Fpr2/3 KO mice (p<0.001). IL-1β mRNA was higher in WT mice (p<0.05). No significant 
changes in protein expression were detected for all TNFα, IL-6 and IL-1β. mRNA data are 
compared with sham mice (taken as 1) and expressed as upregulation (>1) or downregulation (<1) 
of mRNA. GAPDH was used as endogenous control. Data are mean ± SEM of 6 to 10 mice per 
group. 
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Figure 54: Cytokines and inflammatory mediators in kidneys of WT and Fpr2/3 KO mice after 
AMI: IL-10 and SAA. 
Kidneys of WT and Fpr2/3 KO mice where the AMI procedure  (30min of LADCA occlusion and 90 
min of reperfusion) was induced were analysed for mRNA and protein expression of IL-10 and SAA. 
(A) IL-10 mRNA was down regulated in WT mice and upregulated in Fpr2/3 KO mice (p<0.01). The 
protein IL-10 was upregulated by AMI in Fpr2/3 KO mice (p<0.05 vs. KO SHAM and WT AMI). (B) 
SAA mRNA was upregulated by AMI in both WT and Fpr2/3 KO mice. No significant changes in 
protein levels were observed. Using the relative quantification method, mRNA data are showed as 
upregulation (>1) or downregulation (<1) of sham mice, taken as 1. GAPDH was used as 
endogenous control. Data are showed as mean ± SEM of 6 to 10 mice per group. 
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4.4 Activation of the IL-6 and JAK/STAT pathway by 
AnxA1 and Fpr2/3  
Acute myocardial infarct induced an increase of IL-6 in plasma of both WT 
(p<0.001) and Fpr2/3 KO (p<0.001) and only in heart of the KO mice (p<0.05) 
(Figure 55). Several studies show how IL-6, in acute myocardial infarct, is able to 
activate the JAK/STAT3 pathway. The IL-6/JAK/STAT3 pathway elicits 
cardioprotection in the heart (Negoro, Kunisada et al. 2000). This fact may at a first 
sight suggests existence of an apparent contrast with the higher levels of IL-6 
measured in Fpr2/3 KO mice which were concomitant to higher infarct size and 
heart damage markers. However, and in agreement with these differences, when 
we tested Fpr2/3 KO mice, we were unable to measure activation of the STAT3 
(p<0.001 vs. WT AMI) (Figure 56).  
JAK2 kinase plays an essential role in the cross-talk of the JAK/STAT pathway 
(Argetsinger, Campbell et al. 1993). AG-490, a tyrosine kinase inhibitor which 
inhibits protein tyrosine kinases by binding to the substrate binding site, is a potent 
and selective inhibitor of JAK2 kinase, with minimal or no effect on the kinase 
activity of other protein tyrosine kinases (Meydan, Grunberger et al. 1996). For this 
reason AG490 is widely used for inhibiting JAK and STAT3 activation (Negoro, 
Kunisada et al. 2000, Huang, Yang et al. 2010) and it was used here to further 
study the link between JAK/STAT3 and Fpr2/3.  
AG490 (3mg/Kg) (Gross, Hsu et al. 2006, Yan, Jiang et al. 2012), administered 15 
minutes prior ischemia, was able to induce Fpr2 mRNA (p<0.05). Also AnxA1 
mRNA was up-regulated after AG490 administration (Figure 57). It is clear that 
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when some cardioprotective pathways (like JAK/STAT3) are down regulated, other 
protective pathways, like Fpr2/3-AnxA1, are up regulated.  
 
AG490 was also able to decrease the cardioprotective activity induced by AnxA1 
(40 µg/Kg i.v. prior ischemia) showing that the protein need the activation of the 
JAK/STAT3 pathway to induce a cardioprotection. 
In line with that we detected a injured morphology of the heart with infiltrated cells 
(Figure 58), and the same infarct size  (p<0.01 AnxA1 vs. AG490+AnxA1) (Figure 
59 A) and caspase 3 activity (p<0.05 WT AMI or WT AG490+AnxA1 vs. WT Sham) 
(Figure 59 B) in mice treated with vehicle or AG490 and AnxA1. In all cases the 
effects of AnxA1 was lost when administered together with the JAK/STAT3 inhibitor.  
 
Intravenous injection of AG490 was also able to induce IL-6 (p<0.001) mRNA and 
TNFα mRNA (p<0.001) underling the ability of the JAK/STAT3 pathway to induce a 
negative feedback toward IL-6 production and anti-inflammatory effects (Figure 60). 
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Figure 55: IL-6 levels in plasma and heart of WT and Fpr2/3 KO mice after AMI. 
WT and Fpr2/3 KO mice were subjected to LADCA occlusion for 30 minutes and 90 minutes of 
reperfusion. At the end of the procedure whole blood and heart were collected and analysed by 
ELISA for IL-6 expression. Acute myocardial infarct was able to increase IL-6 in plasma of both WT 
and Fpr2/3 KO mice (p<0.001). In the heart, IL-6 was induced by AMI only in Fpr2/3 KO mice 
(p<0.05). Data are showed as mean ± SEM of 8 to 15 mice per group. 
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Figure 56: STAT3 phosphorylation by AMI in heart of WT and Fpr2/3 KO mice. 
In the heart, pSTAT3 was induced by 30 min of LADCA ligation and 90 min of reperfusion in WT 
mice (p<0.001 vs. WT AMI and KO AMI). Protein expression has been monitored by western blot 
analysis using a pSTAT3 antibody (1:1000) and a STAT3 antibody (1:2000). Representative blots 
from more than 3 experiments with distinct cell preparations are shown.  
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Figure 57: Fpr2 and AnxA1 mRNA expression in heart tissue samples after AMI in the 
presence of JAK/STAT3 pathway blockade. 
WT mice were injected i.v., 15 min prior ischemia, with vehicle (PBS) or AG490 (3mg/Kg) and 
subjected to 30 min of LADCA occlusion and 90 min of reperfusion. Hearts were then collected and 
analysed by RT-PCR for Fpr2 and AnxA1 mRNA expression using the relative quantification 
method for data analysis. AMI induced an increase in Fpr2 and AnxA1 mRNA expression. AG490 
increased the induction of Fpr2 mRNA (p<0.05 vs. Vehicle). The response produced in control mice 
(no AMI) was considerated as 1 and the data were expressed as an upregulation (>1) or 
downregulation (<1) of mRNA expression after AMI. GAPDH was used as endogenous control. 
Data are showed as mean ± SEM of 8 to 15 mice per group. 
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Figure 58: Section of hearts after acute myocardial infarct and a treatment of AnxA1 and/or 
the JAK/STAT3 inhibitor.   
H&E staining of WT mice treated with AnxA1 (40 µg/Kg i.v) prior ischemia, AG490 (3mg/Kg i.v.) 15 
minutes prior ischemia or AG490 followed by AnxA1 and following 30 minutes of occlusion of the 
LADCA and 90 minutes of reperfusion. Hearts were then removed, fixed in PFA, paraffin-embedded 
and stained with haematoxylin and eosin. Pictures are representative of at least 6 different slices of 
hearts from 5 to 8 mice per group.  
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Figure 59: The JAK/STAT3 inhibitor AG490 reduces the cardioprotective activity of AnxA1. 
WT mice were treated with, vehicle (PBS), AnxA1 (40 µg/kg i.v) prior ischemia, AG490 (3mg/kg i.v.) 
15 minutes prior ischemia alone or in combination with AnxA1. The infarct size and the caspase 3 
activity were valuated after 30 minutes of ischemia and 90 minutes of reperfusion. (A) AMI caused 
~55% necrosis of the left ventricle (Area at risk) in all conditions. AnxA1 decreased the infarct size, 
shown related to the area at risk, induced by AMI (p<0.01). AG490 reversed this effect (p<0.05). (B) 
AMI induced the activity of caspase 3 (p<0.05). AnxA1 was no longer active when injected with 
AG490 (p<0.05 WT AG490+AnxA1 vs. WT Sham). Data are expressed as mean ± SEM of 6 to 10 
mice per group. 
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Figure 60: Hearts TNFα and IL-6 production by AMI with or without AnxA1 and AG490 
treatment. 
WT mice were subjected to myocardial infarct surgery (30+90 min I/R of the heart) and treated with: 
vehicle (PBS), AnxA1 (40 µg/Kg i.v) prior ischemia, AG490 (3mg/Kg i.v.) 15 minutes prior ischemia 
or AG490 followed by AnxA1. At the end of reperfusion hearts were collected and analysed by RT-
PCR using the relative quantification method for mRNA analyses. AG490 induced IL-6 (p<0.001 vs. 
vehicle, AnxA1, and AnxA1+AG490 treatment) and TNFα (p<0.001 vs. vehicle and AG490 and 
AnxA1 treated mice) mRNA. TNFα mRNA was also induced with the treatment of AG490 and 
AnxA1 (p<0.001 vs. vehicle and AnxA1 treated mice). mRNA data are compared with sham mice 
(taken as 1) and expressed as upregulation (>1) or downregulation (<1) of mRNA. GAPDH was 
used as endogenous control. Data are mean ± SEM of 6 to 10 mice per group. 
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4.5 Role of FPR2/ALX agonists in AMI 
 
4.5.1 Lipoxin A4 
The role of the FPR2/ALX agonist LXA4 in acute myocardial infarct was studied. 
WT mice were treated with 100 ng of LXA4 (Brancaleone, Gobbetti et al. 2013) 
prior ischemia and biochemical analysis was performed in heart and plasma of 
mice at the end of AMI.  
 
Lipoxin A4 was not able to induce a cardioprotection. Indeed the levels of the 
infarct size (Figure 61), troponin I and caspase 3 (Figure 62) were the same in 
mice treated with vehicle and LXA4 and operated with the AMI protocol.  In terms of 
inflammation LXA4 decreased the levels of TNFα (p<0.05) and IL-6 mRNA (p<0.05) 
induced by AMI (Figure 63). LXA4 did not have any effects on the increase of KC 
and IL-6 induced by acute myocardial infarct (Figure 63). 
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Figure 61: Effect of Lipoxin A4 on the infarct size caused by acute myocardial infarct. 
After 30 min of Ischemia and 90 min of reperfusion WT mice treated with vehicle (PBS) or LXA4 
(100ng prior ischemia) showed the same level of area at risk (50%) and infarct size (55%). Infarct 
sizes are shown related to the area at risk. Data are expressed as mean ± SEM of 6 mice per group. 
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Figure 62: Effects of LXA4 on cardiac injury biomarkers after AMI.  
WT mice were subjected to LADCA occlusion for 30 minutes followed by 90 minutes of reperfusion. At 
the end of the procedure whole blood and hearts were collected and analysed by ELISA for troponin I 
levels and caspase 3 activity. LXA4 (100ng) administrated i.v prior ischemia has not changed the levels 
of Troponin I (p<0.05) and Caspase 3 (p<0.05) induced by acute myocardial infarct. Data are showed 
as mean ± SEM of 6 mice per group. 
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Figure 63: Role of LXA4 on the inflammatory response induced by AMI in the heart. 
WT mice were treated i.v with vehicle (PBS) and LXA4 (100ng) prior 30 min of ischemia. At the end of 
90 min of reperfusion hearts were excised and levels of KC, TNFα and IL-6 were analysed. (A) KC 
levels were upregulated by AMI with both vehicle (p<0.05) and LXA4 treatments. (B) TNFα was 
upregulated in terms of mRNA (left panel) and proteins (right panel) (p<0.05). LXA4 reduced the 
increase of TNFα (p<0.05) induced by AMI. (C) I/R of the heart upregulated IL-6 mRNA and proteins 
expression (p<0.05). LXA4 reduced the increase of IL-6 mRNA (p<0.05). Following the relative 
quantification method, mRNA data are compared with sham mice (taken as 1) and expressed as 
upregulation (>1) or downregulation (<1) of this value. GAPDH was used as endogenous control. Data 
are mean ± SEM of 6 mice per group. 
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4.5.2 Resolvin D1 
The role of Resolvin D1, as a novel FPR2/ALX agonist (Krishnamoorthy, Recchiuti 
et al. 2010), was also studied in AMI. WT mice were treated with RvD1 prior 30 
minutes of ischemia and 90 minutes of reperfusion. Heart and plasma were then 
collected and analysed together with the quantification of the infarct size.   
 
Treatment of mice with RvD1 (100 ng i.v.(Norling, Dalli et al. 2012) prior ischemia 
was able to decrease the infarct size induced by AMI (p<0.005) (Figure 64); 
however this macroscopic effect on tissue injury was not paralleled by change in 
the induction of troponin I and caspase 3 activity (Figure 65). In contrast, RvD1 
decreased circulating levels of KC (p<0.001) and IL-6 mRNA (p<0.001) increased 
after acute myocardial infarct (Figure 66). No effects of TNFα and IL-6 modulation 
were detected (Figure 66). 
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Figure 64: Effect of resolvin D1 in the infarct size induced by acute myocardial infarct. 
WT mice were subjected to 30 min of ischemia through occlusion of the LADCA and 90 min of 
reperfusion. All mice were injected intravenously with vehicle (PBS) or RvD1 (100 ng) prior 
ischemia. At the end of reperfusion the area at risk (AAR) and the infarct size were analysed. 
LADCA occlusion induced ~55% necrosis of the AAR in all mice. RvD1 treatment significantly 
decreased the infarct size, showed related to the area at risk, compare with vehicle (p<0.05). Data 
are showed as mean ± SEM of 8 mice per group. 
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Figure 65: Effects of resolvin d1 on cardiac injury biomarkers after AMI. 
WT mice were treated with an i.v injection of vehicle (PBS) or RvD1 (100ng) prior 30 min of 
ischemia and 90 min of reperfusion. At the end of the AMI surgery whole blood and plasma were 
collected and analysed by ELISA. WT mice treated with vehicle or RvD1 showed the same levels of 
Troponin I (p<0.05) and Caspase 3 in the heart (p<0.05) induced by acute myocardial infarct. Data 
are showed as mean ± SEM of 8 mice per group. 
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Figure 66: Role of RvD1 on the inflammatory response induced by AMI in the heart. 
WT mice were treated with vehicle and i.v injection of RvD1 (100ng) prior 30 min of ischemia. At the 
end of reperfusion hearts were removed and KC, TNFα and IL-6 levels studied. (A) KC was 
upregulated by AMI (p<0.05) and reduced by RvD1 (p<0.05). (B,C) TNFα and IL-6 were 
upregulated both in terms of mRNA (left panel) and proteins (right panel) (p<0.05) expression. 
RvD1 reduced the levels of IL-6 mRNA upregulated by AMI (p<0.001). Data are showed as mean ± 
SEM of 8 mice per group. 
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4.5.3 Compound 43 
To compare the effects of endogenous and synthetic FPR2/ALX agonist of AMI, 
the AMGEN compound 43 was administered i.v or i.p prior 30 minutes of ischemia. 
At the end of 90 minutes of reperfusion the infarct size was analysed.  
 
C43 was injected i.v (10µg, 90µg, 150µg) prior ischemia or i.p at 10µg 30 minutes 
prior ischemia. 
 
All the doses of C43, given i.v., were able to decrease the infarct size induced by 
AMI (p<0.05) in the same pattern (Figure 62): the effect was not dose dependent. 
C43 injected i.p was not able to change the infarct size induced by AMI (Figure 67). 
When compared with the activity of AnxA1 on AMI the effect of C43 was 
significantly lower (p<0.001) (Figure 68). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 196 
 
 
 
 
 
 
 
Figure 67: Effect of different doses of compound 43 in the infarct size caused by acute 
myocardial infarct. 
During AMI (30+90 min I/R of the heart through LADCA occlusion) WT mice were treated with 
different doses of C43. Specifically, C43 was injected i.v (10µg, 90µg, 150µg) prior ischemia or i.p 
at 10µg 30 minutes prior ischemia as shown. At the end of reperfusion the infarct sizes, referred to 
the area at risk, were analysed. Mice treated with the i.v injections of C43 showed a decrease in 
infarct size compared with mice treated with vehicle (p<0.05). C43 given i.p was not able to induce 
a cardioprotective effect. Data are showed as mean ± SEM of 6 mice per group. 
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Figure 68: Comparison between the effects of AnxA1 and C43 on AMI. 
The decrease of infarct size induced by showed doses of C43 in WT mice was significantly lower 
(p<0.001) in comparison with the one induced by AnxA1 (1 µg) administrated i.v prior ischemia. 
Data are showed as mean ± SEM of 6 mice per group. 
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4.5.4 Summary 
In summary, as showed in table 4, LXA4 was not able to induce a cardioprotective 
effect in WT mice. The lipid only decreased the levels of TNF-α induce by AMI.  
RVD1 decreased the infarct size and the increase in KC levels induced by LADCA 
occlusion. 
All the doses of C43, injected i.v., decreased the infarct size induced by AMI in a 
not dose dependent way. The other markers of cardiac injury or inflammation were 
not analysed for this synthetic compound. 
 
 
 
 
 
 
 
 
 
Table 4: Summary of LXA4, RvD1 and C43 effects on acute myocardial infarct in WT mice 
WT mice were treated with LXA4 (100ng prior ischemia), RvD1 (100ng prior ischemia) and C43 
(10µg, 90µg, 150µg i.v. prior ischemia or 10µg i.p. 30 minutes prior ischemia). LXA4 induced a 
decreased in TNF-α and RvD1 decreased the infarct size and KC levels. Only i.v. injections of C43, 
were able to decrease the infarct size induced by AMI. 
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CHAPTER 5: IDENTIFICATION 
OF FPR2/ALX DOMAINS 
REQUIRED FOR AGONISTS 
BINDING AND SIGNALLING  
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5.1 Rationale 
G protein-coupled receptors (GPCRs) are the largest family of membrane 
receptors with more than 800 of these proteins encoded in the human genome. 
(Hendriks-Balk, Peters et al. 2008). GPCR are responsible for the regulation of 
different physiological processes. One is the control of the inflammatory reaction 
(Sun and Ye 2012), both in terms of promoting the response (e.g. chemokine-
mediated leukocyte recruitment) and limiting its duration and intensity. However, 
more than 100 different GPCRs are expressed in the cardiovascular system and 
their cardioprotective activity is emerging (Wieland, Lutz et al. 2007, Waterson, 
Thompson et al. 2011). Their role is accomplished via ligand binding to GPCRs, 
activating associated G proteins and intracellular signalling pathways.  
 
Within the context of inflammation, the GPCR FPR2/ALX receptor together with its 
agonist AnxA1, might play an important role, as we shown in this study, in acute 
myocardial infarct. AnxA1 mimetic might be developed to target acute myocardial 
injury. 
However FPR2/ALX is an intriguing receptor: it is the first one that mediates 
actions elicited by both lipids, peptides and proteins, but also it mediate pro-
inflammatory responses, such as those elicited by its agonist serum amyloid 
protein A (SAA). A recent study by Ye’s group chiefly demonstrates the ability of 
FPR2/ALX to modulate cell responsiveness in a ligand-biased fashion (Li, Cai et al. 
2011).  
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For this reason, the adverse effect mediated by the receptor by different FPR2/ALX 
agonists must be considered. To address this problem, an AnxA1-biased agonist 
might result in unique receptor activation that will signal to desirable pathways 
while sparing those pathways mediating undesirable effects.  
 
Several mechanistic hypotheses can be put forward to explain the versatility of the 
FPR2/ALX receptor, including homo- and/or hetero-dimerization as well as the 
recruitment of ligand specific signalling pathways. Another plausible option is that 
ligands might activate specific receptor domains thus promoting at least in part not 
overlapping downstream responses. As an example, the small lipid lipoxin A4 has 
been shown to activate FPR2/ALX by interacting with the III extra-cellular loop and 
associated trans-membrane region (Chiang, Serhan et al. 2006). 
 
For this reason we decided to study the domains required for AnxA1 and SAA-
dependent receptor activation. For completion and to assess the potential impact 
these finding might have on drug discovery, Compound 43, a synthetic pro-
resolving agonist, has also been studied. To do so, we took advantage of recently 
characterized stable clones expressing chimeric receptors with different regions of 
FPR2/ALX and the pro inflammatory receptor FPR1 (Le, Ye et al. 2005).  
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5.2 Native and chimeric human FPR1 and FPR2/ALX 
receptors 
Human FPR1 and FPR2/ALX receptors display ~69% homology (Ye, Boulay et al. 
2009) as illustrated in Figure 69 where, in the human FPR2/ALX sequence, the 
amino acids different from human FPR1 are highlighted in red.  
To evaluate the contribution of single domains in FPR2/ALX activation by selective 
agonists we used eight different chimeric receptors with swapped domains 
between FPR1 and FPR2/ALX, generated as described in (Le, Ye et al. 2005), and 
detailed in Figure 70. The degree of receptor expression of each chimaera was 
assessed using specific monoclonal antibodies (mAb) against FPR1 and 
FPR2/ALX. As shown in figure 71, only Chimaera C, D and G were recognized by 
the anti-FPR2/ALX mAb, whilst all others clones were detected with the anti-FPR1 
mAb. 
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Figure 69: Human FPR2/ALX amino acids sequence. 
Representation of the sequence of the human FPR2/ALX receptor with amino acids different from 
the human FPR1 receptor highlighted in red. 
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Figure 70: Schematic representation of chimeric human FPR1 and FPR2/ALX clones. 
FPR1-FPR2/ALX clones used in this study. Each clone is named alphabetically (A,B,C,D,E,F,G,H) 
and has distinct domains of the FPR1 receptor replaced with the indicated FPR2/ALX amino acid 
sequences (in red-right panel). Amino acids sequence (left panel) and representative receptor (right 
panel) are showed  
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Figure 71: Receptor expression of native and chimeric human FPR1 and FPR/ALX  
transfected in HEK293 cells. 
FPR1 and FPR2/ALX cell surface expression on HEK293 cells transfected with native receptors 
and the clones was analysed by flow cytometry using the anti-FPR1 (A) or anti-FPR2 (B) 
monoclonal antibody (1:100 dilution in both cases). Dashed lines indicate antibody interaction with 
HEK293 cells transfected with empty CMV plasmid. Flow cytometry analysis was performed by 
analyzing ≥10,000 events using a FACSCalibur flow cytometer equipped with CellQuest software 
followed by analysis using FlowJo. Data are expressed as median fluorescence intensity units. Data 
are expressed as means ± S.E.M. of experiments conducted at least 3 times.  
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5.3 Clones-specific calcium mobilization induced by 
AnxA1, SAA and C43 
AnxA1 and its bioactive peptides are able to mobilize intracellular Ca2+ in primary 
PMN (Walther, Riehemann et al. 2000, Solito, Kamal et al. 2003) and cells 
transfected with FPR2/ALX and/or FPR1 (Ernst, Lange et al. 2004).  
In native FPR2/ALX transfected cells, AnxA1, SAA and C43 induced a 
concentration-dependent responses (Figure 72).  
 
To compare the ligand-binding domains activated by the different agonists, Ca2+ 
mobilization in FPR1/FPR2/ALX chimaeric HEK-293 cells was studied with 
concentrations selected from figure 72. 
AnxA1 (10 nM) induced Ca2+ flux in native FPR2/ALX cells with similar responses 
in clones C, G and H (all ranging from 40 to 60% of the maximal response). Little 
or no effect on FPR1 expressing cells and the other clones (Figure 73) were 
detected.  
SAA (100 nM) afforded ~50% of the ionomycin response both with native 
FPR2/ALX cells and clones E, F, G, and H, whilst no responses were detected with 
the other clones, including clone B that bears the III extracellular domain of 
FPR2/ALX (Figure 73).   
The synthetic molecule C43 (1 µM) induced a calcium flux in FPR2/ALX 
transfected cells and only active in clones E and F (Figure 73).  
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Figure 72: Dose response induced by AnxA1, Compound 43 and SAA in HEK293 FPR2 cells. 
Ca2+ flux responses evoked in FPR2/ALX transfected HEK293 cells upon treatment with showed 
concentration of AnxA1 or C43 (left panel) and with SAA (right panel). HEK293 cells were loaded 
with FURA-2 (2 µM), washed and added to 96-well plates prior to stimulation. Fluorescence (Ca2+ 
fluxes) was analysed with a NOVOstar™ microplate reader (BMG Labtech). Data are reported as % 
of Ionomycin (1 µM) response and expressed as means ± S.E.M. of experiments conducted at least 
3 times. 
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Figure 73: Calcium mobilization induced by AnxA1, SAA and C43 in HEK293 cells 
transfected with the chimaeric receptors. 
FURA-2 loaded HEK293 cells expressing native and chimaeric clones were treated with AnxA1 
(10nM), SAA (0.1 µM) or C43 (1 µM) and calcium flux was detected using a fluorescence microplate 
reader. (A) AnxA1 induced Ca2+ flux in native FPR2/ALX cells and clones C, G and H. (B) SAA  
induced a response in FPR2/ALX cells and clones E, F, G, and H. (C) C43 induced a Ca2+ flux in 
FPR2/ALX transfected cells and in clones E and F. Dashed lines indicate the degree of response 
produced with control CMV-empty plasmid transfected HEK293 cells in presence of the respective 
ligand. Data, reported as % of Ionomycin (1 µM) response, are expressed as means ± S.E.M. of 
experiments conducted at least 3 times. Asterisks indicate similarity in responses between each 
clone (as indicated) and native FPR2/ALX transfected cells. 
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5.4 Clones-specific ERK1 and ERK2 phosphorylation 
induced by AnxA1, SAA and C43 
Another readout for the activation of the FPR2/ALX receptor is the phosphorylation 
of ERK (Lala, Gwinn et al. 1999) and can be used to understand if the clone-
specificity that emerged with the calcium flux is linked with other receptor induced 
signalling pathways. For these reasons native and chimaeric receptors were 
treated with AnxA1, SAA and C43 with the concentration used for the calcium flux 
and ERK1/2 phosphorylation analysed by western blotting.  
 
Incubation with AnxA1 (10 nM) for 5 or 10 minutes provoked clear ERK 
phosphorylation both in FPR2/ALX cells and in clones C, G and H (Figure 74 A). 
As a negative control, since it was un-responsive to AnxA1 for the Ca2+ flux, clone 
E was also tested and the same inactivity held true for phospho-ERK.  
 
Also SAA, like for the calcium flux response, induced ERK phosphorylation in 
FPR2/ALX cells as well in clones C, G and H (Figure 74 B). The positive 
association between Ca2+ flux and phospho-ERK was also observed for C43 (1 
µM), since it activated both the native receptor and clones E and F (Figure 74 C).   
As sometimes evident with transfected cells, the over-expressed receptor was in 
some instances already partially activated. 
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Figure 74: Clone-specific ERK1/2 phosphorylation induced by AnxA1, SAA and C43. 
HEK293 cells expressing native FPR1 and FPR2/ALX receptor and chimaeric clones were treated 
with (A) AnxA1 (10nM), (B) SAA (0.1 µM) or (C) C43 (1 µM) for 5 or 10 min, as indicated, and the 
phosphorylation of ERK1/2 monitored by Western blot analysis. (A) AnxA1 induced pERK 1/2 in 
FPR2/ALX cells and in clones C, G and H. Clone E was used as negative control. (B) SAA activated 
both the native receptor and clones C, G and H (C) C43 evoked pERK 1/2 in FPR2/ALX cells as 
well in clones E and F. Representative blots from ≥3 experiments with distinct cell preparations are 
shown. 
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5.5 Clone-specific genomic response evoked by AnxA1 
Confirmed the FPR2/ALX domains-specificity for AnxA1, SAA and C43 using the 
calcium flux and ERK1/2 phosphorylation we then analysed the genomic response 
induced by receptor activation. To do so, we focused our attention on AnxA1 since 
its cardioprotective activity and our interest in the potential of this protein in AnxA1-
mimetic synthesis for drug discoveries. 
 
For this reason we tested whether the rapid responses elicited by the FPR2/ALX 
domains expressed in clones C, G and H upon application of AnxA1 could also 
lead to genomic responses. Specific profiles of gene expression post-
AnxA1/FPR2/ALX interaction has been recently shown with a particular validation 
for the upregulated JAG1 (Jagged1) and SGPP2 (sphingosine-1-phosphate 
phosphatase type 2), and downregulated JAM3 (junctional adhesion molecule-3) 
(Renshaw, Montero-Melendez et al. 2010).  
 
Using FPR2/ALX-HEK 293 cells we confirmed this profile, though JAG1 induction 
was relatively modest in our set of experiments (Figure 75). Using the chimaeric 
receptors, clone H afforded SGPP2 induction similar to the native receptor (Figure 
75), whereas clone C was the most faithful for JAG1 induction (Figure 75). 
Inhibition of JAM3 – strongly evident for the native FPR2/ALX receptor- was 
replicated in all three clones C, G and H (Figure 75).  
Trying to find a link between calcium flux, ERK1/2 phosphorylation and the 
genomic responses pharmacological inhibitors like, the MEK1 inhibitor PD98059 
and the calcium inhibitor BAPTA-AM, were used. 
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As showed in Figure 76, SGPP2 induction in clone H didn’t require calcium 
mobilization or ERK phosphorylation, pathways that - in contrast - were needed for 
JAM3 inhibition in clones C and H. 
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Figure 75: Clone-specific genomic responses evoked by AnxA1 in native and chimaeric 
receptors. 
Real time PCR data for SGPP2, JAG1 and JAM3 gene expression in HEK293 cells transfected with 
native FPR2/ALX or the indicated chimaeric clones after incubation with AnxA1 (0.5 µM) for 4h. 
SGPP2 was induced in FPR2/ALX cells and clone H, JAG1 in FPR2/ALX cells and clone C. JAM3 
inhibition was evident in FPR2/ALX cells and clones C, G and H. Clone E was used as negative 
control. Following the relative quantification method, the response produced with control CMV-
empty plasmid transfected HEK293 cells is taken as 1 and data expressed as upregulation (>1) or 
downregulation (<1) of this value. GAPDH was used as endogenous control. Data are mean ± SEM 
of experiments conducted at least 3 times. (*P<0.05 vs. control CMV-HEK cells). 
 
 
 
 214 
 
 
 
 
 
Figure 76: JAM3 down regulation, but not SGPP2 upregulation, requires AnxA1-induced 
calcium flux and ERK phosphorylation. 
HEK293 cells expressing native and chimaeric clones C and H were incubated for 30min with either 
vehicle, the calcium channel inhibitor BAPTA (30µM) or the MEK1 inhibitor PD98059 (10 µM) to 
prevent phospho-ERK formation prior to addition of AnxA1 (0.5 µM) for further 4 h. SGPP2 
induction in clone H didn’t require calcium mobilization or ERK phosphorylation. JAM3 inhibition, in 
clones C and H, was blocked when the inhibitors were used. Gene product expression of SGPP2 
and JAM3 was then evaluated by real time PCR. The response produced with control CMV-empty 
plasmid transfected HEK293 cells is taken as 1. Data are mean ± SEM of experiments conducted at 
least 3 times. (*P<0.05 vs. vehicle-treated cells) 
 
 
 
 
 
 
 215 
5.6 N-terminal domain of FPR2/ALX is dispensable for 
homologous and heterologous desensitization after 
agonist binding 
Repeated administration of a drug might evoke a reduction of the response, 
phenomenon called tolerance. In terms of receptor agonist this might be link with 
the desensitization in response to multiple activation by one or more agonists.  
 
Since AnxA1 and SAA can induce heterologous desensitization (Dufton, Hannon et 
al. 2010, Li, Cai et al. 2011) we queried if we could identify the receptor domain 
required for this biological response. 
As showed in Figure 77 A we confirmed the homo- and hetero-desensitization 
against AnxA1-induced Ca2+ flux in FPR2/ALX cells, as exerted by pre-incubation 
with AnxA1 or SAA, respectively. The same effect was quantified with clones G 
and H, but not with clone C, indicating that FPR2/ALX N-terminal domain was 
insufficient to afford desensitization of the AnxA1 response (Figure 78).  
To give translation potential to these findings produced with artificial receptors and 
transfected cells, we studied the cross-desensitization between AnxA1 and SAA in 
primary neutrophils. SAA (100 nM) desensitized AnxA1-induced Ca2+ flux (Figure 
77 B) and, conversely, AnxA1 attenuated the SAA response to a similar degree as 
the homo- desensitization (Figure 77 B).  Of interest, when tested at 1 µM C43 also 
provided modest desensitization on the responses in primary neutrophils (Figure 
77 B), whereas it was much more efficient in FPR2/ALX transfected HEK cells 
(Figure 77 A). 
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A. 
 
 
B. 
 
 
 
Figure 77: FPR2/ALX receptor desensitization upon agonist stimulation in HEK293 
transfected cells and neutrophils.  
(A) HEK293 cells expressing native FPR2/ALX or (B) freshly isolated human neutrophils were 
treated with vehicle, AnxA1 (10nM), SAA (0.1 µM) or compound 43 (C43; 1 µM) for 5 min followed 
by a second treatment with AnxA1 (10 nM) (left panel) or SAA (100 nM) (right panel). All cells were 
loaded with FURA-2 and the fluorescence was analysed. Homo- and hetero-desensitization was 
recorded for all the treatment and both cells types. Data are reported as % of Ionomycin (1 µM) 
response. Data are mean ± SEM of experiments conducted at least 3 times. (*P<0.05 vs. native 
vehicle pretreament). 
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Figure 78: N-terminal domain of FPR2/ALX is dispensable for homologous and heterologous 
desensitization. 
FURA-2 loaded HEK293 cells expressing the FPR2/ALX receptor and clones C, G and H were 
treated with vehicle, AnxA1 (10nM) and SAA (0.1 µM) for 5 min followed by a second treatment with 
AnxA1 (10 nM). AnxA1/AnxA1 and SAA/AnxA1 Homo- and hetero-desensitization was confirmed in 
FPR2/ALX cells, clones G and H but not with clone C. Data are reported as % of Ionomycin (1 µM) 
response. Data are mean ± SEM of experiments conducted at least 3 times. (*P<0.05 vs. Vehicle 
pretreatment). 
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5.7 Conclusion 
In conclusion this side project allowed me to learn techniques of cell culture and 
cellular responses in vitro, representing an important complement to the in vivo 
protocol I had learned plus the biochemical and molecular analyses I conducted in 
heart tissue samples and in the secondary organs. Furthermore, from a scientific 
advancement, I have identified AnxA1 distinct domains of FPR2/ALX in relation 
with other FPR2/ALX agonists like the pro inflammatory SAA and the synthetic 
anti-inflammatory compound 43.  
 
To summarise, as shown in the figure 79, AnxA1 requires the N-terminus and/or 
the II extracellular loop to induce FPR2/ALX receptor activation. SAA interacts with 
I and II extracellular loops for FPR2/ALX, whilst the small synthetic compound 43 
penetrates into the I extracellular loop and transmembrane regions for full agonism. 
The reported binding site for Lipoxin A4 (LXA4) is also indicated, as reported in 
(Chiang, Fierro et al. 2000). 
In terms of activated signalling, AnxA1 thought the FPR2/ALX N-terminal domain 
induces calcium mobilization and ERK phosphorylation leading to JAG1 
upregulation and JAM3 downregulation. The II extracellular loop is more complex 
in its downstream AnxA1-evoked events. It participates in AnxA1 mediated JAM3 
downregulation through calcium flux and ERK phosphorylation and it may involve 
unknown pathways for SGPP2 induction.  
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Figure 79: Schematic summary for agonist binding FPR2/ALX and of AnxA1 evoked post-
FPR2/ALX signalling. 
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CHAPTER 6: DISCUSSION  
 
 
 
 
 
 
 
 
 
 
 
 
 221 
One of the major therapeutic goals of modern cardiology is to design strategies 
aimed at minimizing myocardial necrosis and optimizing cardiac repair after acute 
myocardial infarct. However, a deep understanding on the biology of AMI is 
necessary before a specific intervention is pursued on a therapeutic basis.  
 
Along this way, a growing body of evidence suggests that inflammation play an 
important role in acute myocardial infarct. It is now clear that the rapid inflammatory 
response that occurs in the vasculature during AMI is a prerequisite for healing but 
it can paradoxically also extending tissue injury; hence it needs to be modulated.   
An example is the pivotal role of neutrophils: ischaemia–reperfusion injury prompt 
rapid neutrophil extravasation from the circulation to the infarcted myocardium 
mediating tissue damage. As we have recently shown (Cash, Bena et al. 2013) 
reducing neutrophil recruitment can be a successful strategy to decrease heart 
damage. But this is only a little part of the complex inflammatory response during 
acute myocardial infarct. Patients with unstable angina and myocardial infarct have 
also activated circulating neutrophils, lymphocytes, monocytes, increased 
concentrations of proinflammatory cytokines, such as interleukin IL-1 and IL-6 and 
coronary atherosclerotic plaques characterized by macrophages at the site of 
plaque rupture (Biasucci, Liuzzo et al. 2000). Also infiltrating mononuclear cells 
and mast cells appear to orchestrate the cardiac repair process and the healing 
phase. They secrete a variety of growth factors and cytokines, inducing fibroblast 
proliferation (Richard, Murry et al. 1995).  
 
Elucidating the interactions and regulatory mechanisms responsible for myocardial 
inflammation may help to design effective inflammation-related interventions for the 
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treatment of myocardial infarction. For this reason appreciation of the mediators 
operative in the area of resolution of inflammation for AMI is emerging and these 
include the protein Annexin A1 (AnxA1) and its receptor, the GPCR termed 
FPR2/ALX.  
 
In line with that, we have recently shown that AnxA1 mediates the inhibition 
properties of estrogen on PMN activation (Nadkarni, Cooper et al, 2011), female 
sex hormone linked with a reduced incidence of cardiovascular disease (Bakir, 
Mori et al. 2000). Furthermore, AnxA1 (D'Amico, Di Filippo et al. 2000) and 
Annexin-derived peptides such as Ac2-12 and Ac2-26 (La, D'Amico et al. 2001, 
Qin, Buxton et al. 2012, Qin, Buxton et al. 2013) exert protective effects in rodent 
models of AMI. BOC-2, a pan-FPRs antagonist (able to antagonize FPR1 and 
FPR2/ALX in human cells, and Fpr1, Fpr2 and Fpr3 in the mouse) reversed the 
cardioprotective actions of AnxA1 and its N-terminal peptides (La, D'Amico et al. 
2001), demonstrating the involvement of FPRs in the cardioprotective properties of 
these molecules. Ac2-26 improved the recovery of left ventricle function through 
FPR1 (Qin, Buxton et al. 2013) but retained its fully cardioprotective properties in 
Fpr1 KO mice (Gavins, Kamal et al. 2005). Thus, FPR2/ALX may be the receptor 
of the FPRs family with a protective nature in AMI.   
 
For these reasons, here, we have investigated the role of the FPR2/ALX receptor 
in acute myocardial infarct. We explored the damage in the heart and in secondary 
organs such as the lung and the kidney taking advantage of a unique Fpr2/3 KO 
mouse colony with a green fluorescence protein (GFP) gene ‘knocked-in’.  
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Transgenic mice lacking for the Fpr2 and Fpr3 genes compose our mouse colony. 
This is because the human ALX/FPR2 receptor exhibits homology with 2 mouse 
genes, termed Frp2 and Fpr3 (74 and 76%, respectively, at both amino acid and 
RNA level). Like for the human FPR2/ALX, LXA4 binds and activates both mice 
Fpr2 and Fpr3 receptors (Takano, Fiore et al. 1997). We began the project using 
GFP expression to study the cellular localization of the receptors and to monitor 
gene promoter activity during on-going inflammation. GFP expression was 
monitored using fluorescence microscopy (tissue samples) and flow cytometry (cell 
samples).  
 
In the tissues, as a positive control, immunocytochemistry with a rabbit anti-mouse 
Fpr2 antibody was also performed on WT samples. Few antibodies in commerce 
are reactive against mouse Fpr2/3 because most of them react with the human 
receptor. The FPR2 Antibody (M-73) from Santacruz used here, is a rabbit 
polyclonal IgG with an epitope corresponding to amino acids 208-280 mapping 
within an internal region of Fpr2.  
 
In isolated cells like neutrophils and macrophages, GFP expression was analysed 
by flow cytometry using the FL-1 channel for the natural fluorescence and, in some 
cases, with a protocol for intracellular staining using an anti-GFP antibody. 
Quantification of GFP fluorescence revealed that the Fpr2/3 gene is active (or 
expressed by a higher number of positive cells) in the kidney (~45% fluorescence 
positivity), followed by the aorta (35%), heart (30%), lung (15%), liver (10%) and 
spleen (10%). As expected, using the same staining and microscopic conditions, 
green fluorescence was absent in tissues from WT mice. Immunohistochemistry 
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staining for GFP in Fpr2/3 KO samples was validated in WT kidney and lung, 
tissues selected because of their different degree of fluorescence, using an anti-
Fpr2 antibody. It was important in my view to demonstrate that the antibody, albeit 
polyclonal, displayed an at least sufficient degree of specificity since signal was 
lost in Fpr2/3 KO tissues. 
 
As said above, the kidney expressed highest levels of Fpr2/3/GFP in resting 
conditions. Interestingly, it has been published that also the FPR2/ALX agonist 
AnxA1 is expressed in rat kidney: specifically AnxA1 is enriched in epithelia of 
Bowman’s capsule, in the macula densa and in medullary/papillary collecting ducts 
(Markoff and Gerke 2005). The presence of both Fpr2/3 and AnxA1 in the kidney 
suggests a probable correlation of expression between the receptor and its agonist 
(McKanna, Chuncharunee et al. 1992) with downstream implications for some 
renal functions. Indeed, after an ischemia injury AnxA1 levels and distribution in the 
kidney are modified with augmented expression, especially in the ascending limb, 
with approximately a threefold increase after the recovery phase (McKanna, 
Chuncharunee et al. 1992). Moreover, AnxA1 as a mediator in glucocorticoid-
induced cellular response (Kim, Yang et al. 1996, Donnelly and Moss 1998) and 
due to its is possible involvement as a second messenger of hormone release 
(Buckingham, Solito et al. 2003), is also important for kidney development and 
recovery of physiological stress (Markoff and Gerke 2005). 
 
Furthermore, in line with Fpr2/3 gene promoter activity, AnxA1 is also particularly 
abundant in the lung. Again, this emphasizes the existence of a pattern, with a 
correlation of tissue Fpr2/3/GFP and AnxA1 expression and potential physiological 
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functions of this molecule (Wallner, Mattaliano et al. 1986) and its receptor. In the 
lung, AnxA1 is expressed in alveolar macrophages (Ambrose, Bahns et al. 1992, 
Kurosu, Takiguchi et al. 2008), alveolar epithelial type II (Ambrose, Bahns et al. 
1992) and tracheal gland cells (Jacquot, Dupuit et al. 1990). Cellular and in-vivo 
studies indicate that AnxA1 is involved in the anti-inflammatory actions of 
glucocorticoids in the respiratory tract (Hall, Lim et al. 1999). This FPR2/ALX 
agonist has also a role in the regulation of pulmonary surfactant synthesis and 
secretion by alveolar epithelial type II cell (Hall, Lim et al. 1999). 
 
Alongside this pattern, in naïve mice AnxA1, like what we have showed for the 
Fpr2/3 receptors in terms of GFP expression, is almost absent in the liver (de 
Coupade, Ajuebor et al. 2001). However, after LPS induced inflammation, liver 
regeneration after partial hepatectomy (de Coupade, Gillet et al. 2000) or tumour 
(de Coupade, Ajuebor et al. 2001), the levels of AnxA1 in this tissue are increased 
(de Coupade, Ajuebor et al. 2001). Macrophages-derived AnxA1, as we have 
recently shown, is also increased and protective during nonalcoholic 
steatohepatitis (Locatelli, Sutti et al. 2014).   
 
All these examples underline the idea that expression of Fpr2/3 and the protein 
agonist AnxA1 may be correlated and perhaps tightly controlled. Also they might 
be regulated by pro-inflammatory stimuli and/or diseases and, then, be part of a 
circuit involved in the restoration of tissues homeostasis.  
 
Moving to cellular analyses, Fpr2/3/GFP were also expressed in neutrophils, bone 
marrow cells, bone marrow derived macrophages and peritoneal cells. Specifically, 
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Fpr2/3 KO blood neutrophils displayed ~5% of GFP+ve events by flow cytometry 
(raising to 20% after anti-GFP antibody staining). Bone marrow cells and bone 
marrow derived macrophages showed instead ~10% of GFP positive cells. Resting 
peritoneal cells exhibited 5% of GFP positive cells, with a much higher degree of 
positive events (~50%) following anti-GFP antibody staining. Thus, in cell 
suspension use of an anti-GFP antibody was preferred to achieve significant 
numbers of positive events, indicating that GFP was quite weak as a stimulus. We 
note that nowadays enhanced GFP or Yellow Fluorescent Protein are mostly used 
as reporters since they provide stronger signals (Shaner, Steinbach et al. 2005).  
Again, also AnxA1 is expressed in all these cells type (Francis, Balazovich et al. 
1992, Getting, Flower et al. 1997, Dalli, Jones et al. 2012). 
 
Altogether, monitoring the pattern of expression of GFP as an indication of Fpr2/3 
gene activity in resting organs and cells we can conclude that the Fpr2/3 receptor 
is expressed in the organs of our interest (heart, lung and kidney) and also in 
infiltrating cells that characterized the inflammatory response during acute 
myocardial injury. This increases our interest in studying the role of the Fpr2/3 
receptors in AMI, specifically in the heart and in secondary injury organs.  
 
Furthermore, the data for Fpr2/3/GFP expression and the current literature on 
AnxA1 expression, suggest a high degree of co-localization between the receptor 
and its anti-inflammatory ligand in tissues like the kidney, the lung and the liver, 
prompting us to hypothesise that the pair might be operative, or swiftly become 
operative, after tissues injury or disease.  
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Although the previous studies from our lab or Ritchie groups have shown that ANX-
A1 peptides limit neutrophil-dependent myocardial necrosis (D'Amico et al., 2000; 
La et al., 2001; Gavins et al., 2005; 2006) and affects the recovery of left ventricle 
contractive function (Qin, Buxton et al. 2012), no in vivo evidence show expression 
of Fpr2/3 in the heart, its role in AMI and a functional correlation between the whole 
protein AnxA1 and Fpr2/3 in this tissue.  For this reason, Fpr2/3 KO mice and 
littermate controls (WT) were subjected to the left anterior descending coronary 
artery model of acute myocardial infarct and studied. It is noteworthy to mention 
that left ventricle function of sham WT and Fpr2/3 KO mice were analysed by 
echocardiography and both mice revealed the same normal heart activity. 
 
Animal models of myocardial ischemia reperfusion mimic the clinical scenario 
where a period of ischemia is followed by the restoration of myocardial blood flow. 
There are two methods to induce myocardial ischemia in mice: a cryo infarction 
using a cryo-pen on the surface of the heart, an inaccurate technique with side 
effects (Atkins, Hueman et al. 1999, Kolk, Meyberg et al. 2009), and the ligation of 
the left anterior descending coronary artery (LADCA) (Michael, Entman et al. 1995). 
By occluding the LADCA, the ischemia can be detected immediately as no further 
blood flow is permitted in the left ventricle, while the surrounding myocardial tissue 
is almost unaffected. This model is accepted as the model that better shares the 
clinical and pathological features of AMI. Moreover, this protocol allows 
comparative and quantitative studies on the pathobiological and pathophysiological 
aspects occurring in infarction-related myocardial ischemia.  
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To compare the data published on AnxA1-derived peptide with the main protein 
AnxA1, the latter was administered to WT mice. Administration before LADCA 
occlusion afforded significant cardioprotection as compared to vehicle (PBS). 
However, AnxA1 administration at the beginning of reperfusion afforded a much 
lower degree of protection emphasizing a role of the protein in the first phase of 
ischemia/reperfusion injury. Deletion of the Fpr1 gene did not significantly alter the 
cardioprotective effect of AnxA1, whilst the protein was no longer effective in 
Fpr2/3 KO mice. AnxA1 through the Fpr2/3 receptors, significantly decreased the 
levels of Troponin I, a clinical biomarker of cardiac injury, and Caspase 3, a marker 
of apoptosis and TNFα induced by AMI.  These new results provide mechanistic 
support to the studies conducted over 10 years ago (D’Amico eta l., 2000) and 
indicate quite convincingly a functional role for Fpr2/3 over Fpr1, making an 
interesting distinction from the in vitro observations conducted by Ritchie’s lab 
(Ritchie, Sun et al. 2003, Qin, Buxton et al. 2013). 
 
When other FPR2/ALX agonists were tested in WT mice subjected to AMI we 
discovered that only the AnxA1/FPR2/ALX pair affords a characteristic 
cardioprotective function outside the one would expect in view of their anti-
inflammatory properties. Indeed, though reported to be protective in post-
conditiong (Zhao, Shao et al. 2013) and in ischemia-reperfusion injury following 
cardiac arrest in a rabbit model (Chen, Wu et al. 2013), Lipoxin A4 (administered at 
100 ng i.v. prior ischemia) did not induce a cardioprotection in our AMI setting. The 
synthetic FPR2/ALX agonist compound 43, administered i.v or i.p prior ischemia, 
decreased the infarct size induced by AMI but the effect was significantly lower in 
comparison with the one induced by AnxA1. Also, the effect was not dose 
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dependent, perhaps indicating the impact of unfavourable pharmacokinetics 
properties. I also tested the omega-3–derived lipid mediators Resolvin D1 (RvD1, 
100 ng prior ischemia) (Serhan, Clish et al. 2000), since the ability of omega-3 
polyunsaturated fatty acids to induce protective effects in cardiovascular (De 
Caterina 2011) and inflammatory diseases (Calder 2003). In our model we could 
observe that RvD1 decreased infarct size induced by AMI in WT mice, however 
this cardioprotective activity was not characterised by change in cardiac injury 
biomarkers like troponin I levels and caspase 3 activity but was only characterised 
by a decrease in the levels of the neutrophil chemoattractant protein named KC. 
This was in line with the documented role of resolvin D1 in limiting neutrophil 
recruitment during inflammation (Norling, Dalli et al. 2012).  
 
Interesting, acute myocardial infarct upregulated mRNA expression of both AnxA1 
and Fpr2, and together with the notion that AnxA1 injection increased the induction 
of Fpr2 mRNA above the level attained by AMI, these data indicate a potential 
rapid engagement of the pathway in AMI. By strict monitoring the levels of CXCL1 
and KC together with AnxA1 and Fpr2 mRNA in the heart after 30 min ischemia 
and 90 min reperfusion we noticed that only Fpr2 mRNA was significantly 
augmented during ischemia. The increments in CXCL1 and KC mRNA occurred 
during reperfusion and were associated with detectable neutrophil infiltration. 
Therefore, there is a specific phenomenon centred on Fpr2 mRNA whereby its 
induction in the heart, during LADCA occlusion, was not connected with an 
increase in neutrophils infiltration; I think this would indicate myocardial-specific 
functions of Fpr2/3 beyond its known actions on immune cells. Indeed, 
immunofluorescence of Fpr2/3 (GFP) and AnxA1 showed that they were 
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expressed, and co-localized, in cardiomyocytes. The validity of the assay, hence 
the importance of the data produced, was confirmed by detection of both AnxA1 
and Fpr2/3 in neutrophils (Ly6G positive cells) that had infiltrated the hearts 
subjected to acute infarct.  Finally, differently from Fpr2/3 as discussed above, the 
AnxA1 mRNA increased selectively during reperfusion, and this could explain why 
exogenous injection of the protein was active when given at the beginning of 
ischemia (higher degree of Fpr2/3 availability) instead of during reperfusion 
(endogenous increase in AnxA1 with potential Fpr2/3 receptor occupation and/or 
desensitization). 
 
Altogether this large set of data indicates that the AnxA1/Fpr2/3 circuit becomes 
operative during the ischemic phase of AMI in the heart, perhaps to moderate the 
necessary yet potentially harmful reperfusion phase. In line with this hypothesis 
striking observations were made when I tested Fpr2/3 KO mice.  
 
During LADCA occlusion a significant proportion (~40%) of Fpr2/3 KO mice 
perished during the procedure, and those that did survive up to 90 min post-
reperfusion exhibited a larger infarct size (+15%, p<0.05) than WT animals. The 
AMI procedure led to necrosis of ~55% of the area at risk in both mice. Acute 
myocardial infarct also induced a significant increase of Troponin I plasma levels, 
more marked in Fpr2/3 KO. Hearts of Fpr2/3 KO mice were also characterised by a 
decrease in AnxA1 protein after AMI, perhaps suggestive of a positive loop 
whereby Fpr2/3 activation augments agonist generation. A similar in concept, but 
different in players and assay, has been recently been put forward by Brancaleone 
et al. (2013) during mesenteric ischaemia-reperfusion. 
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All together these data indicate that Fpr2/3 play important protective functions in 
acute myocardial infarct, warranting further analysis of the mechanisms behind 
these effects. To do this, further analyses were conducted in myocardial and 
plasma samples of WT and Fpr2/3 KO mice and analysed in comparison with the 
respective sham mice.  
 
Hearts from Fpr2/3 KO exhibited an alteration of cardiac filament and higher 
infiltration of neutrophils as seen by IHC and CXCL1 and KC quantification. Fpr2/3 
KO myocardial tissue samples contained higher TNFα levels, in comparison with 
WT mice, an inflammatory marker associated with a worse coronary artery disease 
prognosis (Sels, Elsenberg et al. 2012).  In addition, Fpr2/3 KO mice displayed an 
unbalance production of pro and anti-inflammatory bioactive lipids as measured by 
metabolo-lipidomics.  
 
Plasma levels of the pro inflammatory PGE2, PGI2, TXB2 and LTB4 were higher in 
the Fpr2/3 KO mice compared to WT mice. On the other hand, the anti 
inflammatory PGA1, RvD2 and the FPR2/ALX agonist LXA4 could be detected only 
in WT mice after acute myocardial infarct.  
 
This is reminiscent of data produced in our lab, before the beginning of my 
studentship, where LXA4 was not detected in Fpr2/3 KO following mesenteric 
ischemia suggesting that, collectively, this receptor can be a master-regulator of 
vascular events that take place during ischemia and reperfusion, with changes in 
specific readouts that can be associated with each vascular bed or organ.  
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Moreover, we have recently shown the existence of an endogenous network in 
anti-inflammation centred on PMN AnxA1 and activated by selective FPR2/ALX 
agonists like LXA4 (Brancaleone, Dalli et al., 2011). Specifically, addition of LXA4 
to human polymorphonuclear leukocytes provoked a concentration- and time-
dependent mobilization of AnxA1 onto the plasma membrane. The FPR2/ALX 
antagonist blocked the effect. This might be the reason why, after AMI, Fpr2/3 KO 
mice lacking of LXA4 had less AnxA1 protein in the heart compared with WT mice, 
a hypothesis discussed above.  
 
Resolvin D2 is an omega-3 fatty acid-derived mediator with anti inflammatory 
effects in microbial sepsis (Spite, Norling et al. 2009), obesity-induced adipose 
inflammation (Clària, Dalli et al. 2012) and colitis (Bento, Claudino et al. 2011).  
Specifically, RvD2 is produced physiologically from the sequential oxygenation of 
DHA by 15- and 5-lipoxygenase through 17-HDoHE (Spite, Norling et al. 2009). 
Interesting, plasma samples from Frp2/3 KO mice contained higher levels of the 
resolvin D precursor 17-hydroxy docosahexaenoic Acid (17-HDoHE) but, crucially, 
lacked RvD2, which was instead increased by AMI in WT mice. This is another 
case where, after AMI, Fpr2/3 KO mice are characterised by less pro resolving 
mediator compared to WT mice: Resolvin D2 (Resolvins: resolution phase 
interaction products) is able to decrease neutrophil trafficking to inflammatory loci 
and promote macrophages influx and phagocytic activity (Spite, Norling et al. 2009).  
 
Aspirin has one of the greatest impacts on acute coronary syndromes affording 
reduction of AMI mortality. It is beneficial in early therapy, especially immediately 
on recognition of AMI symptoms, and in long-term use (Antman, Hand et al. 2008). 
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This is due to its ability to inhibit the formation of thromboxane A2 preventing 
platelet activation, adhesion and cohesion. However, since RvD2 was originally 
identified during resolution in mice treated with aspirin (Serhan, Hong et al. 2002), 
RvD2 synthesis and action might be another reason why aspirin is beneficial in 
these diseases. Moreover, we have recently shown an involvement of Fpr2/3 in the 
vascular protective properties of aspirin after mesenteric I/R (Brancaleone, 
Gobbetti et al. 2013). The inability of Fpr2/3 KO to synthetize RvD2 might be at 
least one of the reasons why aspirin was less effective in this genotype. 
 
All together, this is the first evidence of a hypothetical role of Fpr2/3 in RvD2 
synthesis and aspirin effects in AMI. 
 
In synthesis, so far, data produced with this project established that Fpr2/3 elicits 
anti-inflammatory properties in AMI, that it is expressed in cardiomyocytes and that 
it exerts a specific cardioprotective activity in the heart (e.g. data on Troponin I and 
Caspase 3). How is Fpr2/3 signalling to produce these fundamental actions? 
 
A large number of studies have shown that IL-6 is involved in the induction of the 
cardioprotective JAK/STAT3 signalling (Negoro, Kunisada et al. 2000). In the heart 
there is a basal levels of ~40 pg/mg of IL-6 that increases up to 140 pg/mg after 
one day of myocardial ischemia reperfusion (Danesh, Kaptoge et al. 2008). In the 
infarcted myocardium the major IL-6R-expressing cells are neutrophils, monocytes 
and cardiomyocytes (Negoro, Kunisada et al. 2000). Interesting, I could establish a 
marked increase in IL-6 at 90 min post-reperfusion in the hearts of Fpr2/3 KO mice 
but this occurred without evident STAT3 activation. These results brought me to 
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work further on this pathway in the context of Fpr2/3 and AnxA1, using AG490, a 
janus kinase inhibitor that block the JAK/STAT3 pathway (Seo, Lee et al. 2009, 
Huang, Yang et al. 2010, Heusch, Musiolik et al. 2011, Duan, Yang et al. 2012, 
Ottani, Galantucci et al. 2013). 
 
In WT mice, after AMI, AG490 induced Fpr2 mRNA expression yet it prevented the 
cardio-protective effect of AnxA1. It is clear that when some cardioprotective 
pathways (like JAK/STAT3) are down regulated, the other protective pathways (like 
Fpr2/3-AnxA1) are upregulated.  
Interesting, the modulation of phosphorylation of STAT3 by AnxA1 has been also 
recently proposed in tumorgenesis (Li, Cai et al. 2011). Moreover, AG490 also 
induced TNFα and IL-6 mRNA, pro-inflammatory mediators that, as shown above, 
were significant higher in Fpr2/3 KO mice after AMI. The lack of STAT3 activity 
might be one of the reasons why, after AMI, higher levels of TNFα and IL-6 were 
quantified in Fpr2/3 KO mice in comparison with WT mice. Therefore the cross-talk 
between the AnxA1/Fpr2/3 and the JAK/STAT3 pathways affords not only 
cardioprotection but it is also important for the anti-inflammatory activity as 
measured by cytokines levels.  
 
To summarise, with this set of experiments we have shown for the first time that 
AnxA1 and Fpr2/3 are involved in the induction of the cardioprotective and anti-
inflammatory IL-6/JAK/STAT3 pathway in the injured myocardium.  
 
Ischemia reperfusion injury, after AMI, may also extend beyond the ischaemic area 
and provoke injury of remote non-ischemic organs resulting in multiple organ 
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dysfunction syndrome (MODS), which account for up to 30-40% of intensive care 
unit mortality (Maxwell and Lip 1997, Eltzschig and Collard 2004). Within 24-72h of 
the ischemic event, the pulmonary system is the most frequently injured organ. 
Respiratory failure is often followed by hepatic, renal and gastrointestinal 
dysfunctions (Ware and Matthay 2000). 
 
As we observed by monitoring GFP expression, the receptor Fpr2/3 were also 
expressed in the lungs and in the kidney. Moreover it is published that in the lungs 
the receptor, together with their agonists, protects against lung injury (Chen, Le et 
al. 2010, Barnig, Cernadas et al. 2013, Eickmeier, Seki et al. 2013, Wang, Zheng 
et al. 2014) and against models of cystic fibrosis (Buchanan, McNally et al. 2013), 
chronic obstructive pulmonary disease (Bozinovski, Anthony et al. 2013) and 
pneumosepsis (Sordi, Menezes-de-Lima et al. 2013). In kidneys, the Lipoxin 
A4/AnxA1/Fpr2/3 pathway has a potential therapeutic role in renal 
ischemia/reperfusion injury, acute renal failure and glomerulonephritis (McMahon, 
Stenson et al. 2000, Leonard, Hannan et al. 2002, Araujo, Truzzi et al. 2010, Facio, 
Sena et al. 2011). For this reason we have also studied the role of the Fpr2/3 
receptors in lungs and kidneys after AMI showing that Fpr2/3 activation also 
exerted a protective role in secondary organ injury.  
 
Specifically, lungs of Fpr2/3 KO mice were characterized by partial destruction of 
pulmonary architecture and higher tissues infiltration as seen from H&E staining 
and MPO quantification and higher degree of inflammation (higher IL-6 and less IL-
10) compared with WT mice. Kidneys of Fpr2/3 KO mice contained higher KC 
levels and more TNFα and IL-6 mRNA expression.  Interesting, Fpr2 and AnxA1 
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were upregulated by AMI in both lungs and kidneys. In the lungs they were also 
colocalized particularly in the epithelial cells of bronchioles underling again the high 
degree of co-localization between the receptor and its anti-inflammatory protein, 
hence the likely importance of the AnxA1/Fpr2/3 pathway in AMI-induced 
secondary injury organs.  
 
In summary, these striking events indicate that, after LADCA occlusion, the 
AnxA1/Fpr2/3 circuit is protective during the ischemic phase of AMI and in 
secondary injury organs. The Fpr2/3 KO mice exhibited higher infarct size, 
myocardial injury and inflammation as compared to WT mice in hearts, lungs and 
kidney.  
 
Having established the cardioprotective properties of the AnxA1/Fpr2/3 pathway 
we thought it would be ideal to exploit it to develop a pharmacological treatment 
able to modulate myocardial reperfusion without the collateral risk showed by other 
anti-inflammatory remedies already tried and cited. However FPR2/ALX, as stated 
before, mediates actions elicited by both pro and anti-inflammatory mediators 
(Chiang, Fierro et al. 2000, Ye, Boulay et al. 2009) and modulates cell 
responsiveness in a ligand-biased fashion (Li, Cai et al. 2011). The latter point has 
been chiefly demonstrated in a recent study in macrophages, where both putative 
‘pro-inflammatory’ (or rather activating) FPR2/ALX agonists (such as SAA) and 
inhibitory agonists (such as AnxA1 and lipoxin A4) were able to convey their 
message through this receptor and afford functional antagonism to each other (Li, 
Cai et al. 2011). In it clear that, to use AnxA1 mimetics as a therapeutically 
treatment in AMI, AnxA1-biased agonist must be synthetized resulting in an unique 
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receptor activation that will signal to desirable pathways while sparing those 
mediating undesirable effects. For this reason we moved to the human FPR2/ALX 
receptor and we studied the FPR2/ALX binding domains and ensuing signalling 
required for the activity of the cardioprotective AnxA1 and one of the most pro-
inflammatory agonist studied: the acute phase protein Serum Amyloid A (SAA) 
(Liang, Wang et al. 2000, He, Sang et al. 2003). For completion Compound 43, an 
anti-inflammatory synthetic compound (Burli, Xu et al. 2006), has also been 
analysed.  
 
To do so we took advantage of well-characterised stably transfected HEK293 cells 
with varied FPR1-FPR2/ALX chimeric receptors (Le, Ye et al. 2005). A similar 
approach but using different chimaeric strategy has been already used to identify 
the III extracellular loop as a FPR2/ALX binging site for lipoxin A4 (Chiang, Fierro et 
al. 2000).  An important control useful also for identifying the epitope recognised by 
commercially available mAbs was the overall amount of receptor expression. It 
appeared that the anti-FPR2/ALX mAb likely binds to a tri-dimensional epitope 
formed between the receptor N-terminal domain and the II and III extracellular 
loops. The antibody revealed similar receptor density on the cell surface as native 
FPR2/ALX transfected cells. All other chimeras were detected by anti-FPR1 mAb 
solely. It is evident that the mAbs are able somehow to penetrate within the 
transmembrane domains, since the anti-FPR2/ALX is active on clone D (containing 
sequence 40-86 of the native receptor) whilst the anti-FPR1 mAb is not active on 
clone F (with amino sequence 106-145 of the FPR2/ALX receptor). 
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Following the binding with its agonists, the FPR2/ALX receptor undergoes a 
conformational change that allows functional interaction with Giα1, Giα2 and Giα3 
and association with G0, Gz and Gα16 (Migeotte, Communi et al. 2006). This event 
triggers activation of a variety of signalling pathways including fluxes in intracellular 
calcium, activation of phospholipase A2, C and D, phosphoinositide 3-kinase and 
mitogen-activated protein kinase (Selvatici, Falzarano et al. 2006) and rapid 
phosphorylation leading to a PLC-mediated receptor desensitization and 
internalization (Le, Wetzel et al. 2001).  
 
Here, we used as readout for cells activation after FPR2/ALX binding the calcium 
flux mobilization and the ERK1/2 phosphorylation, since its ability to regulates cell 
chemokinesis (Wenzel-Seifert, Hurt et al. 1998). In selected experiments 
modulation of gene expression was also evaluated. We selected three genes from 
published study (Renshaw, Montero-Melendez et al. 2010): JAG1 (Jagged1), 
SGPP2 (sphingosine-1-phosphate phosphatase type 2), and JAM3 (junctional 
adhesion molecule-3) (Renshaw, Montero-Melendez et al. 2010).  
 
Due to the large structure of AnxA1 (Rosengarth, Gerke et al. 2001) and since in 
presence of calcium it undergoes a conformational change with exposure of its N-
terminal domain (Rosengarth and Luecke 2003, Gerke, Creutz et al. 2005), we 
hypothesise that at least two binding site onto FPR2/ALX for this protein. 
Hypothesis already proposed quite a few years ago when structural data were 
scarce (Perretti, Wheller et al. 1995). 
Indeed, when the chimeric receptors where tested, the N-terminal domain of 
FPR2/ALX was sufficient for AnxA1 to elicit rapid downstream responses, whereas 
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the second extracellular loop was required to provoke more sustained changes, 
such as those leading to modulation of gene expression. Clone C which could 
transduce calcium flux and phospho-ERK did modulate JAG1 and JAM3, but clone 
H with both second and third extracellular loop was nearly as active the native 
receptor for SGPP2 induction. Analyses conducted with clone C, which contains 
solely the FPR2/ALX N-terminal region linked to the nearly full FPR1 sequence, 
corroborated the specificity of full-length AnxA1 for FPR2/ALX, and its inability to 
engage FPR1. This is in contrast to the ability of short AnxA1-derived peptide that 
can activate all members of the human FPRs family (Walther, Riehemann et al. 
2000, Dalli, Montero-Melendez et al. 2012).  
 
When SAA was tested, we confirmed the genuine agonistic activity of SAA on 
FPR2/ALX without any activation of FPR1. In terms of receptor domains, analysis 
of Ca2+ fluxes and ERK phosphorylation indicates an interaction with I and II 
extracellular loop, whilst the N-terminal and III extracellular loop domains are 
dispensable for the Ca2+ response. C43, in line with the ability of small molecules 
to ‘penetrate’ inside GPCR loops (Baker and Hill 2007), was active on native 
FPR2/ALX transfected cells as well as on clones E and F; therefore it binds the I 
extracellular, III trans-membrane region and II intracellular loop of FPR2/ALX. Even 
if some work has claimed an involvement of the Fpr1 receptor (mouse counterpart 
of human FPR1) in C43 anti-inflammatory activity (Sogawa, Shimizugawa et al. 
2009, Sogawa, Ohyama et al. 2011), the synthetic compounds did not elicit Ca2+ 
flux responses in FPR1-transfected cells in our setting of experiment. This was in 
accord with the published data where the in vivo effects of C43 were lost in Fpr2/3 
KO mice (Dufton, Hannon et al. 2010).  
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This section of the project was completed by determining FPR2/ALX homo- and 
hetero-desensitization, since already reported for AnxA1 and SAA (Li, Cai et al. 
2011) and also because of the functional consequences this process may have in 
modulating cell responsiveness in inflammatory settings (Walther, Riehemann et al. 
2000, Dufton, Hannon et al. 2010) and in drug development. AnxA1 engagement of 
FPR2/ALX II extracellular loop was required for the desensitization of the receptor, 
as determined by Ca2+ readout. The C terminal, in clone H, may also have an 
important role in FPR2/ALX desensitization, as it has been recently shown (Rabiet, 
Macari et al. 2011). 
 
In summary, AnxA1 interacts with the N-terminus and/or the II extracellular loop to 
induce FPR2/ALX receptor activation. SAA interacts with the I and the II 
extracellular loops of FPR2/ALX. C43 penetrates into the I extracellular loop and 
the transmembrane regions for full agonism.  Of interest here, a recent study 
proposed a three-point binding model for small molecule ligand interaction with 
FPR2/ALX (Kirpotina, Khlebnikov et al. 2010) confirming original work conducted 
with human FPR1 (Lala, Gwinn et al. 1999). These binding site are within the non-
conserved amino acid residues 84, 85 (point 1), 163 (point 2) and 284 (point 3). 
Also in our model AnxA1 binds the FPR2/ALX receptor in the binding pocket that 
comprises residue 163 (present in clones G).  Residues 84, 85 and 163 are in the 
FPR2/ALX binding region required by C43 and SAA to induce receptor activation.  
 
To conclude, these pharmacological and patho-physiological investigations 
indicate that the Fpr2/AnxA1 pathway is operative in AMI. On one hand, AnxA1 
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delivery affords cardioprotection - partly through Fpr2/3 - on the other hand Fpr2/3 
is upregulated and protective both in the injured heart and in distant organs, like 
the lungs and the kindey. We showed for the first time that Fpr2/3 is expressed in 
the myocardium and that the AnxA1/Fpr2/3 circuit is important in the heart by 
engaging the IL-6/JAK/STAT3 pathway (Figure 80).  
 
We propose that the AnxA1/Fpr2/3 pathway can be harnessed for the development 
of novel therapeutics to prevent primary and secondary tissue damage caused by 
AMI. For this reason we shed initial light on the ligand-specific domains required by 
AnxA1 for classical FPR2/ALX readouts; in comparison with SAA – which elicits 
opposite cellular responses. 
 
AnxA1 mimetic that binds the identified FPR2/ALX domains used by the protein to 
induce a signalling response might be developed avoiding the activation of the 
receptor by other molecules or pro-inflammatory molecules like SAA. Since the 
ability of only AnxA1, and not SAA, to activate FPR2/ALX (calcium mobilization, 
ERK phosphorylation, gene modulation) through the N-terminal domain, AnxA1 
mimetics able to bind and activate only the N-terminal might be the perfect 
molecules to activate the cardioprotective AnxA1/Fpr2 pathway.  
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Figure 80: Modulatory properties of AnxA1 and its receptor in controlling local and distant 
tissue reactivity in AMI. 
Pathophysiology and pharmacology indications for a myocardial specific protective circuit centered 
on the Fpr2/3 receptor and its ligand Annexin A1 with protective effect also in secondary injury 
organs, like the lungs.  
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Based on the results produced with this project, future studies will aim to: 
 
! Investigate the role of the Fpr2/3 receptor in the heart and in cardiomyocyte 
using the Langendorff heart, an isolated perfused heart assay that removes 
the effects of Fpr2/3 and AnxA1 given by circulating cells.   
 
! Investigate the role of the Fpr2/3 receptor in the heart and in cardiomyocyte 
using tissue-specific conditional knockout. The Fpr2/3 target genes can be 
specifically inactivated in specific tissues, like the heart and the 
cardiomyocytes, and functional in all the other tissues and cells.  
 
! Study the expression of the FPR2/ALX receptor and the AnxA1 protein in 
human blood samples of acute myocardial infarct patients.  
 
! Development and analysis of AnxA1 mimetic that binds the identified 
FPR2/ALX domains used by the protein to induce a signalling response.  
 
 
 
I would like to finish this work with some words of my second supervisor Professor 
Rod Flower. I think they underlie one of the big challenges of the pharmacologists: 
understand how the drugs interact with living system. We all know the big role that 
the receptors have in this interaction. A lot of drugs, as well as endogenous 
molecules, have to bind and activate a receptor to afford their “work”. This 
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emphasizes the study of the physiological receptors and this is one the reason that 
led me to choose this project.  
 
“Pharmacology itself is a rather curious discipline. Unlike its sister sciences: 
physiology, biochemistry, anatomy and so on, it wouldn’t have a function at all if we 
didn’t take medicines or drugs. As the cosmologist Martin Rees is fond of noting, 
we know more about what goes on in the center of a star than we do in the brain of 
an insect. Whilst we may never completely fathom the complexity of the cell or the 
physiology of an organism, we are even more at a disadvantage when it comes to 
understanding drug action. The way in which each new drug interacts with living 
systems poses a unique challenge to pharmacologists. …There is a good example 
of this in your bathroom cabinet: aspirin, inhibits the synthesis of prostaglandins 
and reduces fever, pain and inflammation. Salicylic acid, its chief metabolite and 
the drug aspirin replaced, does the same – but apparently through a different 
mechanism entirely.” Pharmacology 2.0 by Rod Flower, William Harvey 
Research Institute, 25th Anniversary 2011.  
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